CTNNB1 |
S33A |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S33A |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
NOTCH2 |
V276G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRAS |
Q61R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
Q61R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
Q61R |
Complete Match |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
Q61R |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
Q61R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
Q61R |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
Q61R |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
Q61R |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
Q61R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
Q61R |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
Q61R |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
Q61R |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
Q61R |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
E221* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E221* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E221* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E221* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E221* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E221* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E221* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E221* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E221* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E221* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E221* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E221* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E221* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E221* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E221* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12D |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12D |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12D |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12D |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12D |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12D |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12D |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12D |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12D |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
R175H |
Complete Match |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R175H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
AKT3 |
splice_donor_variant |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
FLT1 |
splice_donor_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
FBXW7 |
G499C |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
G499C |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
G499C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
G499C |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TSC2 |
splice_donor_variant |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
splice_donor_variant |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
splice_donor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
splice_donor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
splice_donor_variant |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
ROS1 |
W1803L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
W1803L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
W1803L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
W1803L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
W1803L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
MET |
S960L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
MSH2 |
splice_acceptor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
splice_acceptor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRAF |
E611* |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
E611* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
E611* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
E611* |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ALK |
H368Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
H368Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
H368Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
H368Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
H368Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
H368Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
H368Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
H368Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
H368Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
H368Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
H368Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
H368Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
H368Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
H368Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
H368Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
H368Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
H368Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
H368Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
H368Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
R273H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2D |
E3117*), MLL2 MUT (G3666* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
splice_acceptor_variant |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
splice_acceptor_variant |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
splice_acceptor_variant |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
splice_acceptor_variant |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
splice_acceptor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_acceptor_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_acceptor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NOTCH1 |
Q1155H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q1155H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P867T |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BCOR |
E948* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
ABL1 |
R674W |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R674W |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R674W |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R674W |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R674W |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R674W |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
KRAS |
G12R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12R |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12R |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12R |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12R |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12R |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12R |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12R |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12R |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12R |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12R |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12R |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
M237I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M237I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M237I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M237I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M237I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M237I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M237I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M237I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M237I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M237I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R196* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R196* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R196* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R196* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R196* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R196* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R196* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R196* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R196* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R196* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R196* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R196* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R196* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R196* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R196* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FBXW7 |
splice_acceptor_variant |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
splice_acceptor_variant |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
splice_acceptor_variant |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
splice_acceptor_variant |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
I162F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I162F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I162F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I162F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I162F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I162F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I162F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I162F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I162F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I162F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I162F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I162F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I162F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I162F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I162F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
Q61K |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61K |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61K |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61K |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61K |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61K |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61K |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61K |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61K |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61K |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61K |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61K |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61K |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61K |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61K |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61K |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61K |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61K |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61K |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61K |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61K |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61K |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61K |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
R248G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
E1205D |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
APC |
R1450*), APC MUT (S943* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ALK |
E152D |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E152D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
E152D |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
E152D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
E152D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E152D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E152D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
E152D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E152D |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E152D |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
E152D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
E152D |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
E152D |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E152D |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E152D |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E152D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
E152D |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
E152D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E152D |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
R250* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R250* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R250* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R250* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R250* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R250* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R250* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R250* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R250* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R250* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R250* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R250* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R250* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
JAK2 |
K850N |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PIK3CA |
R88Q |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
R88Q |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
R88Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R88Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
R88Q |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R88Q |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
R88Q |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
R88Q |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PTEN |
E7* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
E7* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
E7* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
E7* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
E7* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
E7* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
E7* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
E7* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
E7* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
E7* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
E7* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
E7* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
E7* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
E7* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
E7* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
E7* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
E7* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
E7* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
E7* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
E7* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
E7* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
E7* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
E7* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
E7* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
E7* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PDGFRA |
M900L), PDGFRA MUT* (R585K |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PBRM1 |
R710* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
R710* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
R710* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
R710* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
R710* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
A146T |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
A146T |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
A146T |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
A146T |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
A146T |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
A146T |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
A146T |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
A146T |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
A146T |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
A146T |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
A146T |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146T |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
A146T |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
A146T |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
A146T |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
A146T |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
A146T |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146T |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
A146T |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146T |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
A146T |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146T |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146T |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
A146T |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146T |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
A146T |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146T |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
A146T |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
A146T |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
A146T |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
A146T |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
A146T |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
FAT1 |
E1147*), FAT1 MUT (R2597* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
FLT1 |
R224* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
FBXW7 |
E369* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
E369* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
E369* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
E369* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TSC1 |
E813* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
E813* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
E813* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
E813* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
E813* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
E813* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
E813* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TP53 |
R213* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
Y1631H), ROS1 MUT* (E2201* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
Y1631H), ROS1 MUT* (E2201* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
Y1631H), ROS1 MUT* (E2201* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
Y1631H), ROS1 MUT* (E2201* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
Y1631H), ROS1 MUT* (E2201* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S3643R), MLL MUT* (L2037I), MLL MUT* (V1443A), MLL MUT* (R173* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK1 |
D109Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
D109Y |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
D109Y |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
D109Y |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
BCOR |
S214* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
TP53 |
R248W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12C |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12C |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12C |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12C |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12C |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12C |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12C |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12C |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12C |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12C |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12C |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12C |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12C |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61H |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61H |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61H |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61H |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61H |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61H |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61H |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61H |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61H |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61H |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61H |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61H |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61H |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61H |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
P278R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P278R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P278R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P278R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P278R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P278R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P278R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P278R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P278R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
H1926Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
H1926Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
H1926Y |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
H1926Y |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
H1926Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ATR |
Q39* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
Q39* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
Q39* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
TP53 |
A138V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A138V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A138V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A138V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A138V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A138V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A138V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A138V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A138V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A138V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A138V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A138V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
splice_donor_variant |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
splice_donor_variant |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
splice_donor_variant |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_donor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
splice_donor_variant |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_donor_variant |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
N267D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
N267D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
N267D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
N267D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
N267D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CHEK2 |
Q358* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
CHEK2 |
Q358* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
SMARCA4 |
R381* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
R381* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
R381* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
R381* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
R381* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
PTPRD |
E1682* |
Complete Match |
IGF1R inhibitor |
Responsive |
S |
Case report |
TP53 |
C176G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
M2255I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
M2255I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
D259V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D259V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D259V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D259V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D259V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D259V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D259V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D259V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D259V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D259V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D259V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D259V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
A140T |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
A140T |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
R282W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R282W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R282W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R282W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R282W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R282W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R282W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R282W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R282W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G469A |
Complete Match |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
G469A |
Complete Match |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A), BRAF MUT (G469* |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G469A), BRAF MUT (G469* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G469A), BRAF MUT (G469* |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
R273C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
H1097R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
CDKN2A |
E33* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E33* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E33* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E33* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E33* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E33* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E33* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E33* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
BCR |
V590M |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
V590M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
V590M |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
V590M |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
V590M |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
V590M |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
NTRK1 |
H151Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
H151Q |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
H151Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
H151Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NOTCH1 |
G2126A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2126A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
I300V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BCR |
H184Q |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
H184Q |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
H184Q |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
H184Q |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
H184Q |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
H184Q |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ROS1 |
Y1593F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
Y1593F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
Y1593F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
Y1593F |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
Y1593F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB4 |
R47* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
R47* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
R47* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PDGFRA |
S643Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
TP53 |
R156C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R156C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R156C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R156C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R156C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R156C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R156C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R156C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R156C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R156C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R156C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R156C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
DNMT3A |
splice_donor_variant |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NOTCH1 |
G49C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G49C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BCR |
M998I |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
M998I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
M998I |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
M998I |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
M998I |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
M998I |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ROS1 |
A87T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A87T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A87T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A87T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A87T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
Q331* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q331* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q331* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q331* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q331* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q331* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q331* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q331* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q331* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q331* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q331* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q331* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q331* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q331* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q331* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
S341L |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
JAK2 |
G276A |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
P151S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P151S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P151S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P151S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P151S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P151S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P151S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P151S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P151S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
R1719Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
H83Y |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
H83Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
H83Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
H83Y |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
H83Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
H83Y |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
H83Y |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
H83Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
M246V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M246V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M246V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M246V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M246V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M246V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M246V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M246V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M246V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M246V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
T1379M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T1379M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
K132M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
S795F |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
Q144P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q144P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q144P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q144P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q144P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q144P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q144P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q144P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q144P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q144P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q144P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q144P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q144P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q144P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q144P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
R132* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
Y220C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y220C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y220C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y220C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y220C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y220C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y220C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H214R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H214R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H214R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H214R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H214R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H214R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H214R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H214R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H214R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H214R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H214R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H214R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H214R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H214R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H214R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R249S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R249S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R249S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R249S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R249S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R249S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R249S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R249S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ABL1 |
V268L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
V268L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V268L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
V268L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V268L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
V268L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
M133K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M133K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M133K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M133K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M133K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M133K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M133K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M133K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M133K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M133K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
V600E |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
V600E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
V600E |
Complete Match |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600E |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600E |
Complete Match |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600E |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
V600E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
V600E |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
V600E |
Complete Match |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
V600E |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600E |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
V600E |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600E |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
V600E |
Complete Match |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
V600E |
Complete Match |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600E |
Complete Match |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600E |
Complete Match |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600E |
Complete Match |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
V600E |
Complete Match |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
V600E |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600E |
Complete Match |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
V600E |
Complete Match |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600E |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
V600E |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
V600E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600E |
Complete Match |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
V600E |
Complete Match |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600E |
Complete Match |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
V600E |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
V600E |
Complete Match |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
V600E |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600E |
Complete Match |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
V600E |
Complete Match |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
V600E |
Complete Match |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
V600E |
Complete Match |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600E |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
V600E |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
V600E |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
V600E |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
V600E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FBXW7 |
R479Q |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R479Q |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R479Q |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R479Q |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
ESR1 |
A148T |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
JAK2 |
D894G |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
E51* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E51* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E51* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E51* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E51* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E51* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E51* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E51* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E51* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E51* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E51* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E51* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E51* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E51* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E51* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
intron_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
intron_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
Q192* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q192* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q192* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q192* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q192* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q192* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q192* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q192* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q192* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q192* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q192* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q192* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q192* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q192* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q192* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
splice_acceptor_variant |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_acceptor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_acceptor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
splice_acceptor_variant |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_acceptor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_acceptor_variant |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_acceptor_variant |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_acceptor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
S215I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S215I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S215I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S215I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S215I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S215I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S215I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S215I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S215I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S215I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
Y129* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Y129* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Y129* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
Y129* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Y129* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Y129* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Y129* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Y129* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
BCR |
T634M |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
T634M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
T634M |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
T634M |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
T634M |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
T634M |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
RAF1 |
T310A |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
T310A |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
T310A |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
CDKN2A |
W110* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
W110* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
W110* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
W110* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
W110* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
W110* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
W110* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
W110* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
G101W |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G101W |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G101W |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
G101W |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G101W |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G101W |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G101W |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G101W |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
splice_acceptor_variant |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
splice_acceptor_variant |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
splice_acceptor_variant |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
splice_acceptor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
splice_acceptor_variant |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
splice_acceptor_variant |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
splice_acceptor_variant |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
splice_acceptor_variant |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_acceptor_variant |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
K403R |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
K403R |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
K403R |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
C135* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
R58* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R58* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R58* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R58* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R58* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R58* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R58* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R58* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NF1 |
splice_donor_variant |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
splice_donor_variant |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_donor_variant |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
splice_donor_variant |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
splice_donor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_donor_variant |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
STK11 |
splice_donor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
splice_donor_variant |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
splice_donor_variant |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
splice_donor_variant |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
splice_donor_variant |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
splice_donor_variant |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
splice_donor_variant |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
TP53 |
H179R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
R80* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R80* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R80* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R80* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R80* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R80* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R80* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R80* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
G266E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G266E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G266E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G266E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G266E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G266E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G266E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G266E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G266E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
I2304T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
P1282S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
P1282S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
P1282S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
P1282S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P1282S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
RB1 |
R320* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R320* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R320* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R320* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R320* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R320* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R320* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NOTCH1 |
R2313Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R2313Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12A |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12A |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12A |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12A |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12A |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12A |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12A |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12A |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12A |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12A |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12A |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12A |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12A |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12A |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12A |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12A |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12A |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
FBXW7 |
R465C |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R465C |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R465C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R465C |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
R273S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
R582W |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R582W |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R582W |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P307T |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
JAK2 |
N646H |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
BRCA2 |
R2336H |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
R2336H |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R2336H |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
R2336H |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
R2336H |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
R2336H |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
R2336H |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
R2336H |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R2336H |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R2336H |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2336H |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2336H |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2336H |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R2336H |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
R337L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R337L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R337L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R337L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R337L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R337L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R337L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R337L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R337L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R337L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V172D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V172D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V172D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V172D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V172D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V172D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V172D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V172D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V172D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V172D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V172D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V172D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V172D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V172D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V172D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
I803M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
I803M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I803M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
I803M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I803M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I803M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I803M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I803M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I803M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RB1 |
splice_donor_variant |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
splice_donor_variant |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
splice_donor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
splice_donor_variant |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
splice_donor_variant |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
splice_donor_variant |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
splice_donor_variant |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
SF3B1 |
K741E |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
NTRK3 |
N392S |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N392S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N392S |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
P2300S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BCOR |
E401* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
Y1671* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Y1671* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G245S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G245S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G245S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G245S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G245S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G245S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G245S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G245S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
N2050S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N2050S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
L130P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L130P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L130P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L130P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L130P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L130P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L130P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L130P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L130P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
A105V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
JAK2 |
I136L |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
SMARCB1 |
Y248* |
Complete Match |
HDAC inhibitor |
Responsive |
MRT |
Pre-clinical |
SMARCB1 |
Y248* |
Complete Match |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
SMARCB1 |
Y248* |
Different Alteration |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
BRD4 |
P311A |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
G106R |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G106R |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G106R |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G106R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
C135R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
CdsStartSNV |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
MET |
N375D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
FAT1 |
splice_donor_variant |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
CDKN1B |
splice_acceptor_variant |
Complete Match |
CDK2/4 inhibitor |
Responsive |
CANCER |
Pre-clinical |
CDKN1B |
splice_acceptor_variant |
Different Alteration |
CDK2/4 inhibitor |
Responsive |
CANCER |
Pre-clinical |
MET |
S691*), MET MUT* (IntronicBlockSubstitution |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH1 |
G2345C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2345C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
K125E), ERBB4 MUT* (K137R), ERBB4 MUT* (intron_variant |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
intron_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
intron_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ALK |
T1211A |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
T1211A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
T1211A |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
T1211A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
T1211A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
T1211A |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
T1211A |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
T1211A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
T1211A |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
T1211A |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
T1211A |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
T1211A |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
T1211A |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
T1211A |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
T1211A |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
T1211A |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
T1211A |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
T1211A |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
T1211A |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
I348T |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
I348T |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
I348T |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
I348T |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
I348T |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
I348T |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
I348T |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
I348T |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y336H), PTEN MUT (K267R), PTEN MUT (Y174C), PTEN MUT (R142G), PTEN MUT (A34S |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PDGFRA |
E571E), PDGFRA MUT* (E571K), PDGFRA MUT* (I562V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
M541I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
M541I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
M541I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
M541I |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
M541I |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
M541I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
M541I |
Different Mutation |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
M541I |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
M541I |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
M541I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
M541I |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
M541I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
M541I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
M541I |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
M541I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
M541I |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
M541I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
M541I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
M541I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
FGFR2 |
C555Y), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
C555Y), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant), FGFR2 MUT* (intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant), RET MUT* (D933G |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
MET |
K1262R), MET MUT* (Y1252C), MET MUT* (F1218L), MET MUT* (K1208K), MET MUT* (K1208R), MET MUT* (I1123V), MET MUT* (intron_variant), MET MUT* (T1024A), MET MUT* (V370A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
BRAF |
K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
K439K), BRAF MUT* (R443R), BRAF MUT* (D448G), BRAF MUT* (intron_variant |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
GNAQ |
Q209R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
CM |
Early trials |
GNAQ |
Q209R |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
GNAQ |
Q209R |
Complete Match |
PKC inhibitor |
Responsive |
CM |
Pre-clinical |
GNAQ |
Q209R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
EGFR |
N103K |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
N103K |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
POLE |
W1624* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
POLE |
W1624* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
COREAD |
Case report |
POLE |
W1624* |
Different Mutation |
PD1 Ab inhibitor |
Responsive |
G, ED |
Case report |
POLE |
W1624* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
CDKN2B |
splice_donor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
G, CANCER |
Pre-clinical |
CDKN2B |
splice_donor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
TP53 |
Y234N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y234N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y234N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y234N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y234N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y234N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y234N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y234N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y234N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y234N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
Q2386R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q2386R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
S341* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
S341* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
S341* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
T211I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T211I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T211I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T211I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T211I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T211I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T211I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T211I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T211I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T211I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T211I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T211I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T211I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T211I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T211I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F134L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F134L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F134L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F134L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F134L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F134L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F134L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F134L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F134L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F134L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
H1047R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
H1047R |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047R |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047R |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
H1047R |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047R |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
H1047R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
H1047R |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ROS1 |
L1620F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
L1620F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
L1620F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
L1620F |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
L1620F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
EGFR |
L861P |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
L861P |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
L861P |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
L861P |
Complete Match |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L861P |
Complete Match |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L861P |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
L861P |
Complete Match |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Complete Match |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
L861P |
Complete Match |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
L861P |
Complete Match |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
L861P |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
L861P |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
L861P |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
L861P |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
L861P |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
L861P |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L861P |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
L861P |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
L861P |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
L861P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
L861P |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
L861P |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L861P |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
L861P |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
L861P |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L861P |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
L861P |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
L861P |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L861P |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
L861P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
L861P |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
L861P |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
L861P |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
L861P |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
L861P |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
L861P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
L861P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
L861P |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
L861P |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
L861P |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
L861P |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
L861P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
L861P |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
L861P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L861P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
IDH1 |
R132C |
Complete Match |
Venetoclax (BCL2 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132C |
Complete Match |
IDH1 inhibitor |
Responsive |
AML |
Early trials |
IDH1 |
R132C |
Complete Match |
AG-120 (IDH1 inhibitor) |
Responsive |
G |
Early trials |
IDH1 |
R132C |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CH |
Early trials |
IDH1 |
R132C |
Complete Match |
Ivosidenib (IDH1 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132C |
Complete Match |
BCL2 inhibitor |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132C |
Complete Match |
BCL2 inhibitor (BCL2 inhibitor) |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132C |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
BT |
Pre-clinical |
IDH1 |
R132C |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
PIK3CA |
E545K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E545K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E545K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E545K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E545K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
FBXW7 |
R465L |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R465L |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R465L |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R465L |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
PTEN |
R130Q), ERBB2 MUT (R678Q |
Different Alteration |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
ERBB2 |
R678Q |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
R678Q |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
R678Q |
Different Mutation |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
R678Q |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
R678Q |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
R678Q |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
R678Q |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
R678Q |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
R678Q |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
R678Q |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
R678Q |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678Q |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
R678Q |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
R678Q |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
R678Q |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
R678Q |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
PTEN |
R130Q |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R130Q |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R130Q |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
R130Q |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
R130Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
R130Q |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R130Q |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R130Q |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R130Q |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
R130Q |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R130Q |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R130Q |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
R130Q |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R130Q |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R130Q |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R130Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
R130Q |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R130Q |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R130Q |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R130Q |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R130Q |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R130Q |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R130Q |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R130Q |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R130Q |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
L194R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L194R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L194R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L194R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L194R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L194R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L194R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L194R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L194R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L194R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
intron_variant), EGFR MUT* (intron_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
intron_variant), EGFR MUT* (intron_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
MET |
F389L), MET MUT* (K380K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
R282Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R282Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R282Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R282Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R282Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R282Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R282Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R282Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R282Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R156P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R156P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R156P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R156P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R156P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R156P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R156P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R156P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R156P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R156P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R156P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R156P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
L684L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
L684L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
L684L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
I195S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I195S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I195S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I195S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I195S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I195S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I195S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I195S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I195S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
T140A |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
C176Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
P114R |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P114R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P114R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
P114R |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P114R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P114R |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P114R |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P114R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CTNNB1 |
T41A |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
T41A |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
PTEN |
F271S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
F271S |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
F271S |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
F271S |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
F271S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
F271S |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
F271S |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
F271S |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
F271S |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
F271S |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
F271S |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
F271S |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
F271S |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
F271S |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
F271S |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
F271S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
F271S |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
F271S |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
F271S |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
F271S |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
F271S |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
F271S |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
F271S |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
F271S |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
F271S |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
Q136* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q136* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q136* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q136* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q136* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q136* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q136* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q136* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q136* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q136* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q136* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q136* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
D350G), PIK3CA MUT (R349Q |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
BRAF |
intron_variant |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
intron_variant |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
intron_variant |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
intron_variant |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
KRAS |
G13D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G13D |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G13D |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G13D |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G13D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G13D |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G13D |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G13D |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13D |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G13D |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13D |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G13D |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13D |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G13D |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G13D |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G13D |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G13D |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G13D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13D |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G13D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13D |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G13D |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13D |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13D |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G13D |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13D |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G13D |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13D |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G13D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13D |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G13D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G13D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G13D |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
G266V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G266V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G266V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G266V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G266V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G266V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G266V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G266V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G266V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
P401T |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P401T |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P401T |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
KMT2A |
P3433T |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3433T |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3433T |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3433T |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3433T |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3433T |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
AKT3 |
S210Y |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61R |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61R |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61R |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61R |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61R |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61R |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61R |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61R |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61R |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61R |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61R |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NOTCH1 |
R2372Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R2372Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
V274F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V274F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V274F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V274F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V274F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V274F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V274F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V274F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V274F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V274F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
S462* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S462* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S462* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S462* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S462* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S462* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
Q1970* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q1970* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q1970* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q1970* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1970* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1970* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1970* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q1970* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1970* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1970* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1970* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1970* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1970* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
KRAS |
G13H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G13H |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G13H |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G13H |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G13H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G13H |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13H |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G13H |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G13H |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13H |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G13H |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13H |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G13H |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13H |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G13H |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G13H |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G13H |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G13H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G13H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13H |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G13H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13H |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G13H |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13H |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13H |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G13H |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13H |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G13H |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13H |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G13H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13H |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G13H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G13H |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G13H |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
PBRM1 |
Y1167* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
Y1167* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
Y1167* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
Y1167* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Y1167* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G626S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G626S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G626S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G626S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G626S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G626S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
GNAS |
R201H |
Complete Match |
JAK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q435* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q435* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q435* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q435* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
R1121T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1121T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1121T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1121T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1121T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRD4 |
T195M |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
S127F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S127F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S127F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S127F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S127F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S127F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S127F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S127F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S127F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3R1 |
splice_acceptor_variant |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
splice_acceptor_variant |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61L |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61L |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61L |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61L |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61L |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61L |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61L |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61L |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61L |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61L |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61L |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61L |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61L |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61L |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61L |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61L |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61L |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61L |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61L |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61L |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61L |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61L |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61L |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61L |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61L |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
L257R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L257R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L257R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L257R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L257R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L257R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L257R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L257R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L257R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L257R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E286K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E286K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E286K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E286K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E286K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E286K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E286K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BCR |
A102T |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
A102T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
A102T |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
A102T |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
A102T |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
A102T |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L302F |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
L302F |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L302F |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
L302F |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L302F |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
L302F |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
R282G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R282G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R282G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R282G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R282G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R282G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R282G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R282G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R282G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
P1112L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1112L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P1112L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P1112L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P1112L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1112L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1112L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P1112L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1112L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1112L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P1112L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P1112L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P1112L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1112L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1112L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1112L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P1112L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P1112L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1112L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
R1721* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1721* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1721* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1721* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RB1 |
R445* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R445* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R445* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R445* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R445* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R445* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R445* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
GNAS |
R201C |
Complete Match |
JAK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
L1872V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
L1872V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
L1872V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
L1872V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
L1872V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V272L), TP53 MUT (R158C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272L), TP53 MUT (R158C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ABL1 |
G634C |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G634C |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G634C |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G634C |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G634C |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G634C |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
E271K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E271K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E271K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E271K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E271K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E271K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E271K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E271K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E271K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E271K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E271K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E271K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
intron_variant |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
intron_variant |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
intron_variant |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61H), KRAS MUT (E63D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61H), KRAS MUT (E63D |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61H), KRAS MUT (E63D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61H), KRAS MUT (E63D |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
SETD2 |
K141* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
K141* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
U2AF1 |
Q157R |
Complete Match |
FLT3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
G54C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G54C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
STK11 |
Y246* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Y246* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y246* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Y246* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y246* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y246* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y246* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Y246*), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y246*), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y246*), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
ATM |
R447* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R447* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R447* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R447* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R447* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R447* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R447* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R447* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R447* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R447* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R447* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R447* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R447* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
PIK3CA |
E545G |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E545G |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545G |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545G |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E545G |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545G |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E545G |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E545G |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
NOTCH1 |
A950V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A950V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
U2AF1 |
S34F |
Complete Match |
FLT3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
splice_donor_variant |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NTRK1 |
A500P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
A500P |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
A500P |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
A500P |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
G266R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G266R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G266R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G266R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G266R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G266R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G266R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G266R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G266R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ABL1 |
intron_variant |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
intron_variant |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
intron_variant |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
intron_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
intron_variant |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
intron_variant |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
MSH2 |
E561* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
E561* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
KMT2A |
T2233I |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
T2233I |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
T2233I |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
T2233I |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
T2233I |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
T2233I |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
BRAF |
V765L |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
V765L |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
V765L |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
V765L |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
H193D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H193D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H193D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H193D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H193D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H193D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H193D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H193D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H193D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H193D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
JAK2 |
P279L |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
BRAF |
P318L |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
P318L |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
P318L |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
P318L |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
V157G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V157G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V157G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V157G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V157G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V157G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V157G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V157G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V157G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V157G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V157G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V157G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
V1115M |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1311Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1311Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1311Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1311Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1311Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
V274G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V274G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V274G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V274G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V274G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V274G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V274G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V274G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V274G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V274G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
A147S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
R333C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R333C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R333C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R333C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R333C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R333C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R333C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R333C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R333C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R333C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R333C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R333C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R333C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R333C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R333C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RAF1 |
V312M |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
V312M |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
V312M |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
MSH2 |
A636P), MSH2 MUT (G208* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
A636P), MSH2 MUT (G208* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
KMT2A |
S2159F |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S2159F |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S2159F |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S2159F |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S2159F |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S2159F |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NRAS |
G13V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
G13V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
G13V |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
G13V |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
G13V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
G13V |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
G13V |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
G13V |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
G13V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
G13V |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
G13V |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
G13V |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
G13V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
G13V |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
JAK2 |
G963V |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
CTNNB1 |
S33C |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S33C |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
CTNNB1 |
D32H |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
D32H |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
PDGFRA |
D1071N), PDGFRA MUT* (D1069G |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
TP53 |
V157D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V157D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V157D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V157D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V157D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V157D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V157D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V157D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V157D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V157D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V157D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V157D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
P35H |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ABL1 |
D739N), ABL1 MUT* (D207N |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
D739N), ABL1 MUT* (D207N |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
D739N), ABL1 MUT* (D207N |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
D739N), ABL1 MUT* (D207N |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
D739N), ABL1 MUT* (D207N |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
D739N), ABL1 MUT* (D207N |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
JAK2 |
R234H |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
SMARCA4 |
splice_acceptor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
splice_acceptor_variant |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
splice_acceptor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
splice_acceptor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
splice_acceptor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
PDGFRA |
R481S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
FANCC |
splice_donor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
FANCC |
splice_donor_variant |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
FLT1 |
splice_acceptor_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
FGFR2 |
P808S |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
P808S |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
D281N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D281N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D281N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D281N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D281N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D281N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D281N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D281N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D281N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
splice_acceptor_variant |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
splice_acceptor_variant |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
splice_acceptor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
splice_acceptor_variant |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
splice_acceptor_variant |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
splice_acceptor_variant |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
splice_acceptor_variant |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
CDKN2A |
G45D |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G45D |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G45D |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
G45D |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G45D |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G45D |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G45D |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G45D |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2A |
V1304I |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
V1304I |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
V1304I |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
V1304I |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
V1304I |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
V1304I |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
R1627H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1627H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
G319D |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
A246V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
A246V |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
A246V |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
A246V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
VHL |
G114D |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
CDKN2A |
D108Y |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D108Y |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108Y |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108Y |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
JAK2 |
P796T |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
K132* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PTEN |
Q87* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Q87* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Q87* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Q87* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Q87* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Q87* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Q87* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Q87* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Q87* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Q87* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Q87* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Q87* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Q87* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Q87* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Q87* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Q87* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Q87* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Q87* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Q87* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Q87* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Q87* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Q87* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Q87* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Q87* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Q87* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
CDH1 |
splice_acceptor_variant |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ATM |
W57* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
W57* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
W57* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
W57* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
W57* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
W57* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
W57* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
W57* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
W57* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
W57* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
W57* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
W57* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
W57* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
NTRK1 |
S146L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
S146L |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
S146L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
S146L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
Y205D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M237K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M237K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M237K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M237K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M237K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M237K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M237K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M237K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M237K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M237K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
Y633H |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
Y633H |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
Y633H |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
Y633H |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
E258D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E258D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E258D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E258D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E258D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E258D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E258D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E258D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E258D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
S301C |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
P278S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P278S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P278S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P278S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P278S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P278S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P278S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P278S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P278S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S241F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S241F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S241F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S241F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S241F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S241F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S241F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S241F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S241F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S241F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y163C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y163C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y163C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y163C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y163C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y163C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y163C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y163C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y163C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y163C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
P1039Q |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
P1039Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P1039Q |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
P1039Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P1039Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P1039Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P1039Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P1039Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P1039Q |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRD4 |
A38D |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
R156H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R156H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R156H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R156H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R156H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R156H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R156H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R156H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R156H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R156H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R156H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R156H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R156H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
G221A |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G221A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G221A |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G221A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G221A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G221A |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G221A |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G221A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G221A |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G221A |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G221A |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G221A |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G221A |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G221A |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G221A |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G221A |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G221A |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G221A |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G221A |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PDGFRA |
V10I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
BRCA2 |
K944* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
K944* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K944* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
K944* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
K944* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
K944* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
K944* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
K944* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K944* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K944* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K944* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K944* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
K944* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K944* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ERBB4 |
S1124G |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
R176Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R176Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CTNNB1 |
D32Y |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
D32Y |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
KMT2A |
N1499H |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
N1499H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
N1499H |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
N1499H |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
N1499H |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
N1499H |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
E1958* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1958* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1958* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1958* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
F901L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
F901L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
F901L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
F901L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
F901L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
R273L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
R1722* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1722* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1722* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1722* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C275Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C275Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C275Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C275Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C275Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C275Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C275Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C275Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TSC2 |
W1194* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
W1194* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
W1194* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
W1194* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
W1194* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
W1194* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
W1194* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G13V |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G13V |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G13V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G13V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G13V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G13V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G13V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G13V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G13V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G13V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G13V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G13V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G13V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G13V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G13V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G13V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G13V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G13V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G13V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G13V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G13V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
ALK |
V569G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V569G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
V569G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
V569G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
V569G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V569G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V569G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
V569G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V569G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V569G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
V569G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
V569G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V569G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V569G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V569G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V569G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
V569G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
V569G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V569G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P1028S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
P1028S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
P1028S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
P1028S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P1028S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRAF |
3-UTRSNV |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
3-UTRSNV |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
3-UTRSNV |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
3-UTRSNV |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
NOTCH2 |
A3F |
Different Mutation |
Mk-0752 (Gamma secretase inhibitor) |
Responsive |
ALL, AML, BRCA |
Early trials |
NOTCH2 |
A3F |
Different Mutation |
OMP-59R5 (NOTCH2 inhibitor) |
Responsive |
SOLID |
Early trials |
NOTCH2 |
A3F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
A459S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A459S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A459S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A459S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A459S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
L767H |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
L767H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
L767H |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
L767H |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
L767H |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
L767H |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
Y454* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y454* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y454* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y454* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E258G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E258G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E258G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E258G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E258G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E258G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E258G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E258G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
splice_acceptor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
splice_acceptor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
Q144* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q144* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q144* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q144* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q144* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q144* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q144* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q144* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q144* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q144* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q144* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q144* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q144* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q144* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q144* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
L14F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
ARID1A |
E2032* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2032* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2032* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E2032* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E1983* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E1983* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248L), TP53 MUT (E346* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248L), TP53 MUT (E346* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N235D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N235D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N235D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N235D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N235D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N235D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N235D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N235D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N235D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N235D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N235D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N235D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N235D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N235D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N235D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
E222K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E222K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E222K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E222K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E222K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E222K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E222K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E222K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E222K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
PIK3CA |
G118D |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
G118D |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
G118D |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
G118D |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
G118D |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
G118D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
G118D |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
BAP1 |
CdsStartSNV |
Complete Match |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
CdsStartSNV |
Complete Match |
PARP inhibitor |
Responsive |
R, CANCER |
Pre-clinical |
BAP1 |
CdsStartSNV |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
BAP1 |
CdsStartSNV |
Different Alteration |
PARP inhibitor |
Responsive |
CANCER, R |
Pre-clinical |
BAP1 |
CdsStartSNV |
Different Alteration |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
CdsStartSNV |
Different Alteration |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N239D), TP53 MUT (E294* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239D), TP53 MUT (E294* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281_T284delDRRT |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D281_T284delDRRT |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D281_T284delDRRT |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D281_T284delDRRT |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D281_T284delDRRT |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281_T284delDRRT |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D281_T284delDRRT |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D281_T284delDRRT |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281_T284delDRRT |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
P992L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
P992L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P992L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
P992L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P992L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P992L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P992L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P992L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P992L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RET |
D1031N |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
D1031N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D1031N |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
D1031N |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D1031N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D1031N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D1031N |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D1031N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D1031N |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
PDGFRA |
R979C |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
TP53 |
G199* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G199* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G199* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G199* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G199* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G199* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G199* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G199* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G199* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G199* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G199* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G199* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G199* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G199* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G199* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
splice_acceptor_variant), ATM MUT (E2479* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
V216G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V216G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V216G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V216G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V216G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V216G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V216G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V216G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V216G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V216G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN1A |
W49* |
Complete Match |
CDK2/4 inhibitor |
Responsive |
CANCER |
Pre-clinical |
CDKN1A |
W49* |
Different Alteration |
CDK2/4 inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
E138* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
E138* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E138* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
E138* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
E138* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
E138* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E138* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E138* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
E138* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
E138* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E138* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E138* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E138*), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
E138*), KRAS MUT (G12D |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
E138*), KRAS MUT (G12D |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
E138*), KRAS MUT (G12D |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
TP53 |
C242S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P190L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P190L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P190L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P190L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P190L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P190L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P190L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P190L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P190L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P190L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E171* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E171* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E171* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E171* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E171* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E171* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E171* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E171* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E171* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E171* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E171* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E171* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E171* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E171* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E171* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
L313I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
L313I |
Different Mutation |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
L313I |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
L313I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
L313I |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
L313I |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
L313I |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
L313I |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
L313I |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
L313I |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
L313I |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
L313I |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
L313I |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
L313I |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
L313I |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
L313I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
L313I |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
ALK |
R1061Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1061Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1061Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1061Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1061Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1061Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1061Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1061Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1061Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1061Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1061Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1061Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1061Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1061Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1061Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1061Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1061Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1061Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1061Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ERBB4 |
C824Y |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
R1875* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R1875* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R1875* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R1875* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R1875* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R1875* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R1875* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R1875* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R1875* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R1875* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R1875* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R1875* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R1875* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
NTRK1 |
E223Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
E223Q |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
E223Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
E223Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ERBB4 |
G516V |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FGFR2 |
P23H |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
P23H |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
NOTCH2 |
A1154V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ESR1 |
R243H |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
SETD2 |
R1492* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
R1492* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I232N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I232N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I232N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I232N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I232N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I232N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I232N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I232N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I232N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I232N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
DNMT3A |
R882C |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NTRK1 |
A425G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
A425G |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
A425G |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
A425G |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (D208V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248Q), TP53 MUT (D208V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (D208V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L130H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L130H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L130H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L130H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L130H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L130H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L130H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L130H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L257P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L257P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L257P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L257P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L257P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L257P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L257P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L257P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L257P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L257P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
R348Q |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R348Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R348Q |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R348Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R348Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R348Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R348Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R348Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R348Q |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ROS1 |
T2195S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T2195S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T2195S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T2195S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T2195S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
AKT3 |
R270H |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
V1254A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
V1254A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
V1254A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
V1254A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V1254A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
MET |
T495I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
ERBB4 |
D518G |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
H179D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
E26* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E26* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E26* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E26* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E26* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E26* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E26* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E26* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
EGFR |
A289V |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
A289V |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
A289V |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
A289V |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289V |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289V |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
A289V |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
A289V |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
A289V |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
A289V |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
A289V |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
A289V |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
A289V |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289V |
Complete Match |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
A289V |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289V |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
A289V |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
A289V |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
A289V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
A289V |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
A289V |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A289V |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
A289V |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
A289V |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289V |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
A289V |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
A289V |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289V |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
A289V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
A289V |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
A289V |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
A289V |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
A289V |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
A289V |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
A289V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
A289V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
A289V |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
A289V |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
A289V |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
A289V |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
A289V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
A289V |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
A289V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A289V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
C242F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
G7D |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
G7D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G7D |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
G7D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G7D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G7D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G7D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G7D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G7D |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
CTNNB1 |
S37C |
Complete Match |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S37C |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
TP53 |
N239S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N239S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N239S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N239S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N239S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N239S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N239S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N239S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N239S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N239S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
T298S |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
D391N |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D391N |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D391N |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D391N |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
NTRK1 |
V106M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
V106M |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
V106M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
V106M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
SF3B1 |
E622D |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
JAK2 |
R1113H |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
V203E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V203E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V203E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V203E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V203E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V203E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V203E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V203E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V203E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V203E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V203E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V203E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V203E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V203E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V203E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R306* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R306* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R306* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R306* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R306* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R306* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R306* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R306* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R306* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R306* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R306* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R306* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R306* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R306* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R306* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
D489E |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
D489E |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D489E |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
D489E |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D489E |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D489E |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D489E |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D489E |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D489E |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
V272M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V272M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V272M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V272M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V272M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V272M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V272M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V272M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V272M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
E542K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E542K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E542K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E542K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E542K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E542K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E542K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
R342* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R342* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R342* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R342* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R342* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R342* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R342* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R342* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R342* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R342* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R342* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R342* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R342* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R342* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R342* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
V2054G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
V2054G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
V2054G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
V2054G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V2054G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ARID1A |
Y1211*fs*1 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y1211*fs*1 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y1211*fs*1 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y1211*fs*1 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A161T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A161T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A161T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A161T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A161T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A161T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A161T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A161T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A161T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A161T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E224D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E224D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E224D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E224D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E224D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E224D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E224D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E224D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E224D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E224D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E224D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E224D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E224D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E224D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E224D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
IntronicBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
IntronicBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
IntronicBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12F |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12F |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12F |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12F |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12F |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12F |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12F |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12F |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12F |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12F |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12F |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12F |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12F |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12F |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12F |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12F |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12F |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12F |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12F |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12F |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12F |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12F |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12F |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12F |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12F |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12F |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12F |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12F |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12F |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
W91* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
W91* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
W91* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
W91* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
W91* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
W91* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
W91* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W91* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W91* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
W91* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
W91* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W91* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
W91* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
W91* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
W91* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
JAK2 |
G417S |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
RET |
V223M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V223M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V223M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V223M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V223M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V223M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V223M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V223M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V223M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
Y236C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y236C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y236C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y236C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y236C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y236C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y236C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y236C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y236C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y236C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L257Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L257Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L257Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L257Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L257Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L257Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L257Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L257Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L257Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L257Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
VHL |
G114S |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G469S |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469S |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469S |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469S |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
G469S |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
G469S |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469S |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G469S |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469S |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469S |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G469S |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G469S |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G469S |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G469S |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G469S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G469S |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G469S |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G469S |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469S |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G469S |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G469S |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G469S |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G469S |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G469S |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G469S |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G469S |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
NOTCH1 |
V2529I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V2529I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
M700I |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
M700I |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
M700I |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
P2469S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P2469S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
SRSF2 |
P95H |
Complete Match |
Spliceosome inhibitor |
Responsive |
AML |
Pre-clinical |
FGFR2 |
L258F |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
L258F |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
H193L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H193L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H193L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H193L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H193L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H193L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H193L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H193L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H193L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H193L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
C712* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
C712* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
C712* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
C712* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
C712* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
C712* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
C712* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NOTCH2 |
S2379F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
V172F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V172F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V172F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V172F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V172F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V172F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V172F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V172F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V172F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V172F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V172F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V172F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V172F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V172F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V172F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
A1200V |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1200V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A1200V |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A1200V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A1200V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1200V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1200V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A1200V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1200V |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1200V |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A1200V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A1200V |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A1200V |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1200V |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1200V |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1200V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A1200V |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A1200V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1200V |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
JAK2 |
H608R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
V173G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V173G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V173G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V173G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V173G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V173G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V173G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V173G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V173G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V173G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
S70N |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S70N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S70N |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S70N |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S70N |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S70N |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KMT2A |
G1160S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G1160S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G1160S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G1160S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G1160S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G1160S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ESR1 |
CdsStartSNV |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ERBB4 |
R1112C |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
R110* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R110* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R110* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R110* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R110* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R110* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R110* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R110* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R110* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R110* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R110* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R110* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R110* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
R1446* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1446* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1446* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1446* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
JAK2 |
S523P |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
L145P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L145P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L145P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L145P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L145P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L145P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L145P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L145P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L145P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L145P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L145P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L145P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
A59V |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
MET |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
BRAF |
L485F |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
L485F |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
L485F |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
L485F |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
EGFR |
R671C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R671C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
FGFR3 |
M69V |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
M69V |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
M69V |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
STK11 |
W332* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
W332* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
W332* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
W332* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
W332* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
W332* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
W332* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
W332* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
W332* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
W332* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
W332* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
W332* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
W332*), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
W332*), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
W332*), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
W332*), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
TP53 |
R175G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R175G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RAF1 |
S259Y |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
S259Y |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
S259Y |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
TP53 |
E258K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E258K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E258K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E258K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E258K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E258K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E258K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E258K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E258K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
V126D |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
V126D |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
V126D |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
V126D |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
V126D |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
V126D |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
V126D |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
V126D |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
JAK2 |
G834D |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
CTNNB1 |
S33Y |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S33Y |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
DNMT3A |
R882H |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
E294* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E294* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E294* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E294* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E294* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E294* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E294* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E294* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E294* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E294* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E294* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E294* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E294* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E294* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E294* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E339* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E339* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E339* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E339* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E339* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E339* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E339* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E339* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E339* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E339* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E339* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E339* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E339* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E339* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E339* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
R1276* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1276* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1276* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1276* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y60* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Y60* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y60* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y60* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Y60* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y60* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y60* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y60* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y60* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y60* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y60* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y60* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y60*), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Y60*), KRAS MUT (G12V |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y60*), KRAS MUT (G12V |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y60*), KRAS MUT (G12V |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
TP53 |
V157F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V157F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V157F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V157F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V157F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V157F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V157F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V157F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V157F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V157F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V157F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V157F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V157F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (W110* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NOTCH1 |
V2110E |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V2110E |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
V173L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V173L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V173L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V173L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V173L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V173L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V173L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V173L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V173L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V173L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
R214W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R214W |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R214W |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R214W |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
FGFR3 |
K715K |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
K715K |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
K715K |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
G245V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G245V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G245V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G245V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G245V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G245V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G245V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G245V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G245V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
S2222R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRCA1 |
R1443* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
R1443* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
R1443* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
R1443* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
R1443* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
R1443* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
R1443* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
R1443* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
R1443* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
R1443* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
R1443* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
R1443* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
E285K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E285K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E285K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E285K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E285K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E285K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E285K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E285K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E285K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E285K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E285K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E285K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E285K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E285K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E285K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V216M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V216M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V216M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V216M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V216M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V216M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V216M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V216M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V216M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V216M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S215G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S215G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S215G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S215G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S215G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S215G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S215G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S215G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S215G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S215G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PBRM1 |
E441* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
E441* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
E441* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
E441* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
E441* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TMPRSS2 |
intron_variant |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
intron_variant |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
TP53 |
G244D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G244D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G244D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G244D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G244D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G244D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G244D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G244D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G244D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G244D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
R157H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R157H |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R157H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R157H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NRG1 |
R438H |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
R438H |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ERBB4 |
R544Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
P152L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P152L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P152L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P152L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P152L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P152L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P152L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P152L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P152L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P152L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P152L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P152L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P152L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P152L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P152L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
R519* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDKN2A |
E119Qfs*18 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E119Qfs*18 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E119Qfs*18 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E119Qfs*18 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E119Qfs*18 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E119Qfs*18 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E119Qfs*18 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E119Qfs*18 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
MET |
P4T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
JAK2 |
T7M |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCOR |
Q990* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
TP53 |
G245D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G245D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G245D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G245D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G245D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G245D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G245D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G245D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G245D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
intron_variant |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
D663Y |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D663Y |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D663Y |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D663Y |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
S241C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S241C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S241C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S241C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S241C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S241C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S241C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S241C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S241C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S241C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P250S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P250S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P250S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P250S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P250S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P250S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P250S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P250S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P250S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P250S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P250S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P250S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P250S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P250S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P250S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
V412M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V412M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V412M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V412M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V412M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V412M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V412M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V412M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V412M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NTRK1 |
V710M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
V710M |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
V710M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
V710M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
KMT2A |
R2127* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R2127* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R2127* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R2127* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R2127* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R2127* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
CBL |
C384R |
Complete Match |
JAK inhibitor |
Responsive |
MDPS |
Pre-clinical |
CBL |
C384R |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
MDPS |
Pre-clinical |
TP53 |
R273P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
T542M |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
T542M |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
T542M |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
T542M |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
T542M |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
T542M |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ALK |
E1400D |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E1400D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
E1400D |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
E1400D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
E1400D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E1400D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E1400D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
E1400D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E1400D |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E1400D |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
E1400D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
E1400D |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
E1400D |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E1400D |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E1400D |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E1400D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
E1400D |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
E1400D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E1400D |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
E287* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E287* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E287* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E287* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E287* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E287* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E287* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E287* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E287* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E287* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E287* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E287* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E287* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E287* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E287* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
CdsStopSNV |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
CdsStopSNV |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
CdsStopSNV |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
CdsStopSNV |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FGFR3 |
C545Y |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
C545Y |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
C545Y |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
VHL |
F76Lfs*51 |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
CDKN2A |
splice_donor_variant |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_donor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_donor_variant |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
splice_donor_variant |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_donor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_donor_variant |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_donor_variant |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_donor_variant |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
RAF1 |
R40P |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R40P |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R40P |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NTRK3 |
T269M |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T269M |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T269M |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
S127T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S127T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S127T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S127T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S127T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S127T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S127T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S127T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S127T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
D1151N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
FGFR2 |
R479G |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
R479G |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
BRD4 |
V422I |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
Y327* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y327* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y327* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y327* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y327* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y327* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y327* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y327* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y327* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y327* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y327* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y327* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y327* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y327* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y327* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
G1137A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
SETD2 |
E581* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E581* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TMPRSS2 |
P83L |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
P83L |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
ERBB4 |
T176P |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ERCC2 |
splice_acceptor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ERCC2 |
splice_acceptor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ERCC2 |
splice_acceptor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
EGFR |
E534K), EGFR MUT* (S161N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
E534K), EGFR MUT* (S161N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ATM |
W1750* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
W1750* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
W1750* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
W1750* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
W1750* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
W1750* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
W1750* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
W1750* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
W1750* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
W1750* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
W1750* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
W1750* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
W1750* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
splice_acceptor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
splice_acceptor_variant |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
splice_acceptor_variant |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
T544I), ABL1 MUT* (A102V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
T544I), ABL1 MUT* (A102V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
T544I), ABL1 MUT* (A102V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
T544I), ABL1 MUT* (A102V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
T544I), ABL1 MUT* (A102V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
T544I), ABL1 MUT* (A102V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
SETD2 |
G1231* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
G1231* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
splice_donor_variant |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
splice_donor_variant |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
splice_donor_variant |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
splice_donor_variant |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
splice_donor_variant |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
splice_donor_variant |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
splice_donor_variant |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
splice_donor_variant |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
splice_donor_variant |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
splice_donor_variant |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
splice_donor_variant |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
splice_donor_variant |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
splice_donor_variant |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
splice_donor_variant |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
splice_donor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
splice_donor_variant |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
splice_donor_variant |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
splice_donor_variant |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
splice_donor_variant |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
splice_donor_variant |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
splice_donor_variant |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
splice_donor_variant |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PDGFRA |
S1057F), PDGFRA MUT* (G439D), PDGFRA MUT* (intron_variant), PDGFRA MUT* (G177S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PML |
intron_variant |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
intron_variant |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
intron_variant |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
V555I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
V555I |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
V555I |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
V555I |
Complete Match |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
V555I |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
V555I |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
V555I |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
V555I |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
V555I |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
V555I |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
V555I |
Complete Match |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
V555I |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
V555I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
V555I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
V555I |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
V555I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
V555I |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
V555I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
V555I |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
V555I |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
V555I |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
V555I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
V555I |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
V555I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
V555I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
V555I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
FGFR3 |
P300L), FGFR3 MUT* (D147N |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P300L), FGFR3 MUT* (D147N |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P300L), FGFR3 MUT* (D147N |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TMPRSS2 |
G254D |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
G254D |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
RET |
G1082D |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
G1082D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G1082D |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
G1082D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G1082D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G1082D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G1082D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G1082D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G1082D |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ROS1 |
W119*), ROS1 MUT* (P1454S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
W119*), ROS1 MUT* (P1454S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
W119*), ROS1 MUT* (P1454S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
W119*), ROS1 MUT* (P1454S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
W119*), ROS1 MUT* (P1454S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3791S), MLL MUT* (P2129S), MLL MUT* (P1684S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NF1 |
W2225* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
W2225* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
W2225* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
W2225* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
W2225* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
W2225* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
W2225* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
W2225* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
W2225* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
W2225* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
W2225* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
W2225* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
W2225* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
W2225* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
W2225* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
W2225* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
W2225* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
W2225* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
W2225* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
W2225* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
W2225* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NTRK1 |
G221S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
G221S |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
G221S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G221S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NOTCH2 |
Q2409* |
Complete Match |
Mk-0752 (Gamma secretase inhibitor) |
Responsive |
ALL, AML, BRCA |
Early trials |
NOTCH2 |
Q2409* |
Complete Match |
OMP-59R5 (NOTCH2 inhibitor) |
Responsive |
SOLID |
Early trials |
NOTCH2 |
Q2409*), NOTCH2 MUT* (G1076D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
splice_donor_variant |
Different Mutation |
Gamma secretase inhibitor |
Responsive |
CANCER |
Early trials |
NOTCH1 |
splice_donor_variant |
Different Mutation |
Gamma secretase inhibitor;CDK4 inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_donor_variant |
Different Mutation |
Gamma secretase inhibitor;MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_donor_variant |
Different Mutation |
Gamma secretase inhibitor |
Responsive;Responsive |
ALL |
Early trials;Pre-clinical |
NOTCH1 |
splice_donor_variant |
Different Mutation |
NOTCH1 inhibitor |
Responsive |
ADCC |
Case report |
NOTCH1 |
splice_donor_variant |
Different Mutation |
OMP-52M51 (NOTCH1 inhibitor) |
Responsive |
CANCER |
Early trials |
NOTCH1 |
splice_donor_variant |
Different Mutation |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
splice_donor_variant |
Complete Match |
Gamma secretase inhibitor |
Responsive |
MCL |
Pre-clinical |
NOTCH1 |
splice_donor_variant), NOTCH1 MUT* (P284S), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1072D), NOTCH1 MUT* (V1288A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_donor_variant), NOTCH1 MUT* (P284S), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1072D), NOTCH1 MUT* (V1288A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
A80T), BRD4 MUT* (P760L |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
A404V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
A404V |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
A404V |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
A404V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
BCOR |
Q848* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
STK11 |
R304W |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
R304W |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
R304W |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
R304W |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
R304W |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
R304W |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
R304W |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
R304W |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
R304W |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
R304W |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
R304W |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
R304W |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
FBXW7 |
R278* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R278* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R278* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R278* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
R267W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R267W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R267W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R267W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R267W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R267W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R267W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R267W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R267W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R267W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
P574T |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
W1023* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
W1023* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
W1023* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
W1023* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L265P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L265P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L265P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L265P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L265P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L265P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L265P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L265P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L265P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L265P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L265P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L265P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L265P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L265P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L265P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PTEN |
Y315* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y315* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y315* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y315* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y315* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y315* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y315* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y315* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y315* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y315* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y315* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y315* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y315* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y315* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y315* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y315* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y315* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y315* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y315* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y315* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y315* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y315* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y315* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y315* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y315* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
KMT2D |
R2830* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
PIK3CA |
E545Q |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E545Q |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E545Q |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545Q |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E545Q |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E545Q |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
Y126D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y126D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y126D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y126D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y126D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y126D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y126D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y126D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
V105A |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
V105A |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
V105A |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V105A |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
V105A |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V105A |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
V105A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
V105A |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PTEN |
M270I |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
M270I |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
M270I |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
M270I |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
M270I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
M270I |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
M270I |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
M270I |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
M270I |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
M270I |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
M270I |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
M270I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
M270I |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
M270I |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
M270I |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
M270I |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
M270I |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
M270I |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
M270I |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
M270I |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
M270I |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
M270I |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
M270I |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
M270I |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
M270I |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
FGFR2 |
R447W |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
R447W |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ATM |
E1978* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E1978* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E1978* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E1978* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E1978* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E1978* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E1978* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E1978* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E1978* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E1978* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E1978* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E1978* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E1978* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
V274A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V274A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V274A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V274A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V274A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V274A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V274A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V274A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V274A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V274A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
DNMT3A |
E667* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
FANCA |
E1023* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
E1023* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
AKT3 |
R465Q |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
PDGFRA |
D983H |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PML |
D417H |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
D417H |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
D417H |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
SMARCA4 |
R1189* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
R1189* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
R1189* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
R1189* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
R1189* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
RNF43 |
Q8* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDKN2A |
D108G |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108G |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108G |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D108G |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108G |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108G |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108G |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108G |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E120* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E120* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E120* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E120* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E120* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E120* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E120* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E120* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
ABL1 |
T692M |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
T692M |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
T692M |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
T692M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
T692M |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
T692M |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
E204* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E204* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E204* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E204* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E204* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E204* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E204* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E204* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E204* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E204* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E204* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E204* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E204* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E204* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E204* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
N368D |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
N368D |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
N368D |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
N368D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
A159P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
A87V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A87V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A87V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A87V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A87V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
P151H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P151H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P151H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P151H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P151H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P151H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P151H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P151H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P151H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PALB2 |
Q740* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Q740* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Q740* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q740* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q740* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Q740* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Q740* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q740* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
ARID1A |
Q1473*), ARID1A MUT (E1006* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1473*), ARID1A MUT (E1006* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1473*), ARID1A MUT (E1006* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1473*), ARID1A MUT (E1006* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G701S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G701S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G701S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G701S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G701S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G701S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
PTCH1 |
R1394* |
Complete Match |
Vismodegib (SHH inhibitor) |
Responsive |
BCC, MB |
FDA guidelines |
PTCH1 |
R1394* |
Complete Match |
Foretinib (MET inhibitor) |
Responsive |
MB |
Pre-clinical |
PTCH1 |
R1394* |
Complete Match |
SMO inhibitor |
Responsive |
MB |
Pre-clinical |
TP53 |
Y234C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y234C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y234C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y234C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y234C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y234C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y234C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y234C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y234C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y234C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
Y44* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Y44* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Y44* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
Y44* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Y44* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Y44* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Y44* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Y44* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R58*), CDKN2A MUT (R80* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
RNF43 |
E380* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
FGFR3 |
A150P |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
A150P |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
A150P |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
C238R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ABL1 |
G744Efs*29 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
NCCN guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
NCCN guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CML |
NCCN guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
BCR-ABL inhibitor |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
ALL |
FDA guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Axitinib (VEGFR inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G744Efs*29 |
Different Mutation |
Bosutinib (BCR-ABL inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G744Efs*29 |
Different Mutation |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G744Efs*29 |
Different Mutation |
Crizotinib (ALK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G744Efs*29 |
Different Mutation |
Vandetanib (Pan-TK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G744Efs*29 |
Different Mutation |
Foretinib (MET inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G744Efs*29 |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G744Efs*29 |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G744Efs*29 |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G744Efs*29 |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G744Efs*29 |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G744Efs*29 |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
STK11 |
K44* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
K44* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K44* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
K44* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
K44* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
K44* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K44* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K44* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
K44* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
K44* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K44* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K44* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K44*), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
K44*), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
K44*), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
K44*), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
JAK2 |
I35T |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ARID1A |
S1992* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1992* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1992* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S1992* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NRG1 |
intron_variant |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
intron_variant |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
BRD4 |
S1215P |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRCA2 |
E2663V |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
E2663V |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E2663V |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
E2663V |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
E2663V |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
E2663V |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
E2663V |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
E2663V |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E2663V |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E2663V |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E2663V |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E2663V |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
E2663V |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E2663V |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
NOTCH1 |
G2427S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2427S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
T1057I |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E1366K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E1366K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E1366K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E1366K |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E1366K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB4 |
A17S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
E271V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E271V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E271V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E271V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E271V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E271V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E271V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E271V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E271V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E271V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E271V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E271V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I258T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I258T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I258T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I258T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I258T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q300* |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q300* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Q300* |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Q300* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Q300* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q300* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q300* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Q300* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q300* |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q300* |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Q300* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Q300* |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q300* |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q300* |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q300* |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q300* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Q300* |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Q300* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q300* |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FBXW7 |
Y545C |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
Y545C |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
Y545C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
Y545C |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
Y205F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
R255* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R255* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R255* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R255* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R255* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R255* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R255* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
TP53 |
V272L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V272L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V272L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V272L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V272L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V272L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V272L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V272L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V272L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
G276* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G276* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G276* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
G276* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PML |
S634N |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
S634N |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
S634N |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NOTCH2 |
R1607P |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
R1989* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1989* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1989* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1989* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
G400S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
H193R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H193R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H193R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H193R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H193R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H193R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H193R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H193R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H193R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H193R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H193N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H193N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H193N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H193N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H193N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H193N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H193N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H193N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H193N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H193N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
G13E |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13E |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G13E |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G13E |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G13E |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G13E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G13E |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13E |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G13E |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G13E |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13E |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G13E |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13E |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G13E |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13E |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G13E |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G13E |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G13E |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G13E |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G13E |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13E |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G13E |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13E |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G13E |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13E |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13E |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G13E |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13E |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G13E |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13E |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G13E |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13E |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G13E |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G13E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G13E |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
ERCC6 |
splice_acceptor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
OV |
Pre-clinical |
SF3B1 |
K700E |
Complete Match |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
CTNNB1 |
G34V |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
G34V |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
PML |
R872C |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
R872C |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
R872C |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
ALK |
intron_variant |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
intron_variant |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
intron_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
intron_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
intron_variant |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
intron_variant |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
intron_variant |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
intron_variant |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
intron_variant |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
intron_variant |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
intron_variant |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
SF3B1 |
K666E |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
G816L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
G816L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
G816L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
G816L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
G816L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB4 |
R81* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
R81* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
R81*), ERBB4 MUT* (R95C |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ERBB3 |
G284R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
G284R |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
G284R |
Complete Match |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
G284R |
Complete Match |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB3 |
G284R |
Complete Match |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
G284R |
Complete Match |
ERBB3 mAb inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
G284R |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
APC |
R1450*), APC MUT (R564* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ATM |
E642* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E642* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E642* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E642* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E642* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E642* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E642* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E642* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E642* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E642* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E642* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E642* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E642* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
PIK3R1 |
E458* |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
E458* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
R88Q), PIK3CA MUT (G118D |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
F145C), PTEN MUT (P38S |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
ROS1 |
R1506I), ROS1 MUT* (R2210I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1506I), ROS1 MUT* (R2210I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1506I), ROS1 MUT* (R2210I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1506I), ROS1 MUT* (R2210I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1506I), ROS1 MUT* (R2210I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
RB1 |
E137*), RB1 MUT (E466* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E137*), RB1 MUT (E466* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E137*), RB1 MUT (E466* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E137*), RB1 MUT (E466* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E137*), RB1 MUT (E466* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E137*), RB1 MUT (E466* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E137*), RB1 MUT (E466* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
BCOR |
splice_acceptor_variant |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
JAK2 |
L55Q |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
NOTCH2 |
L775V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PIK3CA |
R108H |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
R108H |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
R108H |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R108H |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
R108H |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
R108H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
R108H |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
CDKN2A |
E69* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E69* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E69* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E69* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E69* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E69* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E69* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E69* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
JAK2 |
N986K |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
TP53 |
E349* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E349* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E349* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E349* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E349* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E349* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E349* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E349* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E349* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E349* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E349* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E349* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E349* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E349* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E349* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TMPRSS2 |
P406S |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
P406S |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
VHL |
V74G |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
ERBB2 |
V842I |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
V842I |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
V842I |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
V842I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
V842I |
Different Mutation |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
V842I |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
V842I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
V842I |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
V842I |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
V842I |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
V842I |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
V842I |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
V842I |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
V842I |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
V842I |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V842I |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
V842I |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
V842I |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
V842I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
V842I |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
TP53 |
I195T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I195T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I195T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I195T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I195T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I195T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I195T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I195T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I195T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
E621K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E621K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E621K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E621K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E621K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E621K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E621K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E621K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E621K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NOTCH1 |
A2452P |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A2452P |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
FGFR2 |
T125S |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
T125S |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ERBB4 |
E1287* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
JAK2 |
H886R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
RB1 |
R467* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R467* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R467* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R467* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R467* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R467* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R467* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
TP53 |
W146* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
W146* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
W146* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
W146* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
W146* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
W146* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
W146* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W146* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W146* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
W146* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
W146* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W146* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
W146* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
W146* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
W146* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
R87P |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R87P |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R87P |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R87P |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R87P |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R87P |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R87P |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R87P |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
C176* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
D153H |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D153H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D153H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D153H |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D153H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D153H |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D153H |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D153H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2A |
S3479A |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S3479A |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S3479A |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S3479A |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S3479A |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S3479A |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KMT2A |
N2484S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
N2484S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
N2484S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
N2484S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
N2484S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
N2484S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TMPRSS2 |
A299T |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
A299T |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
TP53 |
C238F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
Q2292*), SETD2 MUT (Q2329* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q2292*), SETD2 MUT (Q2329* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2A |
V2596A |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
V2596A |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
V2596A |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
V2596A |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
V2596A |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
V2596A |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ERBB4 |
V1134M |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
T155N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T155N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T155N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T155N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T155N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T155N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T155N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T155N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T155N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
K1178* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
K1178* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
K1178* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
K1178* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
K1178* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
K1178* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
K1178* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
K1178* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
K1178* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
K1178* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
K1178* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
K1178* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
K1178* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
I251F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I251F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I251F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I251F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I251F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I251F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I251F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I251F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I251F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I251F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I251F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I251F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I251F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I251F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I251F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ABL1 |
S915L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
S915L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
S915L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
S915L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
S915L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
S915L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ATM |
K2756* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
K2756* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
K2756* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
K2756* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
K2756* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
K2756* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
K2756* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
K2756* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
K2756* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
K2756* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
K2756* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
K2756* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
K2756* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
Q566* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q566* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q566* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q566* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1733* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1733* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1733* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1733* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
EGFR |
P1101L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
P1101L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ABL1 |
R819W |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R819W |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R819W |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R819W |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R819W |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R819W |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
R249W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R249W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R249W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R249W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R249W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R249W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R249W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R249W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R249W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
R2095H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R2095H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (H178P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (H178P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
Q50P |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50P |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50P |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
Q50P |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50P |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50P |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50P |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50P |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
MSH2 |
CdsStartSNV |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
CdsStartSNV |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
TP53 |
C275R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C275R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C275R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C275R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C275R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C275R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C275R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C275R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C275R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
T311M |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ALK |
M1615T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1615T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
M1615T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
M1615T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
M1615T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M1615T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M1615T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
M1615T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M1615T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M1615T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
M1615T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
M1615T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
M1615T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1615T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1615T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M1615T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
M1615T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
M1615T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M1615T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TMPRSS2 |
E426A |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
E426A |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Q762* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Q762* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q762* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q762* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q762* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q762* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q762* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NOTCH2 |
K974R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
A149V |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A149V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A149V |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A149V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A149V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A149V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A149V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A149V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A149V |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A149V |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A149V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A149V |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A149V |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A149V |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A149V |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A149V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A149V |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A149V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A149V |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FGFR3 |
D513N |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
D513N |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
D513N |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248W), TP53 MUT (N131S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248W), TP53 MUT (N131S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
VHL |
R167Q |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
RET |
N783T |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
N783T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N783T |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
N783T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N783T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N783T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N783T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N783T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N783T |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NOTCH2 |
R1895C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ABL1 |
R170K |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R170K |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R170K |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R170K |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R170K |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R170K |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
NRAS |
G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
G12C |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
G12C |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
G12C |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
G12C |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
G12C |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12C |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
G12C |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12C |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
G12C |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
G12C |
Complete Match |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L130V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L130V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L130V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L130V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L130V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L130V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L130V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L130V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L130V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
K994R |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P743L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
P743L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
P743L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
P743L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P743L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
PIK3CA |
E545A |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E545A |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545A |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545A |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E545A |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545A |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E545A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E545A |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
EGFR |
C157S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
C157S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
NOTCH2 |
N1102S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Y316* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y316* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y316* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y316* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V272Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V272Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V272Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V272Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V272Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V272Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V272Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V272Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I1231T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1231T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1231T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1231T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1231T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
M169_H179delinsG |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M169_H179delinsG |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M169_H179delinsG |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M169_H179delinsG |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M169_H179delinsG |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M169_H179delinsG |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M169_H179delinsG |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M169_H179delinsG |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M169_H179delinsG |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M169_H179delinsG |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M169_H179delinsG |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M169_H179delinsG |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M169_H179delinsG |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M169_H179delinsG |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M169_H179delinsG |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
S350L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S350L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S350L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S350L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S350L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S350L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S350L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S350L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S350L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S350L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S350L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S350L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S350L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S350L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S350L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S350L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S350L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S350L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S350L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
E2446* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E2446* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E2446* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E2446* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2446* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2446* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2446* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E2446* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2446* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2446* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2446* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2446* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2446* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
NTRK3 |
splice_donor_variant |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
splice_donor_variant |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
splice_donor_variant |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
P48R |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P48R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P48R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
P48R |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P48R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P48R |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P48R |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P48R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
SETD2 |
R368* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
R368* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RET |
G344S |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
G344S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G344S |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
G344S |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G344S |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G344S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G344S |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G344S |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G344S |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q2859*), BRCA2 MUT (Q1736* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ERBB4 |
R103H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
CTNNB1 |
S37F |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S37F |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
NOTCH2 |
S1564R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2D |
Q827* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TSC2 |
Q1752* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
Q1752* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
Q1752* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
Q1752* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
Q1752* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
Q1752* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
Q1752* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
ARID1A |
D322Afs*41 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
D322Afs*41 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
D322Afs*41 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
D322Afs*41 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH2 |
G1408D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
FANCA |
R52* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
R52* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
NOTCH1 |
R1824W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1824W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
C135W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TMPRSS2 |
A139P |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
A139P |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
SF3B1 |
K666N |
Complete Match |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
HRAS |
G13R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CER |
Pre-clinical |
HRAS |
G13R |
Complete Match |
MEK inhibitor +/- MTOR inhibitor |
Responsive |
AML |
Pre-clinical |
HRAS |
G13R |
Complete Match |
MTOR inhibitor |
Responsive |
CESC |
Pre-clinical |
HRAS |
G13R |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
C72* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
C72* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
C72* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
C72* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
C72* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
C72* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
C72* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
C72* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NOTCH2 |
R1410C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
W15* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
W15* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
W15* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
W15* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
W15* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
W15* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
W15* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
W15* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NOTCH1 |
T2063K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T2063K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRCA2 |
Q175* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q175* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q175* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q175* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q175* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q175* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q175* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q175* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q175* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q175* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q175* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q175* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q175* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q175* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y500* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y500* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y500* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y500* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TMPRSS2 |
S370Y |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
S370Y |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
PML |
R816Q |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
R816Q |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
R816Q |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
PALB2 |
Y1183* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Y1183* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Y1183* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Y1183* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Y1183* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Y1183* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Y1183* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Y1183* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
ATM |
G1016* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
G1016* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
G1016* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
G1016* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
G1016* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
G1016* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
G1016* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
G1016* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
G1016* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
G1016* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
G1016* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
G1016* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
G1016* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
FLT1 |
E345* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
TP53 |
A138D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A138D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A138D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A138D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A138D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A138D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A138D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A138D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A138D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A138D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A138D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A138D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
PDGFRA |
Y206* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
TP53 |
F134S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F134S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F134S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F134S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F134S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F134S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F134S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F134S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F134S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F134S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
P224R |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
Y236N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y236N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y236N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y236N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y236N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y236N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y236N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y236N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y236N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y236N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L130R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L130R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L130R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L130R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L130R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L130R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L130R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L130R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
N754S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N754S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
S3030N |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S3030N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S3030N |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S3030N |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S3030N |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S3030N |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
CDKN2A |
M53I |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
M53I |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
M53I |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
M53I |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
M53I |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
M53I |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
M53I |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
M53I |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
FGFR3 |
A429V |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
A429V |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
A429V |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NTRK3 |
P330Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
P330Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
P330Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
V2153M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V2153M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
T3537A |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
T3537A |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
T3537A |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
T3537A |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
T3537A |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
T3537A |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R280T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R280T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R280T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R280T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R280T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R280T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R280T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R280T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R280T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R280T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R280T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R280T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q2539* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q2539* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q2539* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q2539* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q2539* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q2539* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q2539* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q2539* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
Q38* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q38* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q38* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q38* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q38* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q38* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q38* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q38* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q38* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q38* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q38* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q38* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q38* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q38* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q38* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SRSF2 |
P95A |
Complete Match |
Spliceosome inhibitor |
Responsive |
AML |
Pre-clinical |
PALB2 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
splice_acceptor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
splice_acceptor_variant |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
splice_acceptor_variant |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
splice_acceptor_variant |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
NTRK1 |
F367L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
F367L |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
F367L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
F367L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
MET |
A48T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
JAK2 |
R564L |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
RAF1 |
R215C |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R215C |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R215C |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
splice_acceptor_variant |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
splice_acceptor_variant |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
splice_acceptor_variant |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), KRAS MUT (G12V |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), KRAS MUT (G12V |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), KRAS MUT (G12V |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
BRCA2 |
K2271* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
K2271* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K2271* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
K2271* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
K2271* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
K2271* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
K2271* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
K2271* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K2271* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K2271* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K2271* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K2271* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
K2271* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K2271* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
FGFR3 |
D786N |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
D786N |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
D786N |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
MET |
IntronicBlockSubstitution |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
MET |
T613N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
Y220S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y220S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y220S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y220S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y220S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y220S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y220S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y220S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y220S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
T1987I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T1987I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T1987I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T1987I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T1987I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TSC1 |
R245* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
R245* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
R245* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
R245* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
R245* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
R245* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
R245* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
FBXW7 |
R505C |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R505C |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R505C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R505C |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
NTRK3 |
C320G |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
C320G |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
C320G |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
SF3B1 |
R625C |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F134V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F134V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F134V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F134V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F134V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F134V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F134V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F134V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F134V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F134V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NRG1 |
A240V |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
A240V |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ESR1 |
N53H |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
BRCA1 |
E143* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
E143* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
E143* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
E143* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E143* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E143* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
E143* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
E143* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
E143* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E143* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
E143* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E143* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ERBB4 |
P224L |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
P278L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P278L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P278L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P278L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P278L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P278L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P278L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P278L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P278L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TSC2 |
W1740* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
W1740* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
W1740* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
W1740* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
W1740* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
W1740* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
W1740* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
JAK2 |
L359I |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ROS1 |
S2242T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
S2242T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
S2242T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
S2242T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
S2242T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
S458L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
S458L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
M596T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M596T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
M596T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
M596T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
M596T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M596T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M596T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
M596T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M596T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M596T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
M596T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
M596T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
M596T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M596T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M596T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M596T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
M596T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
M596T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M596T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PDGFRA |
T281M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
KMT2A |
S1440T |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S1440T |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S1440T |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S1440T |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S1440T |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S1440T |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
Q780* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q780* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q780* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q780* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NRG1 |
V114L |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
V114L |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
NOTCH2 |
H107R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
A1601T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1601T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A1601T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A1601T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A1601T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1601T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1601T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A1601T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1601T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1601T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A1601T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A1601T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A1601T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1601T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1601T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1601T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A1601T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A1601T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1601T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
Y126C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y126C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y126C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y126C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y126C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y126C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y126C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y126C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q52* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q52* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q52* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q52* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q52* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q52* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q52* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q52* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q52* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q52* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q52* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q52* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q52* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q52* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q52* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
C312R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
C312R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
A472V |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
A472V |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ERBB4 |
D113N |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q1066* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1066* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1066* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1066* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FGFR3 |
D785D |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
D785D |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
D785D |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NTRK1 |
T434M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
T434M |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
T434M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
T434M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NTRK1 |
V170L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
V170L |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
V170L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
V170L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
K1047* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
K1047* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
K1047* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
K1047* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Q235* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
Q235* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
Q235* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
Q235* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Q235* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RNF43 |
R145* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
NOTCH1 |
intron_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
intron_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRAF |
D213G |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D213G |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D213G |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D213G |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ALK |
F856S |
Different Mutation |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Pre-clinical |
ALK |
F856S |
Different Mutation |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
F856S |
Different Mutation |
Crizotinib (ALK inhibitor) |
Resistant |
LUAD |
Case report |
ALK |
F856S |
Complete Match |
Crizotinib (ALK inhibitor) |
Responsive |
AML |
Pre-clinical |
ALK |
F856S |
Different Mutation |
Alectinib (ALK inhibitor) |
Resistant |
LUAD |
Case report |
ALK |
F856S |
Different Mutation |
Brigatinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
ALK |
F856S |
Different Mutation |
Crizotinib (ALK inhibitor) |
Resistant |
NSCLC |
Case report |
ALK |
F856S |
Different Mutation |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
F856S |
Complete Match |
Crizotinib (ALK inhibitor) |
Resistant |
NSCLC |
Clinical trials |
ALK |
F856S |
Different Mutation |
Ceritinib (ALK inhibitor) |
Resistant |
LUAD |
Case report |
ALK |
F856S |
Different Mutation |
Crizotinib (ALK inhibitor) |
Resistant |
G |
Pre-clinical |
ALK |
F856S |
Different Mutation |
novel ALK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
F856S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Resistant |
LUAD |
Case report |
ALK |
F856S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Resistant |
NSCLC |
Clinical trials |
ALK |
F856S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
ALK |
F856S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
F856S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
F856S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
F856S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
F856S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
F856S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
F856S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
F856S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
F856S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
F856S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
F856S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
F856S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
F856S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
F856S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
F856S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
F856S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
F856S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
F856S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
G2245R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2245R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
G183D |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
G183D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G183D |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
G183D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G183D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G183D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G183D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G183D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G183D |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2D |
G1281* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ERBB4 |
M501V |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BAP1 |
E212* |
Complete Match |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
E212* |
Complete Match |
PARP inhibitor |
Responsive |
R, CANCER |
Pre-clinical |
BAP1 |
E212* |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
BAP1 |
E212* |
Different Alteration |
PARP inhibitor |
Responsive |
CANCER, R |
Pre-clinical |
BAP1 |
E212* |
Different Alteration |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
E212* |
Different Alteration |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
RET |
A228P |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A228P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A228P |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A228P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A228P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A228P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A228P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A228P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A228P |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12I |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12I |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12I |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12I |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12I |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12I |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12I |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12I |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12I |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12I |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12I |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12I |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12I |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12I |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12I |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12I |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12I |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12I |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12I |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12I |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
S166* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S166* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S166* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S166* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S166* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S166* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S166* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S166* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S166* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S166* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S166* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S166* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S166* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S166* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S166* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M246R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M246R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M246R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M246R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M246R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M246R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M246R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M246R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M246R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M246R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CRLF2 |
D202N |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
D202N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
ARID1A |
Y551* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y551* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y551* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y551* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PIK3R1 |
splice_donor_variant |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
splice_donor_variant |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
TMPRSS2 |
V335M |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
V335M |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
KMT2A |
P2988R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P2988R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P2988R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P2988R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P2988R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P2988R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KMT2D |
R2915* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NOTCH2 |
S106P |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
Y205* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FANCA |
Q343* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
Q343* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
PIK3CA |
P366R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
P366R |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
P366R |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P366R |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
P366R |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P366R |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
P366R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
P366R |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
RB1 |
E72* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E72* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E72* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E72* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E72* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E72* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E72* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NRG1 |
N383H |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
N383H |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ALK |
W243* |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
W243* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
W243* |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
W243* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
W243* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
W243* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
W243* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
W243* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
W243* |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
W243* |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
W243* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
W243* |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
W243* |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
W243* |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
W243* |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
W243* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
W243* |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
W243* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
W243* |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ABL1 |
T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
T974I), ABL1 MUT* (A922T), ABL1 MUT* (S840N |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
PIK3R1 |
S565N |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
S565N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
PTEN |
H123Y |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
H123Y |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
H123Y |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
H123Y |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
H123Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
H123Y |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
H123Y |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
H123Y |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
H123Y |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
H123Y |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
H123Y |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
H123Y |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
H123Y |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
H123Y |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
H123Y |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
H123Y |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
H123Y |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
H123Y |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
H123Y |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
H123Y |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
H123Y |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
H123Y |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
H123Y |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
H123Y |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
H123Y |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
FGFR2 |
S689F |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
S689F |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
splice_donor_variant), TSC2 MUT (splice_acceptor_variant |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TMPRSS2 |
T378I |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
T378I |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
RET |
splice_donor_variant |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
splice_donor_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
splice_donor_variant |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
splice_donor_variant |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
splice_donor_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
splice_donor_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
splice_donor_variant |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
splice_donor_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
splice_donor_variant |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ROS1 |
splice_acceptor_variant), ROS1 MUT* (Y1487* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
splice_acceptor_variant), ROS1 MUT* (Y1487* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
splice_acceptor_variant), ROS1 MUT* (Y1487* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
splice_acceptor_variant), ROS1 MUT* (Y1487* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
splice_acceptor_variant), ROS1 MUT* (Y1487* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CDK12 |
W1043* |
Complete Match |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDK12 |
W1043* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
MET |
P857L), MET MUT* (P628L), MET MUT* (Q524* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
G3033S), MLL MUT* (Q1308* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G3033S), MLL MUT* (Q1308* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G3033S), MLL MUT* (Q1308* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G3033S), MLL MUT* (Q1308* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G3033S), MLL MUT* (Q1308* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G3033S), MLL MUT* (Q1308* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH2 |
splice_donor_variant |
Different Mutation |
Mk-0752 (Gamma secretase inhibitor) |
Responsive |
ALL, AML, BRCA |
Early trials |
NOTCH2 |
splice_donor_variant |
Different Mutation |
OMP-59R5 (NOTCH2 inhibitor) |
Responsive |
SOLID |
Early trials |
NOTCH2 |
splice_donor_variant), NOTCH2 MUT* (A1096V), NOTCH2 MUT* (S1275F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
G263R), NOTCH1 MUT* (V1745M), NOTCH1 MUT* (P2199L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G263R), NOTCH1 MUT* (V1745M), NOTCH1 MUT* (P2199L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
G178R), BRD4 MUT* (E323K |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRCA2 |
Q1658* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q1658* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1658* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q1658* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q1658* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q1658* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q1658* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q1658* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1658* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1658* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1658* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1658* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1658* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1658* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TMPRSS2 |
V329M |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
V329M |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
NOTCH2 |
I2282V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
MET |
V13M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
MET |
V504F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH1 |
L2419F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
L2419F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
R1661Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1661Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PML |
A271V |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
A271V |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
A271V |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
RET |
K471M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
K471M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
K471M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
K471M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
K471M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
K471M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
K471M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
K471M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
K471M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
PIK3CA |
H1047L |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
H1047L |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047L |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047L |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
H1047L |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047L |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
H1047L |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
H1047L |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
RNF43 |
R132*), RNF43 MUT (R145* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
NTRK3 |
Y353F |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
Y353F |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
Y353F |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
C176F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
G29* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
FGFR2 |
A97T |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
A97T |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
PALB2 |
Q430* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Q430* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Q430* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q430* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q430* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Q430* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Q430* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q430* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PBRM1 |
Q1348* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
Q1348* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
Q1348* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
Q1348* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Q1348* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V217G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V217G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V217G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V217G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V217G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V217G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V217G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V217G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V217G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V217G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V217G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V217G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V217G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V217G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V217G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
Q501* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q501* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q501* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q501* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRD4 |
A792V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRCA2 |
splice_donor_variant |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
splice_donor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
splice_donor_variant |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
splice_donor_variant |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
splice_donor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
splice_donor_variant |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
splice_donor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
splice_donor_variant |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
splice_donor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
splice_donor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDKN2A |
Q50H |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
Q50H |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50H |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50H |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
C238Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
D50N |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
D50N |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
D50N |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
VHL |
CdsStartSNV |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
ATM |
E1091* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E1091* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E1091* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E1091* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E1091* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E1091* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E1091* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E1091* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E1091* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E1091* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E1091* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E1091* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E1091* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
CDKN2A |
E10* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E10* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E10* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E10* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E10* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E10* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E10* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E10* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NF2 |
E204* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E204* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
E204* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E204* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
E204* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E204* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
E204* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E204* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
E204* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
E204* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
E204* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
E204* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
E204* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E204* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
E204* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E204* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E204* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
E204* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
E204* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
E204* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
E204* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E204* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
E204* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E204* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E204* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NOTCH2 |
K1768R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Q944* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q944* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q944* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q944* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
CDK12 |
Q937* |
Complete Match |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDK12 |
Q937* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
E258Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E258Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E258Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E258Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E258Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E258Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E258Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E258Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E258Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N239D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N239D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N239D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N239D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N239D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N239D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N239D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N239D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N239D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N239D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NRAS |
G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
G12V |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
G12V |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
G12V |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
G12V |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
G12V |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
G12V |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12V |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
G12V |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
G12V |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T125M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T125M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T125M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T125M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T125M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T125M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T125M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T125M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141Y), TP53 MUT (P250L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141Y), TP53 MUT (P250L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NF1 |
R816* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
R816* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
R816* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R816* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
R816* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
R816* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R816* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
R816* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R816* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R816* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R816* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R816* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R816* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R816* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R816* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R816* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
R816* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R816* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R816* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R816* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R816* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R816* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R816* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
BCOR |
R1217* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
ARID1A |
S334* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S334* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S334* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S334* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G464V |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G464V |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G464V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G464V |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
G464V |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
G464V |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G464V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G464V |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G464V |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G464V |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G464V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G464V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G464V |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G464V |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G464V |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G464V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G464V |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G464V |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G464V |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G464V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G464V |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G464V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G464V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G464V |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G464V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G464V |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G464V |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G464V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
T256P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T256P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T256P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T256P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T256P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T256P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T256P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T256P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T256P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T256P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T256P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T256P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T256P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T256P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T256P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
K406E |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
K406E |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ERBB4 |
L1180I |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
S138* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S138* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S138* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S138* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
V840I |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
S603C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
S603C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
S603C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
S603C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
CDH1 |
CdsStopSNV |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
P412L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P412L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P412L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P412L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P412L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P412L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
E1325* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E1325* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E1325* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E1325* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E1325* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E1325* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E1325* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E1325* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E1325* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E1325* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E1325* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E1325* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E1325* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RNF43 |
R113* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ROS1 |
M1643I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
M1643I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
M1643I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
M1643I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
M1643I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB4 |
R1304W |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
JAK2 |
T969R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
FAT1 |
Q824* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
ERBB4 |
G182C |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
E17K |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
E17K |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
TP53 |
E286G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E286G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E286G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E286G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E286G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E286G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E286G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E286G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
E1058G |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E1058G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E1058G |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E1058G |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E1058G |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E1058G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E1058G |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E1058G |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E1058G |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RNF43 |
splice_donor_variant |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
RET |
intron_variant |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
intron_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
intron_variant |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2A |
P172S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P172S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P172S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P172S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P172S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P172S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH2 |
R2347C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
A1230T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1230T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A1230T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A1230T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A1230T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1230T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1230T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A1230T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1230T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1230T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A1230T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A1230T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A1230T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1230T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1230T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1230T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A1230T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A1230T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1230T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
P1382S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NTRK3 |
N714S |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N714S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N714S |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
D108V |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108V |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108V |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D108V |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108V |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108V |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108V |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108V |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
G245C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G245C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G245C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G245C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G245C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G245C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G245C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G245C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G245C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
R413C |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
R213L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
G12L |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12L |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12L |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12L |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12L |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12L |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12L |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12L |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12L |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12L |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12L |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12L |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12L |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12L |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12L |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12L |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12L |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12L |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12L |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12L |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12L |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12L |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12L |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12L |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12L |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12L |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12L |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12L |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12L |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12L |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12L |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12L |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
Y126N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y126N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y126N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y126N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y126N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y126N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y126N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y126N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
splice_acceptor_variant |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
splice_acceptor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
splice_acceptor_variant |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
splice_acceptor_variant |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
splice_acceptor_variant |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
splice_acceptor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
splice_acceptor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
splice_acceptor_variant |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
splice_acceptor_variant |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
splice_acceptor_variant |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ROS1 |
N1272S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
N1272S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
N1272S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
N1272S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
N1272S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRAF |
E24D |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
E24D |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
E24D |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
E24D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
W53* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
W53* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
W53* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
W53* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
W53* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
W53* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
W53* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W53* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W53* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
W53* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
W53* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
W53* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
W53* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
W53* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
W53* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
C655F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
C655F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R745Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R745Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R745Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
T731M |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
E347* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E347* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E347* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E347* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E347* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E347* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E347* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E347* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E347* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E347* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E347* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E347* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E347* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
NRG1 |
M42V |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
M42V |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
AKT3 |
intron_variant |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G596D |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G596D |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G596D |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G596D |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
G596D |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
G596D |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G596D |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G596D |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G596D |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G596D |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G596D |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G596D |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G596D |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G596D |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G596D |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G596D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G596D |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G596D |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G596D |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G596D |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G596D |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G596D |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G596D |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G596D |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G596D |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G596D |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G596D |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G596D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
I251N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I251N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I251N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I251N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I251N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I251N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I251N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I251N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I251N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I251N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I251N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I251N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I251N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I251N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I251N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
S316L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S316L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S316L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S316L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S316L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S316L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
RB1 |
W516* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
W516* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
W516* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
W516* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
W516* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
W516* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
W516* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
BCOR |
splice_donor_variant |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
NOTCH2 |
E723K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
M1655T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
M1655T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
M1655T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
M1655T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
M1655T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRD4 |
T28A |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ARID1A |
Q583* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q583* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q583* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q583* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NTRK3 |
R116Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R116Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R116Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
PBRM1 |
E1189* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
E1189* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
E1189* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
E1189* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
E1189* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRD4 |
S891L |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
EGFR |
L828S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L828S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
PBRM1 |
E970* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
E970* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
E970* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
E970* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
E970* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
E198K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
E198K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
L19F |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
L19F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
L19F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
L19F |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
L19F |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
L19F |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
L19F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
L19F |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
L19F |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
L19F |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
L19F |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
L19F |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
L19F |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
L19F |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
L19F |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
L19F |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
L19F |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
L19F |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
L19F |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
L19F |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
L19F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
L19F |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
L19F |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
L19F |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
L19F |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
L19F |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
L19F |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
L19F |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
L19F |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
L19F |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
L19F |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
L19F |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
L19F |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
L19F |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
L19F |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
L19F |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
ALK |
D885G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D885G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D885G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D885G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D885G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D885G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D885G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D885G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D885G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D885G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D885G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D885G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D885G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D885G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D885G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D885G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D885G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D885G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D885G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
E2419K |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
E2419K |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
E2419K |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
E2419K |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
E2419K |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
E2419K |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK3 |
G67E |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
G67E |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
G67E |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
FGFR3 |
intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
Y103* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y103* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y103* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y103* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y103* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y103* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y103* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y103* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y103* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y103* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y103* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y103* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y103* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y103* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y103* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G266* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G266* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G266* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G266* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G266* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G266* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G266* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G266* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
R686P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R686P |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R686P |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R686P |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ROS1 |
K2111N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
K2111N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
K2111N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
K2111N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
K2111N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
MET |
G578R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
CTNNB1 |
S45F |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S45F |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
NRG1 |
A547T |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
A547T |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ABL1 |
E431D |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
E431D |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
E431D |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
E431D |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
E431D |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
E431D |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
NTRK3 |
R116W |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R116W |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R116W |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
Q167* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q167* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q167* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q167* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q167* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q167* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q167* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q167* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q167* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q167* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
R999H |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R999H |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
APC |
R1450* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ALK |
D1270G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D1270G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D1270G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D1270G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D1270G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D1270G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D1270G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D1270G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D1270G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D1270G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D1270G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D1270G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D1270G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D1270G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D1270G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D1270G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D1270G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D1270G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D1270G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ABL1 |
G254R |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G254R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G254R |
Different Mutation |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
NCCN guidelines |
ABL1 |
G254R |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
NCCN guidelines |
ABL1 |
G254R |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G254R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CML |
NCCN guidelines |
ABL1 |
G254R |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G254R |
Different Mutation |
BCR-ABL inhibitor |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G254R |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
ALL |
FDA guidelines |
ABL1 |
G254R |
Different Mutation |
Axitinib (VEGFR inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G254R |
Different Mutation |
Bosutinib (BCR-ABL inhibitor) |
Resistant |
CML |
European LeukemiaNet guidelines |
ABL1 |
G254R |
Different Mutation |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G254R |
Different Mutation |
Crizotinib (ALK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G254R |
Different Mutation |
Vandetanib (Pan-TK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G254R |
Different Mutation |
Foretinib (MET inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G254R), ABL1 MUT* (T204M |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G254R), ABL1 MUT* (T204M |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G254R), ABL1 MUT* (T204M |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G254R), ABL1 MUT* (T204M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G254R), ABL1 MUT* (T204M |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G254R), ABL1 MUT* (T204M |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
SETD2 |
R2040* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
R2040* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
R850* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
R850* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
R850* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
R850* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
R850* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
FBXW7 |
R689W |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R689W |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R689W |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R689W |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TMPRSS2 |
G179R |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
G179R |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
RET |
R231C |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R231C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R231C |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R231C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R231C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R231C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R231C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R231C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R231C |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RNF43 |
R371* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
KMT2D |
R2801* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KMT2A |
R1264* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R1264* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R1264* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R1264* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R1264* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R1264* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH2 |
A2319V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
E61* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E61* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E61* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E61* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E61* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E61* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E61* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E61* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NTRK3 |
P383T |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
P383T |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
P383T |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ABL1 |
R589C |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R589C |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R589C |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R589C |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R589C |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R589C |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
AKT3 |
R325* |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
PBRM1 |
splice_donor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
splice_donor_variant |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
splice_donor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PML |
G461A |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
G461A |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
G461A |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
ERBB4 |
Y807C |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_acceptor_variant |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_acceptor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
splice_acceptor_variant |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
splice_acceptor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
splice_acceptor_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
splice_acceptor_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
splice_acceptor_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
splice_acceptor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
splice_acceptor_variant |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
splice_acceptor_variant |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
splice_acceptor_variant |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
splice_acceptor_variant |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
splice_acceptor_variant |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_acceptor_variant |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_acceptor_variant |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
splice_acceptor_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
splice_acceptor_variant |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
splice_acceptor_variant |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
splice_acceptor_variant |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
SMARCB1 |
R53* |
Complete Match |
HDAC inhibitor |
Responsive |
MRT |
Pre-clinical |
SMARCB1 |
R53* |
Complete Match |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
SMARCB1 |
R53* |
Different Alteration |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
PIK3R1 |
N564D |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
N564D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
FBXW7 |
Y519C |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
Y519C |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
Y519C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
Y519C |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FGFR2 |
N403S |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
N403S |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
RNF43 |
R650* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
KMT2D |
W339* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NOTCH2 |
G736* |
Different Mutation |
Mk-0752 (Gamma secretase inhibitor) |
Responsive |
ALL, AML, BRCA |
Early trials |
NOTCH2 |
G736* |
Different Mutation |
OMP-59R5 (NOTCH2 inhibitor) |
Responsive |
SOLID |
Early trials |
NOTCH2 |
G736*), NOTCH2 MUT* (G1707D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
R1663W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1663W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
DNMT3A |
splice_donor_variant), DNMT3A MUT (Q656* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NOTCH1 |
T2132M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T2132M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
S522L |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
S198N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
S198N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
RAF1 |
D486G |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
D486G |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
D486G |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
CRLF2 |
P196L |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
P196L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
ERBB4 |
R782Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PDGFRA |
intron_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
ABL1 |
R473* |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R473* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R473* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R473* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R473* |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R473* |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
G245F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G245F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G245F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G245F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G245F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G245F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G245F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G245F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G245F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G245F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G245F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G245F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (R1549I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
E1583D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
E1583D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
K1457E |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K1457E |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K1457E |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K1457E |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K1457E |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K1457E |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ALK |
Q39E |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q39E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Q39E |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Q39E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Q39E |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q39E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q39E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Q39E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q39E |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q39E |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Q39E |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Q39E |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q39E |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q39E |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q39E |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q39E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Q39E |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Q39E |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q39E |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
S455L |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
S455L |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ARID1A |
P1553Rfs*12 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P1553Rfs*12 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P1553Rfs*12 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
P1553Rfs*12 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FGFR3 |
L589V |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
L589V |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
L589V |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
ROS1 |
W1289G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
W1289G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
W1289G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
W1289G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
W1289G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CTNNB1 |
S45P |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S45P |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
ALK |
K572N |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K572N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
K572N |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
K572N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
K572N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
K572N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
K572N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
K572N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
K572N |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
K572N |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
K572N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
K572N |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
K572N |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K572N |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K572N |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
K572N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
K572N |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
K572N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
K572N |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
R177W |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R177W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R177W |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R177W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R177W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R177W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R177W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R177W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R177W |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ESR1 |
M490T |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
Q317* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q317* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q317* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q317* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q317* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q317* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q317* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q317* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q317* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q317* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q317* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q317* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q317* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q317* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q317* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
P1469S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1469S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P1469S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P1469S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P1469S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1469S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1469S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P1469S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1469S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1469S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P1469S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P1469S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P1469S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1469S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1469S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1469S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P1469S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P1469S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1469S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1970*), ATM MUT (splice_donor_variant |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
L2447* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
L2447* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
L2447* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
L2447* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
L2447* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
L2447* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
L2447* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
L2447* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
L2447* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
L2447* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
L2447* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
L2447* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
L2447* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ZNRF3 |
R245* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Pre-clinical |
NTRK1 |
M375I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
M375I |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
M375I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
M375I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
Y205S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
R616W |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ABL1 |
N231S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
N231S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
N231S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
N231S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
N231S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
N231S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ROS1 |
S744R), ROS1 MUT* (K2319I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
S744R), ROS1 MUT* (K2319I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
S744R), ROS1 MUT* (K2319I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
S744R), ROS1 MUT* (K2319I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
S744R), ROS1 MUT* (K2319I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ABL1 |
V1031M |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
V1031M |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V1031M |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
V1031M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V1031M |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
V1031M |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
MSH2 |
Q314* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
Q314* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
TSC2 |
splice_acceptor_variant |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
splice_acceptor_variant |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
splice_acceptor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
splice_acceptor_variant |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TP53 |
E326* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E326* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E326* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E326* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E326* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E326* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E326* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E326* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E326* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E326* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E326* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E326* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E326* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E326* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E326* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
T395A |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
T395A |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
PDGFRA |
T16S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
NOTCH2 |
T1716I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
T2455A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T2455A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
S183* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S183* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S183* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S183* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S183* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S183* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S183* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S183* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S183* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S183* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S183* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S183* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S183* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S183* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S183* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
M264V |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
CDKN2A |
Q50R |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
Q50R |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50R |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50R |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
EGFR |
L1077F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L1077F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
JAK2 |
Q1112* |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
CHEK2 |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
CHEK2 |
splice_acceptor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
ALK |
C1255F |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
C1255F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
C1255F |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
C1255F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
C1255F |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
C1255F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
C1255F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
C1255F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
C1255F |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
C1255F |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
C1255F |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
C1255F |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
C1255F |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
C1255F |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
C1255F |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
C1255F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
C1255F |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
C1255F |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
C1255F |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R2039H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R2039H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R2039H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R2039H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R2039H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH2 |
D1533V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
R196P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R196P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R196P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R196P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R196P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R196P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R196P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R196P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R196P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R196P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R196P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R196P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R196P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R196P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R196P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
Q546K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Q546K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Q546K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Q546K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Q546K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ROS1 |
R1182S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1182S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1182S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1182S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1182S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
Y2116N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Y2116N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
T125K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T125K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T125K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T125K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T125K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T125K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T125K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T125K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T125K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C124* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C124* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C124* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C124* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C124* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C124* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C124* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C124* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C124* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C124* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C124* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C124* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
R1875W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ATM |
splice_donor_variant |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
splice_donor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
splice_donor_variant |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
splice_donor_variant |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
splice_donor_variant |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
splice_donor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
splice_donor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
splice_donor_variant |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
splice_donor_variant |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
splice_donor_variant |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
MSH2 |
CdsStopSNV |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
CdsStopSNV |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135F), TP53 MUT (V157I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135F), TP53 MUT (V157I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NF2 |
Y221* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
Y221* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
Y221* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y221* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
Y221* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
Y221* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
Y221* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y221* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y221* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
Y221* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
Y221* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
Y221* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
Y221* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y221* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
Y221* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
Y221* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
Y221* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NTRK1 |
R583C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R583C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R583C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R583C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
R267P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R267P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R267P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R267P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R267P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R267P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R267P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R267P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R267P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R267P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PALB2 |
K1124Qfs*30 |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
K1124Qfs*30 |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
K1124Qfs*30 |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
K1124Qfs*30 |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
K1124Qfs*30 |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
K1124Qfs*30 |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
K1124Qfs*30 |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
K1124Qfs*30 |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PML |
splice_donor_variant |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
splice_donor_variant |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
splice_donor_variant |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
MET |
P822S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH2 |
P2297H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
V1172M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V1172M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
Y412C |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ROS1 |
D331V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
D331V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
D331V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
D331V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D331V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NTRK1 |
A549V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
A549V |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
A549V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
A549V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ERBB4 |
P1297L |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
D1021H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
D1021H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
P278T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P278T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P278T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P278T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P278T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P278T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P278T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P278T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P278T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
R119C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R119C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R119C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R119C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
E2023* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2023* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2023* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E2023* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRCA2 |
K3083* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
K3083* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K3083* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
K3083* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
K3083* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
K3083* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
K3083* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
K3083* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K3083* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K3083* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K3083* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K3083* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
K3083* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K3083* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
E56* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E56* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E56* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E56* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E56* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E56* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E56* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E56* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E56* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E56* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E56* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E56* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E56* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E56* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E56* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
MET |
V427I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
ERBB4 |
F689Y |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
splice_acceptor_variant |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
splice_acceptor_variant |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
splice_acceptor_variant |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
splice_acceptor_variant |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
splice_acceptor_variant |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
splice_acceptor_variant |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
R750* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R750* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R750* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R750* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
T454M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T454M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T454M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T454M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T454M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G850R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G850R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G850R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G850R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G850R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G850R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G850R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G850R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G850R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G850R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G850R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G850R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G850R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G850R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G850R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G850R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G850R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G850R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G850R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
S929C |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S929C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S929C |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S929C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S929C |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S929C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S929C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S929C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S929C |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S929C |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S929C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S929C |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S929C |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S929C |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S929C |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S929C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S929C |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S929C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S929C |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PDGFB |
intron_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
DFS |
FDA guidelines |
CTNNB1 |
D32N |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
D32N |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
ESR1 |
intron_variant |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ABL1 |
A647V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
A647V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A647V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
A647V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A647V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
A647V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
RNF43 |
S468* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
PML |
S774G |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
S774G |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
S774G |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NTRK1 |
R49G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R49G |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R49G |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R49G |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ATR |
splice_acceptor_variant |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
splice_acceptor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
PML |
G448R |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
G448R |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
G448R |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
T125T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T125T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T125T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T125T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T125T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T125T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T125T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T125T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T125T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
G1915R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
G1915R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
G1915R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
G1915R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
G1915R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V827I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V827I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
V827I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
V827I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
V827I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V827I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V827I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
V827I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V827I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V827I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
V827I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
V827I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V827I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V827I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V827I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V827I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
V827I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
V827I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V827I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q1409* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1409* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1409* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1409* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FGFR3 |
S804S |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
S804S |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
S804S |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
BRD4 |
I820V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
PDGFRA |
A509V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
EGFR |
A289D |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
A289D |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
A289D |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
A289D |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289D |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289D |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
A289D |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
A289D |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
A289D |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
A289D |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
A289D |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
A289D |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289D |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
A289D |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
A289D |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
A289D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
A289D |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A289D |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
A289D |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
A289D |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
A289D |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
A289D |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
A289D |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
A289D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
A289D |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
A289D |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
A289D |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
A289D |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
A289D |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
A289D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
A289D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
A289D |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
A289D |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
A289D |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
A289D |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
A289D |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
A289D |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
A289D |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A289D |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
C176R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
F161V |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
F161V |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
F161V |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
PTEN |
R173H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R173H |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R173H |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
R173H |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
R173H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
R173H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R173H |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R173H |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R173H |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
R173H |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R173H |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R173H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
R173H |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R173H |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R173H |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R173H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
R173H |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R173H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R173H |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R173H |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R173H |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R173H |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R173H |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R173H |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R173H |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
E180* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E180* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E180* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E180* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E180* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E180* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E180* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E180* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E180* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E180* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E180* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E180* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E180* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E180* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E180* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V143A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V143A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V143A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V143A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V143A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V143A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V143A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V143A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V143A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V143A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V143A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V143A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
L653I |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
L653I |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
L653I |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
L155H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ERBB4 |
R847H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R118* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R118* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R118* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R118* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R118* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
RB1 |
R500* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R500* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R500* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R500* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R500* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R500* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R500* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
KMT2A |
S2741C |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S2741C |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S2741C |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S2741C |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S2741C |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S2741C |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK1 |
intron_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
intron_variant |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
intron_variant |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
intron_variant |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
CRLF2 |
splice_donor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
splice_donor_variant |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
MET |
P668S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
EGFR |
D1063G |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
D1063G |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
R248L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R248L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F270S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F270S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F270S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F270S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F270S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F270S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F270S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F270S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CRLF2 |
I35N |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
I35N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
D238N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
D238N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NF1 |
K1099* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
K1099* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
K1099* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K1099* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
K1099* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
K1099* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K1099* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
K1099* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K1099* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K1099* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K1099* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K1099* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K1099* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K1099* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K1099* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
K1099* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K1099* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K1099* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K1099* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K1099* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K1099* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
ARID1A |
P729Lfs*85 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P729Lfs*85 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P729Lfs*85 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
P729Lfs*85 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NF2 |
E129* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E129* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
E129* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E129* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
E129* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E129* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
E129* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E129* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
E129* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
E129* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
E129* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
E129* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
E129* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E129* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
E129* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E129* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E129* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
E129* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
E129* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
E129* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
E129* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E129* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
E129* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E129* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E129* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
D594G |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594G |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594G |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594G |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
D594G |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
D594G |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
D594G |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
D594G |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
D594G |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
D594G |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594G |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
D594G |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
D594G |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
D594G |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
D594G |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
D594G |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
D594G |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
D594G |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
D594G |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594G |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
D594G |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
D594G |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
D594G |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594G |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
D594G |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D594G |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D594G |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D594G |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ARID1A |
R1528* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1528* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1528* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1528* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PML |
P26S |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
P26S |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
P26S |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
L201* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L201* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L201* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L201* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L201* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L201* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L201* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L201* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L201* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L201* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L201* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L201* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L201* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L201* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L201* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
R1212C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1212C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1212C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1212C |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1212C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERCC2 |
Y339* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ERCC2 |
Y339* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ERCC2 |
Y339* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
RET |
E527K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E527K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E527K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E527K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E527K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E527K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E527K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E527K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E527K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ROS1 |
E1244D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E1244D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E1244D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E1244D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E1244D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NTRK1 |
R654H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R654H |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R654H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R654H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
Y163N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y163N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y163N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y163N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y163N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y163N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y163N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y163N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y163N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y163N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P177R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P177R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P177R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P177R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P177R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P177R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P177R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P177R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P177R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P177R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P177R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P177R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P177R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P177R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P177R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
V1739M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V1739M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RNF43 |
Y177* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
R249M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R249M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R249M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R249M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R249M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R249M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R249M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R249M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R249M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
DNMT3A |
splice_acceptor_variant |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
D259Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D259Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D259Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D259Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D259Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D259Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D259Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D259Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D259Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D259Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D259Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D259Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E298* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E298* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E298* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E298* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E298* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E298* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E298* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E298* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E298* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E298* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E298* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E298* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E298* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E298* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E298* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
R368C |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R368C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R368C |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R368C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R368C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R368C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R368C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R368C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R368C |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NOTCH2 |
intron_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERCC4 |
W193* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
OV |
Pre-clinical |
TP53 |
G244S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G244S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G244S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G244S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G244S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G244S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G244S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G244S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G244S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G244S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
STK11 |
P89Afs*6 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
P89Afs*6 |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P89Afs*6 |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
P89Afs*6 |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
P89Afs*6 |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
P89Afs*6 |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P89Afs*6 |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P89Afs*6 |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
P89Afs*6 |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
P89Afs*6 |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P89Afs*6 |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
P89Afs*6 |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
N3267Y |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
N3267Y |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
N3267Y |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
N3267Y |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
N3267Y |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
N3267Y |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
E2145* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E2145* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E2145* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E2145* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2145* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2145* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2145* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E2145* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2145* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2145* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2145* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2145* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2145* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
C141Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
P820S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P820S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
AKT3 |
K20E |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
R1120W |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1120W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1120W |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1120W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1120W |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1120W |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1120W |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1120W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1120W |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1120W |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1120W |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1120W |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1120W |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1120W |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1120W |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1120W |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1120W |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1120W |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1120W |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FGFR3 |
C597F |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
C597F |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
C597F |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), STK11 MUT (splice_acceptor_variant), KRAS MUT (G12D |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
FGFR3 |
H208Y |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
H208Y |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
H208Y |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
C135G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
N849Kfs*2 |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
N849Kfs*2 |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
N849Kfs*2 |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
N849Kfs*2 |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
N849Kfs*2 |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
N849Kfs*2 |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
N849Kfs*2 |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
CTNNB1 |
G34E |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
G34E |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
KMT2D |
Q2553* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
G244A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G244A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G244A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G244A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G244A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G244A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G244A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G244A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G244A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G244A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P151R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P151R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P151R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P151R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P151R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P151R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P151R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P151R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
S12* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
S12* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
S12* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
S12* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
S12* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
S12* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
S12* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
S12* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NOTCH1 |
D1064N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
D1064N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ATM |
R1882* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R1882* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R1882* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R1882* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R1882* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R1882* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R1882* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R1882* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R1882* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R1882* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R1882* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R1882* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R1882* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
BRD4 |
N852K |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
PML |
A502S |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
A502S |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
A502S |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
CDKN2A |
Q50* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
Q50* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
Q50* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
Q50* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
Q50* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
ALK |
R510Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R510Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R510Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R510Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R510Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R510Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R510Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R510Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R510Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R510Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R510Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R510Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R510Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R510Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R510Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R510Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R510Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R510Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R510Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TMPRSS2 |
T324N |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
T324N |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
NTRK3 |
N338H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N338H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N338H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
L546I |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
L546I |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
TP53 |
I195N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I195N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I195N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I195N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I195N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I195N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I195N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I195N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I195N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TMPRSS2 |
A139T |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
A139T |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
ESR1 |
R158H |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
I232F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I232F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I232F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I232F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I232F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I232F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I232F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I232F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I232F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I232F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E258* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E258* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E258* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E258* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E258* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E258* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E258* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E258* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E258* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E258* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E258* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
I531V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
E88* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E88* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E88* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
E88* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E88* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
E88* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
E88* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
E88* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
V197G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V197G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V197G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V197G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V197G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V197G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V197G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V197G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V197G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V197G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V197G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V197G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V197G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V197G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V197G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
R410C |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
NTRK1 |
I510F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
I510F |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
I510F |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
I510F |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ERBB4 |
R196H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1038F |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1038F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S1038F |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S1038F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S1038F |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S1038F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S1038F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S1038F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S1038F |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S1038F |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S1038F |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S1038F |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S1038F |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1038F |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1038F |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S1038F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S1038F |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S1038F |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S1038F |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK3 |
N35D |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N35D |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N35D |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
D84Y |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D84Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D84Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D84Y |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D84Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D84Y |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D84Y |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D84Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NOTCH2 |
S2103C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
T591M |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
T591M |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
SMARCA4 |
Q722* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Q722* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
Q722* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
Q722* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Q722* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
TP53 |
R158L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R158L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R158L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R158L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R158L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R158L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R158L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R158L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R158L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G262V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G262V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G262V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G262V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G262V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G262V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G262V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G262V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G262V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G262V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G262V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G262V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G262V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G262V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G262V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
D596N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
D596N |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
D596N |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
D596N |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
BRAF |
T491S |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
T491S |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
T491S |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
T491S |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
DNMT3A |
Q692* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
RNF43 |
S262* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
MET |
N642S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
RNF43 |
C309* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
NOTCH1 |
G1072S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G1072S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
T221M |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
APC |
R2204* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
CRLF2 |
G195_P200delinsVPDTYR |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
G195_P200delinsVPDTYR |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
NRG1 |
N305K |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
N305K |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
NTRK3 |
H825R |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
H825R |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
H825R |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
PTEN |
D92G |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
D92G |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
D92G |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
D92G |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
D92G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
D92G |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
D92G |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
D92G |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
D92G |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
D92G |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
D92G |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
D92G |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
D92G |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
D92G |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
D92G |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
D92G |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
D92G |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
D92G |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
D92G |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
D92G |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
D92G |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
D92G |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
D92G |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
D92G |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
D92G |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
ROS1 |
R1212H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1212H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1212H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1212H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1212H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
SETD2 |
Q1272* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1272* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RNF43 |
S41* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Y587F |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Y587F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Y587F |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Y587F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Y587F |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Y587F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Y587F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Y587F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Y587F |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Y587F |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Y587F |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Y587F |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Y587F |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Y587F |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Y587F |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Y587F |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Y587F |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Y587F |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Y587F |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
V1014I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
W619C |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
W619C |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
W619C |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
W619C |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
W619C |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
W619C |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V218G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V218G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V218G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V218G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V218G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V218G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V218G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V218G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V218G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V218G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V218G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V218G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
Q61A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61A |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61A |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61A |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61A |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61A |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61A |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61A |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61A |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61A |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61A |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61A |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61A |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61A |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61A |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61A |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61A |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61A |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61A |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
FGFR2 |
E778D |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
E778D |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
KMT2A |
R2890C |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R2890C |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R2890C |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R2890C |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R2890C |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R2890C |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
Q2384E |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q2384E |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
D1848Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
Y220N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y220N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y220N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y220N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y220N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y220N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y220N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y220N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y220N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
E872G |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2D |
Q4230* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
PML |
R120W |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
R120W |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
R120W |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
BRCA2 |
E1812* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
E1812* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E1812* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
E1812* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
E1812* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
E1812* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
E1812* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
E1812* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E1812* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E1812* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E1812* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E1812* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
E1812* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E1812* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
RET |
T636M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
T636M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T636M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
T636M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T636M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T636M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T636M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T636M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T636M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NOTCH1 |
intron_variant), NOTCH1 MUT* (A796V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
intron_variant), NOTCH1 MUT* (A796V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRAF |
T395A |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
T395A |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
T395A |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
T395A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FGFR2 |
G584R |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
G584R |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ESR1 |
V533M |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
JAK2 |
T842R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PML |
A93G |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
A93G |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
A93G |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
F270L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F270L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F270L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F270L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F270L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F270L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F270L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F270L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F270L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q852* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q852* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q852* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q852* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q852* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q852* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q852* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q852* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q852* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q852* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q852* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q852* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q852* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
NRG1 |
R438C |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
R438C |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
ATM |
R2849* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2849* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2849* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2849* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2849* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2849* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2849* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2849* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2849* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2849* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2849* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2849* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2849* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
Y216* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y216* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y216* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y216* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
R1082H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1082H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
R342P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R342P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R342P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R342P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R342P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R342P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R342P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R342P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R342P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R342P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R342P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R342P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R342P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R342P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R342P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
R138Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R138Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R138Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
V661I |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
V661I |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
V661I |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
V661I |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
V661I |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
V661I |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ERBB4 |
R612Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
STAG2 |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
G |
Pre-clinical |
FBXW7 |
T463I |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
T463I |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
T463I |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
T463I |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
NOTCH1 |
R1438H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1438H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EGFR |
H584Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
H584Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
C176S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I195F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I195F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I195F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I195F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I195F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I195F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I195F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I195F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2D |
Q3953* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q167*), TP53 MUT (R175C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q167*), TP53 MUT (R175C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
E706K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
E706K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
FGFR3 |
R158W |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R158W |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R158W |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
V216E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V216E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V216E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V216E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V216E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V216E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V216E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V216E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V216E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V216E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
N63S |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
NTRK1 |
Y359* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
Y359* |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
Y359* |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
Y359* |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
BRAF |
G209D |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G209D |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G209D |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G209D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FGFR3 |
P300L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P300L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P300L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NTRK1 |
E480K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
E480K |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
E480K |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
E480K |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
KMT2A |
R331Q |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R331Q |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R331Q |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R331Q |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R331Q |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R331Q |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E224* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E224* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E224* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E224* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E224* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E224* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E224* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E224* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E224* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E224* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E224* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E224* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E224* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E224* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E224* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
A1732V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A1732V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
P250L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P250L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P250L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P250L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P250L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P250L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P250L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P250L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P250L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P250L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P250L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P250L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P250L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P250L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P250L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
E81K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E81K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E81K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E81K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E81K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E81K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E81K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E81K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
Y126* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y126* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y126* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y126* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y126* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y126* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y126* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y126* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
R507G |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R507G |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R507G |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
RET |
R189G |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R189G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189G |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R189G |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189G |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189G |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189G |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189G |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
PML |
S84A |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
S84A |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
S84A |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
R249T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R249T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R249T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R249T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R249T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R249T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R249T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R249T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R249T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P151A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P151A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P151A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P151A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P151A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P151A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P151A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P151A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R3008C), ATM MUT (K2756* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R3008C), ATM MUT (K2756* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R3008C), ATM MUT (K2756* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R3008C), ATM MUT (K2756* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant), KRAS MUT (G12D |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12D |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12D |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
SF3B1 |
G740E |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
PDGFRA |
A396T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
CTNNB1 |
H36_S37delinsQF |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
H36_S37delinsQF |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
KMT2A |
R2211Q |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R2211Q |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R2211Q |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R2211Q |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R2211Q |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R2211Q |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK1 |
G743* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
G743* |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
G743* |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G743* |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ERCC2 |
R683W |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ERCC2 |
R683W |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ERCC2 |
R683W |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ALK |
G902R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G902R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G902R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G902R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G902R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G902R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G902R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G902R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G902R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G902R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G902R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G902R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G902R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G902R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G902R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G902R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G902R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G902R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G902R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MSH2 |
W117* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
W117* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ALK |
C480* |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
C480* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
C480* |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
C480* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
C480* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
C480* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
C480* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
C480* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
C480* |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
C480* |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
C480* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
C480* |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
C480* |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
C480* |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
C480* |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
C480* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
C480* |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
C480* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
C480* |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PBRM1 |
S888* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
S888* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
S888* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
S888* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
S888* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
FGFR3 |
Y107* |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
Y107* |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
Y107* |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
MET |
Q265K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
S997R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S997R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S997R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S997R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S997R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S997R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
Y815* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y815* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y815* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y815* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R282_R283delinsQG |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R282_R283delinsQG |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R282_R283delinsQG |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R282_R283delinsQG |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R282_R283delinsQG |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R282_R283delinsQG |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R282_R283delinsQG |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282_R283delinsQG |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
D651G |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
D651G |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
Y163* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y163* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y163* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y163* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y163* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y163* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y163* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y163* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y163* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y163* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
K1833R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K1833R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K1833R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K1833R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K1833R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K1833R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TMPRSS2 |
D211E |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
D211E |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
TP53 |
R213G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
N1221S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N1221S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RNF43 |
Q233* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
Y430* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y430* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y430* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y430* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
R544W |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
R544W |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
R544W |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
DNMT3A |
C494* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
PDGFRA |
P577L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
TMPRSS2 |
R219W |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
R219W |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
ROS1 |
W1101* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
W1101* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
W1101* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
W1101* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
W1101* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
FGFR2 |
Q285E |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
Q285E |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ABL1 |
A1110V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
A1110V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A1110V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
A1110V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A1110V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
A1110V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
DNMT3A |
I670Vfs*34), DNMT3A MUT (R736H |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NTRK3 |
N79H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N79H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N79H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
D549N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
G1135E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
G1135E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
G1135E |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
G1135E |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
G1135E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CDKN2A |
P114H |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P114H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P114H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
P114H |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P114H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P114H |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P114H |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P114H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NRG1 |
S384C |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
S384C |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
TP53 |
V197M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V197M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V197M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V197M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V197M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V197M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V197M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V197M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V197M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V197M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V197M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V197M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V197M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V197M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V197M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RAF1 |
R391S |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R391S |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R391S |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NOTCH2 |
L1663V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
Q165* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q165* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q165* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q165* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q165* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q165* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q165* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q165* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q165* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q165* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q165* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q165* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q165* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q165* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q165* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
L505F |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
L505F |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
L505F |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
L505F |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ALK |
P835S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P835S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P835S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P835S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P835S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P835S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P835S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P835S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P835S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P835S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P835S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P835S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P835S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P835S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P835S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P835S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
A639T |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A639T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A639T |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A639T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A639T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A639T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A639T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A639T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A639T |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
MET |
R417* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH1 |
T66N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T66N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R326L |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R326L |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R326L |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
D281E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D281E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D281E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D281E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D281E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D281E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D281E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D281E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D281E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
CdsStopSNV |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
CdsStopSNV |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
CdsStopSNV |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
CDKN2A |
A76Lfs*70 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A76Lfs*70 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A76Lfs*70 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
A76Lfs*70 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A76Lfs*70 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A76Lfs*70 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A76Lfs*70 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A76Lfs*70 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2A |
F1938L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
F1938L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
F1938L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
F1938L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
F1938L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
F1938L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
MET |
T273N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
T125P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T125P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T125P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T125P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T125P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T125P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T125P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T125P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T125P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
R1250Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
G244C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G244C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G244C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G244C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G244C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G244C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G244C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G244C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G244C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G244C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
A999V |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A999V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A999V |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A999V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A999V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A999V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A999V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A999V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A999V |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ATM |
Q561* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q561* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q561* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q561* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q561* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q561* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q561* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q561* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q561* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q561* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q561* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q561* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q561* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
CRLF2 |
L56P |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
L56P |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH2 |
D2040N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
AKT3 |
G10V |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
S241Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S241Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S241Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S241Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S241Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S241Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S241Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S241Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S241Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S241Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
Q242* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
EGFR |
M600T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
M600T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
V173M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V173M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V173M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V173M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V173M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V173M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V173M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V173M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V173M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V173M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
Q546R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Q546R |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546R |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546R |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Q546R |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546R |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Q546R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Q546R |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PBRM1 |
Q64* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
Q64* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
Q64* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
Q64* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Q64* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2A |
S3484Y |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S3484Y |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S3484Y |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S3484Y |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S3484Y |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S3484Y |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TMPRSS2 |
T95M |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
T95M |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
KMT2D |
R2635* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
C242W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
Y1369* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y1369* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y1369* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y1369* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R283C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R283C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R283C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R283C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R283C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R283C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R283C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R283C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R283C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R283C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R283C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R283C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R283C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R283C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R283C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
R805G |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R805G |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R805G |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NTRK3 |
D50Y |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
D50Y |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
D50Y |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
A2018S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
T304*fs*1 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T304*fs*1 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T304*fs*1 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T304*fs*1 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T304*fs*1 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T304*fs*1 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T304*fs*1 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T304*fs*1 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T304*fs*1 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T304*fs*1 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T304*fs*1 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T304*fs*1 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T304*fs*1 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T304*fs*1 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T304*fs*1 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
R205W |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R205W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R205W |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R205W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R205W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R205W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R205W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R205W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R205W |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
A161D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A161D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A161D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A161D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A161D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A161D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A161D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A161D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A161D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A161D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TSC2 |
E1239* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
E1239* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
E1239* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
E1239* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
E1239* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
E1239* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
E1239* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
ABL1 |
G778S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G778S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G778S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G778S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G778S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G778S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
PDGFRA |
E262Q |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
DNMT3A |
W305* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
ALK |
splice_donor_variant |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_donor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
splice_donor_variant |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
splice_donor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
splice_donor_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
splice_donor_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
splice_donor_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
splice_donor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
splice_donor_variant |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
splice_donor_variant |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
splice_donor_variant |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
splice_donor_variant |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
splice_donor_variant |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_donor_variant |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
splice_donor_variant |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
splice_donor_variant |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
splice_donor_variant |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
splice_donor_variant |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
splice_donor_variant |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ERBB4 |
P557S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R1882*), ATM MUT (R35* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R1882*), ATM MUT (R35* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R1882*), ATM MUT (R35* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R1882*), ATM MUT (R35* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T125M), TP53 MUT (V203M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T125M), TP53 MUT (V203M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
G843R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G843R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G843R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G843R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G843R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G843R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G843R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G843R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G843R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G843R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G843R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G843R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G843R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G843R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G843R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G843R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G843R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G843R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G843R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
L576P |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
L576P |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
L576P |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
L576P |
Complete Match |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
L576P |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
L576P |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
L576P |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
L576P |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
L576P |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
L576P |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
L576P |
Complete Match |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
L576P |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
L576P |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
L576P |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
L576P |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
L576P |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
L576P |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
L576P |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
L576P |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
L576P |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
L576P |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
L576P |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
L576P |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
L576P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
L576P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
L576P |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
FGFR2 |
P805A |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
P805A |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ROS1 |
P1662R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
P1662R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
P1662R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
P1662R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P1662R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
T2240A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T2240A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
splice_acceptor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
splice_acceptor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
splice_acceptor_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
splice_acceptor_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
splice_acceptor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ROS1 |
V423A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
V423A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
V423A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
V423A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V423A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
RNF43 |
W165* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
NOTCH2 |
F524L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RNF43 |
Q409* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDK12 |
S4* |
Complete Match |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDK12 |
S4* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
KMT2A |
P1134L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P1134L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P1134L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P1134L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P1134L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P1134L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
AKT3 |
M400V |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
PML |
Q660* |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
Q660* |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
Q660* |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
RAF1 |
P30S |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
P30S |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
P30S |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
PML |
K821R |
Different Alteration |
Volasertib (PLK1 inhibitor) |
Responsive |
AML |
Early trials |
PML |
K821R |
Different Alteration |
Tretinoin (Retinoid) |
Responsive |
APML |
FDA guidelines |
PML |
K821R |
Different Alteration |
Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) |
Responsive |
AML |
FDA guidelines |
ALK |
R1212H |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1212H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1212H |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1212H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1212H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1212H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1212H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1212H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1212H |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1212H |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1212H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1212H |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1212H |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1212H |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1212H |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1212H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1212H |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1212H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1212H |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q321* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
W111* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
W111* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
W111* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
W111* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
W111* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
W111* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
W111* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
W111* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
W111* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
W111* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
W111* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
W111* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
W111* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
W111* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
W111* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
W111* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
W111* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
W111* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
W111* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
W111* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
W111* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
W111* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
W111* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
W111* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
W111* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
ERBB4 |
G573S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
T488S |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
T488S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T488S |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
T488S |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T488S |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T488S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T488S |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T488S |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T488S |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
P151T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P151T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P151T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P151T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P151T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P151T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P151T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P151T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P151T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P151T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P151T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P151T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
splice_donor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
splice_donor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
splice_donor_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
splice_donor_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
splice_donor_variant |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V448D |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V448D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
V448D |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
V448D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
V448D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V448D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V448D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
V448D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V448D |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V448D |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
V448D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
V448D |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V448D |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V448D |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V448D |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V448D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
V448D |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
V448D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V448D |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RICTOR |
L28Gfs*3 |
Different Alteration |
MTORC1/2 inhibitor |
Responsive |
L |
Case report |
AKT3 |
P42H |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
E171G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E171G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E171G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E171G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E171G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E171G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E171G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E171G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E171G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E171G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E171G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E171G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E171G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E171G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E171G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
R869Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
P1195S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
U2AF1 |
Q157P |
Complete Match |
FLT3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y126C), TP53 MUT (H214R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126C), TP53 MUT (H214R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SF3B1 |
R625S |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRD4 |
A276T |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
STK11 |
Q170* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Q170* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q170* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Q170* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Q170* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Q170* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q170* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q170* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Q170* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Q170* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q170* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q170* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q170*), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Q170*), KRAS MUT (G12D |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Q170*), KRAS MUT (G12D |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Q170*), KRAS MUT (G12D |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
TP53 |
H193Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H193Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H193Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H193Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H193Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H193Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H193Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H193Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H193Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H193Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H193Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H193Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
STK11 |
Y60*), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Y60*), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y60*), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y60*), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
TP53 |
T155I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T155I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T155I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T155I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T155I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T155I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T155I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T155I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T155I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y236* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y236* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y236* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y236* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y236* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y236* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y236* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y236* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y236* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y236* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
L1033H |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L1033H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L1033H |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L1033H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L1033H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L1033H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L1033H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L1033H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L1033H |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
MET |
T557A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
BAP1 |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
R, CANCER |
Pre-clinical |
BAP1 |
splice_donor_variant |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
BAP1 |
splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
CANCER, R |
Pre-clinical |
BAP1 |
splice_donor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
splice_donor_variant |
Different Alteration |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
ARID1A |
S1151Rfs*9 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1151Rfs*9 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1151Rfs*9 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S1151Rfs*9 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
E874* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
E874* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
E874* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
K1205Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K1205Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
K1205Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
K1205Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
K1205Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
K1205Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
K1205Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
K1205Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
K1205Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
K1205Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
K1205Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
K1205Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
K1205Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K1205Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K1205Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
K1205Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
K1205Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
K1205Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
K1205Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRCA2 |
K2013* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
K2013* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K2013* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
K2013* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
K2013* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
K2013* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
K2013* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
K2013* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K2013* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K2013* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K2013* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K2013* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
K2013* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K2013* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
RET |
A1020V |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A1020V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1020V |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A1020V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1020V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1020V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A1020V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A1020V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A1020V |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRD4 |
A589V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
E62Afs*83 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E62Afs*83 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E62Afs*83 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E62Afs*83 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E62Afs*83 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E62Afs*83 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E62Afs*83 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E62Afs*83 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E62Afs*83 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E62Afs*83 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E62Afs*83 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E62Afs*83 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E62Afs*83 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E62Afs*83 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E62Afs*83 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
A120D |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A120D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A120D |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A120D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A120D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A120D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A120D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A120D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A120D |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A120D |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A120D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A120D |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A120D |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A120D |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A120D |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A120D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A120D |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A120D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A120D |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FGFR2 |
A415T |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
A415T |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ALK |
G875R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G875R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G875R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G875R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G875R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G875R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G875R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G875R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G875R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G875R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G875R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G875R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G875R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G875R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G875R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G875R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G875R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G875R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G875R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
CDH1 |
I612Nfs*16 |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
N2779S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
N2779S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
N2779S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
N2779S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
N2779S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
N2779S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ESR1 |
S338G |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
KMT2A |
M2410V |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
M2410V |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
M2410V |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
M2410V |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
M2410V |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
M2410V |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
A2044T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A2044T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRAF |
K483T |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
K483T |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
K483T |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
K483T |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ERBB4 |
R306H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
K132E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
L712P |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L712P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L712P |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L712P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L712P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L712P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L712P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L712P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L712P |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
A146V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
A146V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
A146V |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
A146V |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
A146V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
A146V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
A146V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
A146V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
A146V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
A146V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
A146V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
A146V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
A146V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
A146V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
A146V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
A146V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
A146V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
A146V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
A146V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
A146V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
A146V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
A146V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
A146V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
A146V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
A146V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
RB1 |
Y325* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Y325* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y325* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Y325* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y325* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y325* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Y325* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NTRK3 |
T707M |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T707M |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T707M |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
P349S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
E271* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E271* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E271* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E271* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E271* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E271* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E271* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E271* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E271* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E271* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E271* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E271* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E271* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
S837* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
S837* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
S837* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
S837* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
S837* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
S837* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
S837* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
S837* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
S837* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
S837* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
S837* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
S837* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
S837* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
KMT2D |
Y5426* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
H1047R), PIK3CA MUT (E542K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213*), TP53 MUT (R273L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213*), TP53 MUT (R273L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CTNNB1 |
S45P), CTNNB1 MUT (P44A |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S45P), CTNNB1 MUT (P44A |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
ERBB4 |
R1139Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
V503I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V503I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
V503I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
V503I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
V503I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V503I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V503I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
V503I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V503I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V503I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
V503I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
V503I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V503I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V503I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V503I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V503I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
V503I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
V503I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V503I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK3 |
E360K |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E360K |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E360K |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
V1182I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
V272G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V272G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V272G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V272G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V272G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V272G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V272G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V272G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V272G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
splice_acceptor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
splice_acceptor_variant |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PDGFRA |
S636T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
RNF43 |
Q22*), RNF43 MUT (R337* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
JAK2 |
S1054R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ALK |
V1045M |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V1045M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
V1045M |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
V1045M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
V1045M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V1045M |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V1045M |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
V1045M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V1045M |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V1045M |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
V1045M |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
V1045M |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V1045M |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V1045M |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V1045M |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V1045M |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
V1045M |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
V1045M |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V1045M |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
S241A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S241A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S241A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S241A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S241A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S241A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S241A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S241A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S241A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S241A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Q546K), PIK3CA MUT (D538E |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
JAK2 |
L805I |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
LRP1B |
splice_donor_variant |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
splice_donor_variant |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
ARID1A |
Y447* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y447* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y447* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y447* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T253A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T253A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T253A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T253A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T253A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T253A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T253A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T253A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T253A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T253A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T253A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T253A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T253A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T253A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T253A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
R7* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R7* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R7* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R7* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R7* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R7* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R7* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
KMT2A |
P2620S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P2620S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P2620S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P2620S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P2620S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P2620S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
R1234W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1234W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EGFR |
D1084N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
D1084N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
V216L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V216L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V216L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V216L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V216L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V216L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V216L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V216L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V216L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V216L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V216L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V216L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
G2262S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2262S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PIK3CA |
K111E |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
K111E |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
K111E |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
K111E |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
K111E |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
K111E |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
K111E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
K111E |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2832C), ATM MUT (K2089* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2832C), ATM MUT (K2089* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2832C), ATM MUT (K2089* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2832C), ATM MUT (K2089* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RAF1 |
E286Q |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
E286Q |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
E286Q |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
BRD4 |
L247M |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194R), TP53 MUT (E271*), TP53 MUT (E287Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRD4 |
K99N |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ABL1 |
V722I |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
V722I |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V722I |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
V722I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V722I |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
V722I |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
L130F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L130F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L130F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L130F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L130F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L130F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L130F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L130F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L130F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L130F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L130F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L130F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
APC |
E225* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
FANCC |
R185* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
FANCC |
R185* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
FGFR3 |
R498W |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R498W |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R498W |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
RAF1 |
L300P |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
L300P |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
L300P |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
PIK3CA |
K111N |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
K111N |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
K111N |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
K111N |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
K111N |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
K111N |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
K111N |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
K111N |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
CDKN2A |
D108H |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108H |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D108H |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D108H |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D108H |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D108H |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2D |
E1832* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ROS1 |
I1825M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1825M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1825M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1825M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1825M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
A11T |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
A11T |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
A11T |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
A11T |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
A11T |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
A11T |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
BRAF |
D677N |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D677N |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D677N |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D677N |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FGFR3 |
R439G |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R439G |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R439G |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
CDKN2A |
I49N |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
I49N |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
I49N |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
I49N |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
I49N |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
I49N |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
I49N |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
I49N |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NOTCH1 |
A150T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A150T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NF2 |
E38* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E38* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
E38* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E38* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
E38* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E38* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
E38* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E38* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
E38* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
E38* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
E38* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
E38* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
E38* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E38* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
E38* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E38* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E38* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
E38* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
E38* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
E38* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
E38* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E38* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
E38* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
E38* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
E38* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
CTNNB1 |
S33P |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S33P |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
KMT2D |
E1080* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
JAK2 |
W659R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PIK3R1 |
R557Q |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
R557Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
ALK |
S1081R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1081R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S1081R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S1081R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S1081R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S1081R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S1081R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S1081R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S1081R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S1081R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S1081R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S1081R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S1081R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1081R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1081R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S1081R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S1081R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S1081R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S1081R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
CHEK2 |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
CHEK2 |
splice_donor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
NTRK1 |
T734M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
T734M |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
T734M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
T734M |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
E286* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E286* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E286* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E286* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E286* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E286* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E286* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E286* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
P877L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P877L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
H179Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I1051V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1051V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1051V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1051V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1051V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1019P |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A1019P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1019P |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A1019P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1019P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A1019P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A1019P |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A1019P |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A1019P |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
CDKN2A |
L94Rfs*52 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L94Rfs*52 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L94Rfs*52 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
L94Rfs*52 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L94Rfs*52 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L94Rfs*52 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L94Rfs*52 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L94Rfs*52 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2A |
T3577M |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
T3577M |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
T3577M |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
T3577M |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
T3577M |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
T3577M |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NF2 |
splice_donor_variant |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
splice_donor_variant |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_donor_variant |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
splice_donor_variant |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
splice_donor_variant |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_donor_variant |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_donor_variant |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
splice_donor_variant |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
splice_donor_variant |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
splice_donor_variant |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_donor_variant |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
splice_donor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
splice_donor_variant |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
splice_donor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
KMT2A |
A3729T |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
A3729T |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
A3729T |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
A3729T |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
A3729T |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
A3729T |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C229* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C229* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C229* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C229* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C229* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C229* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C229* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C229* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C229* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C229* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C229* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C229* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C229* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C229* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C229* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R202P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R202P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R202P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R202P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R202P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R202P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R202P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R202P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R202P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R202P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R202P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R202P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R202P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R202P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R202P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
P1191P |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1191P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P1191P |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P1191P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P1191P |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1191P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1191P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P1191P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P1191P |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1191P |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P1191P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P1191P |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P1191P |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1191P |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P1191P |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P1191P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P1191P |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P1191P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P1191P |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PDGFRA |
A663A |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
T544S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
T544S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
T544S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
T544S |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
T544S |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
T544S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
T544S |
Different Mutation |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
T544S |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
T544S |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
T544S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
T544S |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
T544S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
T544S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
T544S |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
T544S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
T544S |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
T544S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
T544S |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
T544S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
RET |
H784H |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
H784H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
H784H |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
H784H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
H784H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
H784H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
H784H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
H784H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
H784H |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
S240G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S240G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S240G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S240G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S240G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S240G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S240G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S240G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S240G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S240G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S240G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S240G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S240G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S240G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S240G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
IntronicDeletion |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
CDKN2A |
R138K |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R138K |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R138K |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R138K |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R138K |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R138K |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R138K |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R138K |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KRAS |
G12E |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12E |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12E |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12E |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12E |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12E |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12E |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12E |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12E |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12E |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12E |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12E |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12E |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12E |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12E |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12E |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12E |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12E |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12E |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12E |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12E |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12E |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12E |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12E |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12E |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12E |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12E |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12E |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12E |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12E |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
Y234* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y234* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y234* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y234* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y234* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y234* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y234* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y234* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y234* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y234* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y126H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y126H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y126H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y126H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y126H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y126H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y126H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y126H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y126H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y126H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y126H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S127P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S127P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S127P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S127P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S127P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S127P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S127P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S127P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
G469A |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G469A |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469A |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469A |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G469A |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469A |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469A |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G469A |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G469A |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G469A |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G469A |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G469A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G469A |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G469A |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G469A |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469A |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G469A |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G469A |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G469A |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469A |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G469A |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G469A |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G469A |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G469A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R248Q), TP53 MUT (splice_acceptor_variant |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
intron_variant), FGFR2 MUT* (V270V |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
intron_variant), FGFR2 MUT* (V270V |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
FGFR3 |
A797T), FGFR3 MUT* (R252W |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
A797T), FGFR3 MUT* (R252W |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
A797T), FGFR3 MUT* (R252W |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y163C), TP53 MUT (E287K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163C), TP53 MUT (E287K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
intron_variant), RET MUT* (P766L), RET MUT* (intron_variant |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NOTCH1 |
T1602I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T1602I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
E198* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E198* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E198* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E198* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E198* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E198* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E198* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E198* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E198* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E198* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E198* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E198* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E198* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E198* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E198* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
splice_acceptor_variant), TP53 MUT (P278H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
L690L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
L690L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
L690L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L194R), TP53 MUT (M243I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194R), TP53 MUT (M243I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FBXW7 |
R465H |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R465H |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R465H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R465H |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
M133T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M133T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M133T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M133T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M133T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M133T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M133T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M133T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M133T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M133T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I232S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I232S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I232S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I232S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I232S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I232S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I232S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I232S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I232S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I232S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
L782F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L782F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
FGFR3 |
P795L), FGFR3 MUT* (F273F |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P795L), FGFR3 MUT* (F273F |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P795L), FGFR3 MUT* (F273F |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
FGFR2 |
S267S |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
S267S |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
E339K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E339K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E339K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E339K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E339K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E339K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E339K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E339K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E339K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E339K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E339K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E339K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E339K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E339K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E339K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q781*), RET MUT* (intron_variant), RET MUT* (L629L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ERBB4 |
P943P |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
P753S |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
P753S |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
P753S |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
P753S |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
P753S |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
P753S |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
P753S |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
P753S |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
P753S |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
P753S |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
P753S |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
P753S |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
P753S |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
P753S |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
P753S |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
P753S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
P753S |
Complete Match |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
P753S |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
P753S |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
P753S |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
P753S |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
P753S |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
P753S |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
P753S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
P753S |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
P753S |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
P753S |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
P753S |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
P753S |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
P753S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
P753S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
P753S |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
P753S |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
P753S |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
P753S |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
P753S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
P753S |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
P753S), EGFR MUT* (C775C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
P753S), EGFR MUT* (C775C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ATM |
R3008C |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R3008C |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R3008C |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R3008C |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R3008C |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R3008C |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R3008C |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R3008C |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R3008C |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R3008C |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R3008C |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R3008C |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R3008C |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
JAK2 |
K603K |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PIK3CA |
A1046V |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
A1046V |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
A1046V |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
A1046V |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
A1046V |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
A1046V |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
A1046V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
A1046V |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PDGFRA |
C677Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
P573S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
P573S |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
P573S |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
P573S |
Complete Match |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
P573S |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
P573S |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
P573S |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
P573S |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
P573S |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
P573S |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
P573S |
Complete Match |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
P573S |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
P573S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
P573S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
P573S |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
P573S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
P573S |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
P573S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
P573S |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
P573S |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
P573S |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
P573S |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
P573S |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
P573S |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
P573S |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
P573S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
FBXW7 |
R505H |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R505H |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R505H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R505H |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FGFR3 |
S378S |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
S378S |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
S378S |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A189T), TP53 MUT (P191S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A189T), TP53 MUT (P191S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
L998L), MET MUT* (R359Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
BRAF |
G593D |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G593D |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G593D |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G593D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
VHL |
P86S |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
CDKN2A |
G139S |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G139S |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G139S |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
G139S |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G139S |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G139S |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G139S |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G139S |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
G12D |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
G12D |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
G12D |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
G12D |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
G12D |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
G12D |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
G12D |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
G12D |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
G12D |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G469V |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469V |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469V |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
G469V |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
G469V |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G469V |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G469V |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469V |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G469V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G469V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G469V |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G469V |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G469V |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G469V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G469V |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G469V |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G469V |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G469V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G469V |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G469V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G469V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G469V |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G469V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G469V |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G469V |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G469V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FGFR3 |
P260L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P260L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P260L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
V274D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V274D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V274D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V274D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V274D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V274D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V274D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V274D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V274D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V274D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E346* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E346* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E346* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E346* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E346* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E346* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E346* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E346* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E346* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E346* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E346* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E346* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E346* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E346* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E346* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
IDH1 |
R132H |
Complete Match |
Venetoclax (BCL2 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132H |
Complete Match |
IDH1 inhibitor |
Responsive |
AML |
Early trials |
IDH1 |
R132H |
Complete Match |
AG-120 (IDH1 inhibitor) |
Responsive |
G |
Early trials |
IDH1 |
R132H |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CH |
Early trials |
IDH1 |
R132H |
Complete Match |
Ivosidenib (IDH1 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132H |
Complete Match |
BCL2 inhibitor |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132H |
Complete Match |
BCL2 inhibitor (BCL2 inhibitor) |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132H |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
BT |
Pre-clinical |
IDH1 |
R132H |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P278H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P278H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P278H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P278H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P278H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P278H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P278H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P278H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12R), KRAS MUT (V14I |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12R), KRAS MUT (V14I |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
Y234H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y234H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y234H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y234H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y234H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y234H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y234H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y234H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y234H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y234H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R249G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R249G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R249G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R249G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R249G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R249G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R249G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R249G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R249G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R249G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R249G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R158H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R158H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R158H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R158H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R158H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R158H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R158H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R158H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y220H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y220H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y220H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y220H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y220H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y220H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y220H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y220H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (R248Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R248Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T155N), TP53 MUT (N247I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155N), TP53 MUT (N247I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
Q598K |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
L703L), EGFR MUT* (L104L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L703L), EGFR MUT* (L104L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ABL1 |
G383S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G383S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G383S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G383S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G383S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G383S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
PDGFRA |
V832M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (P190L), TP53 MUT (M246I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
V742I |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
V742I |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
H179L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E336* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E336* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E336* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E336* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E336* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E336* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E336* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E336* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E336* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E336* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E336* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E336* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E336* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E336* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E336* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
Q626Q |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
Q626Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q626Q |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
Q626Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q626Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q626Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q626Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q626Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q626Q |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
L206* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L206* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L206* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L206* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L206* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L206* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L206* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L206* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L206* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L206* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L206* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L206* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L206* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L206* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L206* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F270C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F270C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F270C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F270C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F270C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F270C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F270C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F270C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PDGFRA |
H687Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
W110*), CDKN2A MUT (E120* |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
FGFR3 |
G637G |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
G637G |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
G637G |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
CTNNB1 |
G34R |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
G34R |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
EGFR |
R831H |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R831H |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
PTEN |
R335* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R335* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R335* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
R335* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
R335* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
R335* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R335* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R335* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R335* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
R335* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R335* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R335* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
R335* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R335* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R335* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R335* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
R335* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R335* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R335* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R335* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R335* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R335* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R335* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R335* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R335* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
RET |
N783K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
N783K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N783K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
N783K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N783K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N783K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N783K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N783K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N783K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
V218A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V218A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V218A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V218A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V218A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V218A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V218A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V218A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V218A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V218A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V218A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V218A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
V1599M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V1599M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
F270I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F270I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F270I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F270I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F270I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F270I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F270I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F270I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F270I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR3 |
R805Q |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R805Q |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R805Q |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
APC |
R876* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
FAT1 |
Q1441* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
CRLF2 |
Q210* |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
Q210* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
TP53 |
R280G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R280G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R280G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R280G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R280G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R280G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R280G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R280G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R280G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R280G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R280G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R280G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
E2034* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E2034* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TSC1 |
K629* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
K629* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
K629* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
K629* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
K629* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
K629* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
K629* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
PTEN |
splice_acceptor_variant |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
splice_acceptor_variant |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
splice_acceptor_variant |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
splice_acceptor_variant |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
splice_acceptor_variant |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
splice_acceptor_variant |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
splice_acceptor_variant |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
splice_acceptor_variant |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
splice_acceptor_variant |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
splice_acceptor_variant |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
splice_acceptor_variant |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
splice_acceptor_variant |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
splice_acceptor_variant |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
splice_acceptor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
splice_acceptor_variant |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
splice_acceptor_variant |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
splice_acceptor_variant |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
splice_acceptor_variant |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
splice_acceptor_variant |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
splice_acceptor_variant |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
splice_acceptor_variant |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
POLE |
Q1430* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
POLE |
Q1430* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
COREAD |
Case report |
POLE |
Q1430* |
Different Mutation |
PD1 Ab inhibitor |
Responsive |
G, ED |
Case report |
POLE |
Q1430* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ARID1A |
Q563* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q563* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q563* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q563* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
I471T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
I471T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
Q136E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q136E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q136E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q136E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q136E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q136E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q136E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q136E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q136E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q136E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q136E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q136E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
S595* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
S595* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2A |
P10L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P10L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P10L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P10L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P10L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P10L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
VHL |
S65T |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
SETD2 |
Q2266* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q2266* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
EGFR |
A1181P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A1181P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ARID1A |
K1808* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
K1808* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
K1808* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
K1808* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
EGFR |
A1118T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A1118T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
JAK2 |
C787R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PALB2 |
R414* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
R414* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
R414* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
R414* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
R414* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
R414* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
R414* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
R414* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
FGFR3 |
G697S |
Different Mutation |
FGFR inhibitor |
Responsive |
MYMA |
Pre-clinical |
FGFR3 |
G697S |
Different Mutation |
Bortezomib (Proteasome inhibitor) |
Responsive |
MYMA |
Pre-clinical |
FGFR3 |
G697S |
Different Mutation |
FGFR inhibitor |
Responsive |
LUAD |
Pre-clinical |
FGFR3 |
G697S |
Different Mutation |
FGFR inhibitor |
Resistant |
MYMA |
Pre-clinical |
FGFR3 |
G697S |
Complete Match |
FGFR inhibitor |
Responsive |
BLCA |
Early trials |
FGFR3 |
G697S |
Different Mutation |
Bortezomib (Proteasome inhibitor) |
Resistant |
MYMA |
Pre-clinical |
FGFR3 |
G697S |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
G697S |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
G697S |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
KMT2A |
K3557R), MLL MUT* (R1665C |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K3557R), MLL MUT* (R1665C |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K3557R), MLL MUT* (R1665C |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K3557R), MLL MUT* (R1665C |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K3557R), MLL MUT* (R1665C |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K3557R), MLL MUT* (R1665C |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
R1523C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1523C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
E1123K), BRD4 MUT* (H1136Y |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
KMT2D |
Q3634* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
Y236D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y236D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y236D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y236D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y236D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y236D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y236D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y236D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y236D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y236D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
D24N |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RNF43 |
W159* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
EGFR |
A313S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A313S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
AKT3 |
S238L |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
JAK2 |
G76A |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
IDH2 |
R140W |
Different Mutation |
AG-221 (IDH2 inhibitor) |
Responsive |
HEMATO |
Early trials |
IDH2 |
R140W |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
BT |
Pre-clinical |
IDH2 |
R140W |
Different Mutation |
Enasidenib (IDH2 inhibitor) |
Responsive |
AML |
FDA guidelines |
IDH2 |
R140W |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CH |
Early trials |
IDH2 |
R140W |
Complete Match |
Venetoclax (BCL2 inhibitor) |
Responsive |
AML |
Early trials |
NF1 |
K50*fs*1 |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
K50*fs*1 |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K50*fs*1 |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K50*fs*1 |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K50*fs*1 |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K50*fs*1 |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
TP53 |
K132N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
R1886H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EGFR |
L25V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L25V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ABL1 |
E38D |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
E38D |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
E38D |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
E38D |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
E38D |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
E38D |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ERBB3 |
V104L |
Different Mutation |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB3 |
V104L |
Different Mutation |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Mutation |
ERBB3 mAb inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104L |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
BRCA2 |
L2696* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
L2696* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
L2696* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
L2696* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
L2696* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
L2696* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
L2696* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
L2696* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
L2696* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
L2696* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
L2696* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
L2696* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
L2696* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
L2696* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
P190T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P190T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P190T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P190T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P190T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P190T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P190T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P190T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P190T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P190T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
V578I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
V578I |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
V578I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
V578I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ESR1 |
R211S |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ROS1 |
L1672V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
L1672V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
L1672V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
L1672V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
L1672V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
PIK3CA |
D350N |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
D350N |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
D350N |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
D350N |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
D350N |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
D350N |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
D350N |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
D350N |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
KMT2D |
Q5365* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NTRK1 |
R507H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R507H |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R507H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R507H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
PIK3CA |
E726K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E726K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E726K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E726K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E726K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E726K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E726K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E726K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
APC |
splice_donor_variant |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
JAK2 |
S507* |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
FGFR2 |
N123I |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
N123I |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12C), KRAS MUT (G12D |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12C), KRAS MUT (G12D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12C), KRAS MUT (G12D |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NRAS |
Q61K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
Q61K |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
Q61K |
Complete Match |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
Q61K |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
Q61K |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
Q61K |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
Q61K |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
Q61K |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
Q61K |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
Q61K |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
Q61K |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
Q61K |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
Q61K |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
Q61K |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ALK |
S1086L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1086L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S1086L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S1086L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S1086L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S1086L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S1086L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S1086L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S1086L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S1086L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S1086L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S1086L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S1086L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1086L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S1086L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S1086L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S1086L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S1086L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S1086L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
H2769R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
H2769R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
H2769R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
H2769R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
H2769R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
H2769R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
E1766* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1766* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1766* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1766* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
EGFR |
S177L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
S177L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ARID1A |
L113Qfs*119 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
L113Qfs*119 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
L113Qfs*119 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
L113Qfs*119 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E95* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E95* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TSC2 |
CdsStartSNV |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
CdsStartSNV |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
CdsStartSNV |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
CdsStartSNV |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
CdsStartSNV |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
CdsStartSNV |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
CdsStartSNV |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
ARID1A |
E2120* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2120* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2120* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E2120* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RAF1 |
V537I |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
V537I |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
V537I |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
H83Y), CDKN2A MUT (P48L |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
ARID1A |
L2279Vfs*106 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
L2279Vfs*106 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
L2279Vfs*106 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
L2279Vfs*106 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2A |
D2713G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
D2713G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
D2713G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
D2713G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
D2713G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
D2713G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
E2139* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E2139* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E2139* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E2139* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2139* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2139* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2139* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E2139* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2139* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2139* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2139* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2139* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2139* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
SETD2 |
S1442* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
S1442* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
S229* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
S229* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
S229* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
S229* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
S229* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
S229* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
S229* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
S229* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
S229* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
S229* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
S229* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
S229* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
S229* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
S229* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
S229* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
S229* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
S229* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
S229* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
S229* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
S229* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
S229* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
S229* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
S229* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
S229* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
S229* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
CDH1 |
E167* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
POLE |
Q345* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
POLE |
Q345* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
COREAD |
Case report |
POLE |
Q345* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
G, ED |
Case report |
POLE |
Q345* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
PTEN |
S59* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
S59* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
S59* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
S59* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
S59* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
S59* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
S59* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
S59* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
S59* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
S59* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
S59* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
S59* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
S59* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
S59* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
S59* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
S59* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
S59* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
S59* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
S59* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
S59* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
S59* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
S59* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
S59* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
S59* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
S59* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
RAF1 |
S204T |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
S204T |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
S204T |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NF1 |
E2753* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
E2753* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
E2753* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
E2753* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
E2753* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
E2753* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2753* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
E2753* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2753* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
E2753* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
E2753* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2753* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
E2753* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
E2753* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
E2753* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
E2753* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2753* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2753* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
E2753* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
E2753* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2753* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
AKT3 |
R66P |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
SETD2 |
Y2286* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Y2286* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
G919R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G919R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
B2M |
CdsStartSNV |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Case report |
TP53 |
M246T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M246T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M246T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M246T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M246T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M246T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M246T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M246T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M246T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M246T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3R1 |
CdsStartSNV |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
CdsStartSNV |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
RAF1 |
Y458F |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
Y458F |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
Y458F |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
KMT2A |
S2872* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S2872* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S2872* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S2872* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S2872* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S2872* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
AKT3 |
R478* |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A161_I162delinsPS |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A161_I162delinsPS |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A161_I162delinsPS |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A161_I162delinsPS |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A161_I162delinsPS |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A161_I162delinsPS |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A161_I162delinsPS |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A161_I162delinsPS |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I254S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I254S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I254S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I254S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I254S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I254S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I254S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I254S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I254S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I254S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I254S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I254S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
P1300T |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
APC |
E1544* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
TP53 |
F270V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F270V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F270V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F270V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F270V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F270V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F270V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F270V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F270V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F270V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F270V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F270V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
M1941I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R), KRAS MUT (G12V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12R), KRAS MUT (G12V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
L257R), TP53 MUT (K321* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L257R), TP53 MUT (K321* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L257R), TP53 MUT (K321* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NF2 |
R341* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
R341* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
R341* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
R341* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
R341* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
R341* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
R341* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
R341* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
R341* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
R341* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
R341* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
R341* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
R341* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
R341* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
R341* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
R341* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
R341* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
R341* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
R341* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
R341* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
R341* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
R341* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
R341* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
R341* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
R341* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
TP53 |
E286Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E286Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E286Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E286Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E286Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E286Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E286Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E286Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
E1138* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
D208H |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
D208H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
D208H |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
D208H |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
D208H |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
D208H |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ROS1 |
N2220I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
N2220I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
N2220I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
N2220I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
N2220I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
P278A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P278A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P278A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P278A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P278A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P278A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P278A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P278A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P278A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P278A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P278A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P278A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V173_R175delinsGG |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V173_R175delinsGG |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V173_R175delinsGG |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V173_R175delinsGG |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V173_R175delinsGG |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V173_R175delinsGG |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V173_R175delinsGG |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V173_R175delinsGG |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V173_R175delinsGG |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
A4V |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A4V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A4V |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A4V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A4V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A4V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A4V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A4V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A4V |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ERBB4 |
L1247M |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
Q1052* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
Q1052* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
Q1052* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
Q1052* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
Q1052* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
Q1052* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
AKT3 |
R166Q |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TMPRSS2 |
V86M |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
V86M |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
BRD4 |
E718G |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
KMT2D |
S4669* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
CTNNB1 |
D32G |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
D32G |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
RB1 |
Q217* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Q217* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q217* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q217* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q217* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q217* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q217* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NOTCH2 |
E1190K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
H61R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
H61R |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
H61R |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
H61R |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
H61R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
H61R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
H61R |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
H61R |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
H61R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
H61R |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
H61R |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
H61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
H61R |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
H61R |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
H61R |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
H61R |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
H61R |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
H61R |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
H61R |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
H61R |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
H61R |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
H61R |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
H61R |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
H61R |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
H61R |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
AKT1 |
E17K |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Case report |
AKT1 |
E17K |
Complete Match |
allosteric AKT inhibitor |
Responsive |
CANCER |
Early trials |
AKT1 |
E17K |
Complete Match |
non-allosteric AKT inhibitor |
Responsive |
CANCER |
Early trials |
AKT1 |
E17K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
AKT1 |
E17K |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Early trials |
AKT1 |
E17K |
Complete Match |
AKT inhibitor |
Responsive |
CANCER |
Pre-clinical |
AKT1 |
E17K |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
FH |
Case report |
TP53 |
N263Kfs*8 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N263Kfs*8 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N263Kfs*8 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N263Kfs*8 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N263Kfs*8 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N263Kfs*8 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N263Kfs*8 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N263Kfs*8 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N263Kfs*8 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N263Kfs*8 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N263Kfs*8 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N263Kfs*8 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N263Kfs*8 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N263Kfs*8 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N263Kfs*8 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S215R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S215R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S215R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S215R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S215R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S215R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S215R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S215R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S215R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S215R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S215R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S215R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
R556* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R556* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R556* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R556* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R556* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R556* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R556* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
TP53 |
N131I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N131I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N131I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N131I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N131I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N131I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N131I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N131I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N131I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N131I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N131I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N131I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
E110* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ALK |
I1116T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
I1116T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
I1116T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
I1116T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
I1116T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
I1116T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
I1116T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
I1116T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
I1116T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
I1116T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
I1116T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
I1116T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
I1116T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
I1116T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
I1116T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
I1116T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
I1116T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
I1116T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
I1116T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
V276I |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V276I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V276I |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V276I |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V276I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V276I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V276I |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V276I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V276I |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NTRK3 |
R201C |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R201C |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R201C |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
D2031Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Q1327* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1327* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1327* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1327* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
T1152N |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
P152R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P152R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P152R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P152R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P152R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P152R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P152R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P152R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P152R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P152R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P152R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P152R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P152R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P152R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P152R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
E134* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
E134* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ARID1A |
S1798* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1798* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1798* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S1798* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SF3B1 |
R625H |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
APC |
Q222* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T155P), TP53 MUT (R156L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155P), TP53 MUT (R156L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
E1200* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E1200* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2D |
K3551* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
S241P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S241P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S241P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S241P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S241P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S241P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S241P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S241P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S241P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S241P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S241P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S241P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
S103* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S103* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S103* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S103* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ALK |
G1100C |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1100C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G1100C |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G1100C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G1100C |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1100C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1100C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G1100C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1100C |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1100C |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G1100C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G1100C |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G1100C |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1100C |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1100C |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1100C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G1100C |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G1100C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1100C |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RNF43 |
splice_acceptor_variant |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
NOTCH2 |
E710K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
T555A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T555A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EPHA3 |
splice_acceptor_variant |
Different Alteration |
EPHA3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
EPHA3 |
splice_donor_variant |
Different Alteration |
EPHA3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
Q44K |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
CTNNB1 |
S45F), CTNNB1 MUT (S45C |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S45F), CTNNB1 MUT (S45C |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
NTRK1 |
P311L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
P311L |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
P311L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
P311L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
AKT3 |
M117L |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
L188Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L188Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L188Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L188Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L188Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L188Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L188Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L188Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L188Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L188Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L188Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L188Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L188Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L188Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L188Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TSC1 |
R484Efs*48 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
R484Efs*48 |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
R484Efs*48 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
R484Efs*48 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
R484Efs*48 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
R484Efs*48 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
R484Efs*48 |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
PTEN |
L247* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
L247* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
L247* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
L247* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
L247* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
L247* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
L247* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
L247* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
L247* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
L247* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
L247* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
L247* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
L247* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
L247* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
L247* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
L247* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
L247* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
L247* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
L247* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
L247* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
L247* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
L247* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
L247* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
L247* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
L247* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
Y236H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y236H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y236H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y236H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y236H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y236H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y236H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y236H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y236H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y236H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y236H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y236H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I1517T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1517T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1517T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1517T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1517T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ROS1 |
A1919D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A1919D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A1919D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A1919D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A1919D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2D |
Q3333* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
I255F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I255F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I255F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I255F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I255F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I255F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I255F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I255F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRCA1 |
E1258* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
E1258* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
E1258* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
E1258* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E1258* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E1258* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
E1258* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
E1258* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
E1258* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E1258* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
E1258* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E1258* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
MET |
R359Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
FGFR2 |
R190Q |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
R190Q |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
CDKN2A |
A86Wfs*31 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A86Wfs*31 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A86Wfs*31 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
A86Wfs*31 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A86Wfs*31 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A86Wfs*31 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A86Wfs*31 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A86Wfs*31 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
R209* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R209* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R209* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R209* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R209* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R209* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R209* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R209* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R209* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R209* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R209* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R209* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R209* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R209* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R209* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2D |
splice_donor_variant |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ARID1A |
Q1212*), ARID1A MUT (S350* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1212*), ARID1A MUT (S350* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1212*), ARID1A MUT (S350* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1212*), ARID1A MUT (S350* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
CDKN2A |
P114L |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P114L |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P114L |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
P114L |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P114L |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P114L |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P114L |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P114L |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
Q100* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q100* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q100* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q100* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q100* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q100* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q100* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q100* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q100* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q100* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q100* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q100* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q100* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q100* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q100* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MAP2K2 |
L46F |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Pre-clinical |
MAP2K2 |
L46F |
Complete Match |
MEK inhibitor |
Resistant |
CM |
Pre-clinical |
MAP2K2 |
L46F |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K2 |
L46F |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
TP53 |
L194F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L194F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L194F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L194F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L194F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L194F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L194F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L194F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L194F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L194F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
Q1388* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
Q1388* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
Q1388* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
Q1388* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
Q1388* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
Q1388* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
KMT2A |
Q3086H |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
Q3086H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
Q3086H |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
Q3086H |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
Q3086H |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
Q3086H |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
PIK3CA |
H1047Y |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
H1047Y |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
H1047Y |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047Y |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
H1047Y |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
H1047Y |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
H1047Y |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
H1047Y |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
C124L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C124L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C124L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C124L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C124L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C124L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C124L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C124L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C124L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C124L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C124L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C124L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
V600R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
V600R |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
V600R |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
V600R |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600R |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600R |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
V600R |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
V600R |
Complete Match |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600R |
Complete Match |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600R |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
V600R |
Complete Match |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Complete Match |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Complete Match |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
V600R |
Complete Match |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Complete Match |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Complete Match |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Complete Match |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600R |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
V600R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
V600R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600R |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
V600R |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
V600R |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
V600R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
V600R |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
V600R |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
V600R |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
V600R |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
V600R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
V600R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
V600R |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
V600R |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
V600R |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
V600R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
RET |
R897* |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R897* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R897* |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R897* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R897* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R897* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R897* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R897* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R897* |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
V274L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V274L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V274L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V274L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V274L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V274L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V274L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V274L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V274L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V274L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V274L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V274L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
VHL |
F136Lfs*20 |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
TSC1 |
S282* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
S282* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
S282* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
S282* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
S282* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
S282* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
S282* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
ERBB4 |
I481M |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FBXW7 |
R689Q |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R689Q |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R689Q |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R689Q |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
BRAF |
N236K |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
N236K |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
N236K |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
N236K |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
RB1 |
E313* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E313* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E313* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E313* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E313* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E313* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E313* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NOTCH1 |
V485L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V485L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PBRM1 |
R1160* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
R1160* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
R1160* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
R1160* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
R1160* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NTRK1 |
G89D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
G89D |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
G89D |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G89D |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NTRK3 |
E344D |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E344D |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E344D |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
EGFR |
R574Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R574Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ALK |
R1060H |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1060H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1060H |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1060H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1060H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1060H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1060H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1060H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1060H |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1060H |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1060H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1060H |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1060H |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1060H |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1060H |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1060H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1060H |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1060H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1060H |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
C420R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
C420R |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
C420R |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
C420R |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
C420R |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
C420R |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
C420R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
C420R |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
NTRK1 |
F669V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
F669V |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
F669V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
F669V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
APC |
R805* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ALK |
Q1188* |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1188* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Q1188* |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Q1188* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Q1188* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q1188* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q1188* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Q1188* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q1188* |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q1188* |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Q1188* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Q1188* |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q1188* |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1188* |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1188* |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q1188* |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Q1188* |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Q1188* |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q1188* |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FAT1 |
R2597* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
FGFR2 |
K540E |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
K540E |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
KMT2A |
P569L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P569L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P569L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P569L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P569L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P569L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
Y1034* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Y1034* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Y1034* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Y1034* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Y1034* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Y1034* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Y1034* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Y1034* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Y1034* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Y1034* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Y1034* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Y1034* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Y1034* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
C141G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SMARCA4 |
E1148* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
E1148* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
E1148* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
E1148* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
E1148* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
KMT2A |
P436A |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P436A |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P436A |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P436A |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P436A |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P436A |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ERBB3 |
V104M |
Different Mutation |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104M |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104M |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104M |
Complete Match |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB3 |
V104M |
Different Mutation |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104M |
Different Mutation |
ERBB3 mAb inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
V104M |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
TP53 |
P295Vfs*50 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P295Vfs*50 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P295Vfs*50 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P295Vfs*50 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P295Vfs*50 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P295Vfs*50 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P295Vfs*50 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P295Vfs*50 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P295Vfs*50 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P295Vfs*50 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P295Vfs*50 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P295Vfs*50 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P295Vfs*50 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P295Vfs*50 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P295Vfs*50 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
AKT3 |
I36T |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
K575T |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
K575T |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
K575T |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Y2031* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y2031* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y2031* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y2031* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H168R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H168R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H168R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H168R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H168R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H168R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H168R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H168R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H168R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H168R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H168R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H168R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
Y3917C |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
Y3917C |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
Y3917C |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
Y3917C |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
Y3917C |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
Y3917C |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ARID1A |
N1253Tfs*5 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N1253Tfs*5 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N1253Tfs*5 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
N1253Tfs*5 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PIK3CA |
N1044K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
N1044K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
N1044K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N1044K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
N1044K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N1044K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
N1044K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
N1044K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
FGFR3 |
R399H |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R399H |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R399H |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
M133R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M133R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M133R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M133R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M133R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M133R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M133R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M133R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M133R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M133R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R337C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R337C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R337C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R337C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R337C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R337C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R337C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R337C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R337C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R337C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
P48L |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P48L |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P48L |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
P48L |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P48L |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P48L |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P48L |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P48L |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
splice_acceptor_variant), TSC2 MUT (Q785* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
NTRK1 |
R682C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R682C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R682C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R682C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
FBXW7 |
Q220* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
Q220* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
Q220* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
Q220* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TSC2 |
G20Ffs*11 |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
G20Ffs*11 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
G20Ffs*11 |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
G20Ffs*11 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
G20Ffs*11 |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
G20Ffs*11 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
G20Ffs*11 |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
PTEN |
R130* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R130* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
R130* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
R130* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
R130* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
R130* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R130* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R130* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R130* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
R130* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R130* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R130* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
R130* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R130* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R130* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R130* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
R130* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
R130* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
R130* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
R130* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
R130* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
R130* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
R130* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
R130* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
R130* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
JAK2 |
K776Q |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
NOTCH2 |
E2461K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
P690Afs*124 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P690Afs*124 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P690Afs*124 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
P690Afs*124 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
G626D |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G626D |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G626D |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G626D |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G626D |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G626D |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
V147G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V147G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V147G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V147G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V147G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V147G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V147G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V147G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V147G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V147G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V147G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V147G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V147G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V147G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V147G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
V573L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V573L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V573L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V573L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V573L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V573L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V573L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V573L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V573L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
MET |
R143Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
ATM |
Q1627* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q1627* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q1627* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q1627* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1627* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1627* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1627* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q1627* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1627* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1627* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1627* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1627* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1627* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RNF43 |
R337* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ERBB4 |
P1206T |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
VHL |
R167W |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
RNF43 |
E74* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
PTEN |
Y68C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y68C |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y68C |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y68C |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y68C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y68C |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y68C |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y68C |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y68C |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y68C |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y68C |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y68C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y68C |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y68C |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y68C |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y68C |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y68C |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y68C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y68C |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y68C |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y68C |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y68C |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y68C |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y68C |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y68C |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
AKT3 |
L109M |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
Venetoclax (BCL2 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
IDH1 inhibitor |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
AG-120 (IDH1 inhibitor) |
Responsive |
G |
Early trials |
IDH1 |
R132L |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CH |
Early trials |
IDH1 |
R132L |
Complete Match |
Ivosidenib (IDH1 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132L |
Complete Match |
BCL2 inhibitor |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
BCL2 inhibitor (BCL2 inhibitor) |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
BT |
Pre-clinical |
IDH1 |
R132L |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
EGFR |
N816S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
N816S |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
PIK3R1 |
E439* |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
E439* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
NTRK3 |
R201H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R201H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R201H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R582Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R582Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R582Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
A138P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A138P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A138P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A138P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A138P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A138P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A138P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A138P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A138P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A138P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A138P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A138P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A138P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
R242S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
C238G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
V14I |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
V14I |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
V14I |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
V14I |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
V14I |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
V14I |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
V14I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
V14I |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
V14I |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
V14I |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
V14I |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
V14I |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
V14I |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
V14I |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
V14I |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
V14I |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
V14I |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
V14I |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
V14I |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
V14I |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
V14I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
V14I |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
V14I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
V14I |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
V14I |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
V14I |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
V14I |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
V14I |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
V14I |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
V14I |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
V14I |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
V14I |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
V14I |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
V14I |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
V14I |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
V14I |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NOTCH2 |
A1654T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Q1493* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1493* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1493* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1493* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q789* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q789* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q789* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q789* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ATM |
R2993* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2993* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2993* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2993* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2993* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2993* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2993* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2993* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2993* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2993* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2993* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2993* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2993* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
PTEN |
Y65* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y65* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y65* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y65* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y65* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y65* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y65* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y65* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y65* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y65* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y65* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y65* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y65* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y65* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y65* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y65* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y65* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y65* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y65* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y65* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y65* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y65* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y65* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y65* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y65* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
L194H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L194H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L194H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L194H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L194H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L194H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L194H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L194H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L194H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L194H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CRLF2 |
D176H |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
D176H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
NTRK3 |
I783N |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
I783N |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
I783N |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
BRCA2 |
S1385* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
S1385* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
S1385* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
S1385* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
S1385* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
S1385* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
S1385* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
S1385* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
S1385* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
S1385* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
S1385* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
S1385* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
S1385* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
S1385* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
BRCA2 |
Q3295* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q3295* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q3295* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q3295* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q3295* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q3295* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q3295* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q3295* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q3295* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q3295* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q3295* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q3295* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q3295* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q3295* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
V272E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V272E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V272E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V272E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V272E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V272E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V272E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V272E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V272E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V272E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V272E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V272E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P190S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P190S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P190S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P190S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P190S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P190S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P190S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P190S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P190S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P190S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
L1180F |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
AKT3 |
D219N), AKT3 MUT* (E226* |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
N131_F134delinsL |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N131_F134delinsL |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N131_F134delinsL |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N131_F134delinsL |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N131_F134delinsL |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N131_F134delinsL |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N131_F134delinsL |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131_F134delinsL |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131_F134delinsL |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N131_F134delinsL |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N131_F134delinsL |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131_F134delinsL |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N131_F134delinsL |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N131_F134delinsL |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N131_F134delinsL |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12_G13delinsAC |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12_G13delinsAC |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12_G13delinsAC |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12_G13delinsAC |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12_G13delinsAC |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12_G13delinsAC |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12_G13delinsAC |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12_G13delinsAC |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12_G13delinsAC |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12_G13delinsAC |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12_G13delinsAC |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12_G13delinsAC |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12_G13delinsAC |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
FGFR1 |
K687E |
Different Alteration |
FGFR inhibitor |
Responsive |
ED |
Case report |
FGFR1 |
K687E |
Different Alteration |
FGFR inhibitor |
Responsive |
HNC |
Pre-clinical |
FGFR1 |
K687E |
Different Alteration |
FGFR inhibitor |
Responsive;Responsive |
LUSC |
Case report;Early trials |
FGFR1 |
K687E |
Different Alteration |
FGFR inhibitor |
Responsive |
BRCA |
Early trials |
NOTCH1 |
E556G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
E556G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
H856Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
I255T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I255T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I255T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I255T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I255T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I255T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I255T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I255T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
L80R |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L80R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L80R |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L80R |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L80R |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L80R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L80R |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L80R |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L80R |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RNF43 |
W302* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
Q136P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q136P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q136P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q136P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q136P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q136P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q136P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q136P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q136P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q136P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q136P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q136P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q136P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
D761N |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
D761N |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
D761N |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
D761N |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
D761N |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
D761N |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
D761N |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
D761N |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
D761N |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
D761N |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
D761N |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
D761N |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
D761N |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
D761N |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
D761N |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
D761N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
D761N |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
D761N |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
D761N |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
D761N |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
D761N |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
D761N |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
D761N |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
D761N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
D761N |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
D761N |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
D761N |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
D761N |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
D761N |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
D761N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
D761N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
D761N |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
D761N |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
D761N |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
D761N |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
D761N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
D761N |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
D761N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
D761N |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
KMT2D |
E1816* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
FGFR3 |
E458V |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
E458V |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
E458V |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
DNMT3A |
E408* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TSC2 |
Y130* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
Y130* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
Y130* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
Y130* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
Y130* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
Y130* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
Y130* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
ABL1 |
R764Q |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R764Q |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R764Q |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R764Q |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R764Q |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R764Q |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R738L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R738L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R738L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R738L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R738L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R738L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
SETD2 |
R424* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
R424* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
Y138C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y138C |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y138C |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y138C |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y138C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y138C |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y138C |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y138C |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y138C |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y138C |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y138C |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y138C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y138C |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y138C |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y138C |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y138C |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y138C |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y138C |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y138C |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y138C |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y138C |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y138C |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y138C |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y138C |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y138C |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
FGFR3 |
G549R |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
G549R |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
G549R |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
ROS1 |
V612A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
V612A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
V612A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
V612A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V612A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
R3889Q |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R3889Q |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R3889Q |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R3889Q |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R3889Q |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R3889Q |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK1 |
G91E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
G91E |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
G91E |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G91E |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
T284P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T284P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T284P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T284P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T284P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T284P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T284P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T284P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T284P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T284P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T284P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T284P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T284P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T284P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T284P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PTEN |
C105F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
C105F |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
C105F |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
C105F |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
C105F |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
C105F |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
C105F |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
C105F |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
C105F |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
C105F |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
C105F |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
C105F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
C105F |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
C105F |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
C105F |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
C105F |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
C105F |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
C105F |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
C105F |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
C105F |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
C105F |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
C105F |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
C105F |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
C105F |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
C105F |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
ATM |
Q1274* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q1274* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q1274* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q1274* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1274* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1274* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1274* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q1274* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1274* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q1274* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q1274* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q1274* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q1274* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
Q1346* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1346* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1346* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1346* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SF3B1 |
R625G |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q589* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q589* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q589* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q589* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FAT1 |
K1926* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
TP53 |
V143M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V143M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V143M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V143M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V143M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V143M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V143M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V143M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V143M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V143M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V143M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V143M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
splice_acceptor_variant), TSC2 MUT (splice_acceptor_variant |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213*), TP53 MUT (L130V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213*), TP53 MUT (L130V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
E453* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
RET |
E734K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E734K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E734K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E734K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E734K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E734K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E734K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E734K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E734K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NTRK3 |
E318K |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E318K |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E318K |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
R1163Q |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
PTEN |
Y88* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y88* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y88* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y88* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y88* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y88* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y88* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y88* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y88* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y88* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y88* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y88* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y88* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y88* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y88* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y88* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y88* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y88* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y88* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y88* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y88* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y88* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y88* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y88* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y88* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
ESR1 |
V392I |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
Y205N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
V1970I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
V1970I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
V1970I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
V1970I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V1970I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
D820Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
D820Y |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
D820Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
D820Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
D820Y |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
D820Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D820Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D820Y |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D820Y |
Complete Match |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D820Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
D820Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D820Y |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D820Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D820Y |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
D820Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D820Y |
Complete Match |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
D820Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D820Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
D820Y |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D820Y |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D820Y |
Complete Match |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D820Y |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D820Y |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
D820Y |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
D820Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
CDKN2A |
G89Afs*38 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G89Afs*38 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G89Afs*38 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
G89Afs*38 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G89Afs*38 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G89Afs*38 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G89Afs*38 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G89Afs*38 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
A159D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S127Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S127Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S127Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S127Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S127Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S127Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S127Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S127Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S127Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S127Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S127Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
JAK2 |
S936N |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PIK3CA |
V344G |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
V344G |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
V344G |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V344G |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
V344G |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V344G |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
V344G |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
V344G |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
STK11 |
Y131* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Y131* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y131* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y131* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Y131* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y131* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y131* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y131* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y131* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y131* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y131* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y131* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y131*), KRAS MUT (Q61L |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Y131*), KRAS MUT (Q61L |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y131*), KRAS MUT (Q61L |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y131*), KRAS MUT (Q61L |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
NOTCH1 |
R1962H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1962H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PIK3R1 |
K567N |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
K567N |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
PDGFRA |
H974Q |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
ROS1 |
Q26* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
Q26* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
Q26* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
Q26* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
Q26* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRAF |
T241P |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
T241P |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
T241P |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
T241P |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
H168P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H168P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H168P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H168P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H168P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H168P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H168P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H168P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H168P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H168P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H168P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H168P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PALB2 |
R1086* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
R1086* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
R1086* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
R1086* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
R1086* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
R1086* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
R1086* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
R1086* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
ESR1 |
R164T |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
BRCA2 |
E2872* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
E2872* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E2872* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
E2872* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
E2872* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
E2872* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
E2872* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
E2872* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E2872* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E2872* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E2872* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E2872* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
E2872* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E2872* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D), KRAS MUT (G12V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (G12V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12D), KRAS MUT (G12V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NOTCH1 |
T586A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T586A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
D1972N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
D1972N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
D2032N |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
D2032N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
D2032N |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
D2032N |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
D2032N |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
D2032N |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
HRAS |
Q61K |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CER |
Pre-clinical |
HRAS |
Q61K |
Complete Match |
MEK inhibitor +/- MTOR inhibitor |
Responsive |
AML |
Pre-clinical |
HRAS |
Q61K |
Complete Match |
MTOR inhibitor |
Responsive |
CESC |
Pre-clinical |
HRAS |
Q61K |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
Responsive |
CANCER |
Early trials |
MET |
G391R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
K132Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K132Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K132Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K132Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K132Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K132Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K132Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K132Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K132Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
A2323S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
A2323S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
A2323S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
A2323S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
A2323S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
A2323S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
APC |
Q161* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
TP53 |
H179N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
R1662Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1662Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
G244V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G244V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G244V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G244V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G244V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G244V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G244V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G244V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G244V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G244V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
P539R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
P539R |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
P539R |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P539R |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
P539R |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P539R |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
P539R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
P539R |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
NTRK3 |
S775* |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
S775* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
S775* |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
KMT2D |
Q4103* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
FGFR3 |
N644S |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
N644S |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
N644S |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
ARID1A |
R1335* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1335* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1335* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1335* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PALB2 |
Q988* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Q988* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Q988* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q988* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q988* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
Q988* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
Q988* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
Q988* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
ABL1 |
R191H |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R191H |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R191H |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R191H |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R191H |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R191H |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ALK |
P117L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P117L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P117L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P117L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P117L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P117L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P117L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P117L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P117L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P117L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P117L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P117L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P117L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P117L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P117L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P117L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P117L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P117L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P117L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
A1225V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
SMARCA4 |
R1077* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
R1077* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
R1077* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
R1077* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
R1077* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
TP53 |
G199V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G199V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G199V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G199V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G199V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G199V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G199V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G199V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G199V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G199V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G199V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G199V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G199V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G199V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G199V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CTNNB1 |
S33F |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S33F |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
TP53 |
R280I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R280I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R280I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R280I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R280I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R280I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R280I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R280I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R280I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R280I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R280I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R280I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R280I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
E141* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
E141* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
E141* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
SETD2 |
Q1794* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1794* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RB1 |
Q471* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Q471* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q471* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q471* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q471* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q471* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q471* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
KMT2A |
R2078H |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R2078H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R2078H |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R2078H |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R2078H |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R2078H |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
RET |
V706M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V706M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V706M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V706M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V706M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V706M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V706M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V706M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V706M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ERCC2 |
R722W |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ERCC2 |
R722W |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ERCC2 |
R722W |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (E271* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (E271* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (E271* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
G865* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
G865* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
G865* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
G865* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
G865* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
G865* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
G865* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RET |
R694W |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R694W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R694W |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R694W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R694W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R694W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R694W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R694W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R694W |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RET |
T742M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
T742M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T742M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
T742M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T742M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T742M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T742M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T742M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T742M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
STK11 |
D194N |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
D194N |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
D194N |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
D194N |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
D194N |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
D194N |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
D194N |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
D194N |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
D194N |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
D194N |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
D194N |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
D194N |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
PIK3R1 |
CdsStopSNV |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
CdsStopSNV |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
PDGFRA |
A1014T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
STK11 |
D194N), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
D194N), KRAS MUT (G12V |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
D194N), KRAS MUT (G12V |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
D194N), KRAS MUT (G12V |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
MET |
H1154R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
R2207W |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R2207W |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R2207W |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R2207W |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R2207W |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R2207W |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK3 |
N278S |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N278S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
N278S |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R518H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R518H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R518H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Complete Match |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
S310F |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
S310F |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
S310F |
Complete Match |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
S310F |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
S310F |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
S310F |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
S310F |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
S310F |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
S310F |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
S310F |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
S310F |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
S310F |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
S310F |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310F |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
S310F |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
S310F |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
S310F |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
S310F |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
BRCA2 |
Q1551* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q1551* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1551* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q1551* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q1551* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q1551* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q1551* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q1551* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1551* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1551* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1551* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1551* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1551* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1551* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
KMT2D |
Q4210* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ERBB4 |
H647R |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RB1 |
Q444* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Q444* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q444* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q444* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q444* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Q444* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Q444* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
JAK2 |
N1085S |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
KMT2D |
C255* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
RB1 |
L335* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
L335* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
L335* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
L335* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
L335* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
L335* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
L335* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
BCOR |
S1437* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
BRD4 |
S601L |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ARID1A |
E2035* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2035* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2035* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E2035* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
U2AF1 |
S34Y |
Complete Match |
FLT3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P177S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P177S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P177S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P177S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P177S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P177S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P177S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P177S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P177S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P177S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P177S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P177S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P177S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P177S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P177S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
VHL |
V165D |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
TP53 |
H168L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H168L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H168L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H168L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H168L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H168L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H168L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H168L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H168L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H168L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H168L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H168L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H168L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I1268T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1268T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1268T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1268T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1268T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
Q104* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q104* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q104* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q104* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q104* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q104* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q104* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q104* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q104* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q104* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q104* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q104* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q104* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q104* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q104* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C135F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C135F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C135F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C135F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C135F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C135F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C135F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C135F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C135F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C135F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C135F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
M315I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M315I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
M315I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
M315I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
M315I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M315I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M315I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
M315I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M315I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M315I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
M315I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
M315I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
M315I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M315I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M315I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M315I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
M315I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
M315I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M315I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
G1298V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G1298V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
MET |
G774C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
C275S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C275S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C275S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C275S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C275S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C275S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C275S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C275S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C275S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L145Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L145Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L145Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L145Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L145Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L145Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L145Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L145Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L145Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L145Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L145Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L145Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
E539* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E539* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E539* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E539* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E539* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E539* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E539* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NTRK1 |
V524F |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
V524F |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
V524F |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
V524F |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
KMT2D |
E431* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
TP53 |
N131Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N131Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N131Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N131Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N131Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N131Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N131Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N131Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N131Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N131Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N131Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N131Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N131Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
S95V |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S95V |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S95V |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S95V |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S95V |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S95V |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
RAF1 |
E478K |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
E478K |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
E478K |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RNF43 |
E149*), RNF43 MUT (Q180* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
BRD4 |
L407V), BRD4 MUT* (D414N), BRD4 MUT* (G419S), BRD4 MUT* (R423P), BRD4 MUT* (D436H |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ATM |
Q445* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q445* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q445* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q445* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q445* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q445* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q445* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q445* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q445* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q445* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q445* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q445* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q445* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
Q1519* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1519* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1519* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1519* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FBXW7 |
Q508* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
Q508* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
Q508* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
Q508* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
MET |
S701G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
E180K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E180K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E180K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E180K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E180K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E180K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E180K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E180K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E180K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E180K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E180K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E180K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E180K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E180K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E180K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
C563S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
C563S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ATM |
Y947* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Y947* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Y947* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Y947* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Y947* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Y947* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Y947* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Y947* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Y947* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Y947* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Y947* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Y947* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Y947* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
PBRM1 |
splice_acceptor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
splice_acceptor_variant |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
splice_acceptor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
splice_acceptor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
D565E |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D565E |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D565E |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D565E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
C176W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D60Vfs*9 |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
D60Vfs*9 |
Different Mutation |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D60Vfs*9 |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
D60Vfs*9 |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
D60Vfs*9 |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D60Vfs*9 |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D60Vfs*9 |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
D60Vfs*9 |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
D60Vfs*9 |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
D60Vfs*9 |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
NOTCH2 |
R1069Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PBRM1 |
K277* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
K277* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
K277* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
K277* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
K277* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRCA2 |
Q1148* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q1148* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1148* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q1148* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q1148* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q1148* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q1148* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q1148* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1148* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1148* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1148* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1148* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1148* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1148* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
A159T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PDGFRA |
A921T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
RNF43 |
Q379* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
BCOR |
K395* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
TP53 |
V218E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V218E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V218E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V218E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V218E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V218E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V218E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V218E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V218E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V218E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V218E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V218E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V218E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
EGFR |
T1029M |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
T1029M |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
RNF43 |
V211Afs*40 |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDKN2A |
R58Gfs*84 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R58Gfs*84 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R58Gfs*84 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R58Gfs*84 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R58Gfs*84 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R58Gfs*84 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R58Gfs*84 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R58Gfs*84 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NTRK3 |
E360D |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E360D |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E360D |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ATM |
C465Efs*2 |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
C465Efs*2 |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
C465Efs*2 |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
C465Efs*2 |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
C465Efs*2 |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
C465Efs*2 |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
C465Efs*2 |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
C465Efs*2 |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
C465Efs*2 |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
C465Efs*2 |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
C465Efs*2 |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
C465Efs*2 |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
C465Efs*2 |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
splice_donor_variant), KRAS MUT (G12V |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12V |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_donor_variant), KRAS MUT (G12V |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
JAK2 |
splice_donor_variant |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PIK3R1 |
R642* |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
R642* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
NTRK3 |
W88*), NTRK3 MUT* (R169H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
W88*), NTRK3 MUT* (R169H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
W88*), NTRK3 MUT* (R169H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
FGFR2 |
G503A |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
G503A |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
BRCA2 |
Q73* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q73* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q73* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q73* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q73* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q73* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q73* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q73* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q73* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q73* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q73* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q73* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q73* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q73* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
RET |
P218L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
P218L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P218L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
P218L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P218L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P218L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P218L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P218L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P218L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRCA2 |
Y600* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Y600* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Y600* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Y600* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Y600* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Y600* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Y600* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Y600* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Y600* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Y600* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y600* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y600* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y600* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Y600* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G466V |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
G466V |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G466V |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G466V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G466V |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
G466V |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
G466V |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
G466V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
G466V |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
G466V |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G466V |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
G466V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
G466V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
G466V |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
G466V |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
G466V |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
G466V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
G466V |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
G466V |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
G466V |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
G466V |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
G466V |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
G466V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
G466V |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
G466V |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
G466V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G466V |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G466V |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G466V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
CTNNB1 |
S37A |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
S37A |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
RAF1 |
M469I |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
M469I |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
M469I |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
KMT2A |
S1685Y |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S1685Y |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S1685Y |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S1685Y |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S1685Y |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S1685Y |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TMPRSS2 |
G362E |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
G362E |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
KMT2D |
R4319* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
RET |
R355W |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R355W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R355W |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R355W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R355W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R355W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R355W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R355W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R355W |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
Y205C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y205C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y205C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y205C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y205C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y205C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y205C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y205C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y205C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y205C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y205C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y205C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D281Y |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D281Y |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D281Y |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D281Y |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D281Y |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281Y |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281Y |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281Y |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D281Y |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D281Y |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281Y |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281Y |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D281Y |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281Y |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
C2081* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
C2081* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
C2081* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
C2081* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FBXW7 |
G419* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
G419* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
G419* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
G419* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
ROS1 |
E1518D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E1518D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E1518D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E1518D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E1518D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
R158P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R158P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R158P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R158P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R158P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R158P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R158P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R158P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R158P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
L802V |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L802V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L802V |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L802V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L802V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L802V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L802V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L802V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L802V |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ABL1 |
N368S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
N368S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
N368S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
N368S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
N368S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
N368S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
RNF43 |
W194* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
Q1131* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1131* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1131* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1131* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
R389H |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
R389H |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
R389H |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
R389H |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
BRCA2 |
R3052W |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
R3052W |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R3052W |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
R3052W |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
R3052W |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
R3052W |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
R3052W |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
R3052W |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R3052W |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R3052W |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R3052W |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R3052W |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
R3052W |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R3052W |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
SETD2 |
Q1422* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1422* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
R525W |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R525W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R525W |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R525W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R525W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R525W |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R525W |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R525W |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R525W |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RNF43 |
E131* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
AKT3 |
R220H |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
RB1 |
Y606* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Y606* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y606* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Y606* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y606* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y606* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Y606* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
ERBB4 |
Q1181E |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
R376Gfs*15 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R376Gfs*15 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R376Gfs*15 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R376Gfs*15 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RET |
R694Q |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R694Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R694Q |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R694Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R694Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R694Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R694Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R694Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R694Q |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TMPRSS2 |
S270L |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
S270L |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
APC |
R2237* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
PTPRD |
W1038* |
Complete Match |
IGF1R inhibitor |
Responsive |
S |
Case report |
TP53 |
L252P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L252P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L252P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L252P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L252P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L252P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L252P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L252P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L252P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L252P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L252P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L252P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L252P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L252P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L252P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R283P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R283P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R283P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R283P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R283P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R283P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R283P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R283P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R283P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R283P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R283P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R283P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R283P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R283P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R283P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BCOR |
Q596* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
TP53 |
A83Ffs*66 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A83Ffs*66 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A83Ffs*66 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A83Ffs*66 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A83Ffs*66 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A83Ffs*66 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A83Ffs*66 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A83Ffs*66 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A83Ffs*66 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A83Ffs*66 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A83Ffs*66 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A83Ffs*66 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A83Ffs*66 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A83Ffs*66 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A83Ffs*66 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
Q502* |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ARID1A |
Q844* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q844* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q844* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q844* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
FBXW7 |
E110* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
E110* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
E110* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
E110* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
ERBB4 |
R524H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q482* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q482* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q482* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q482* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E286V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E286V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E286V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E286V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E286V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E286V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E286V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TSC2 |
G1172Ffs*61 |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
G1172Ffs*61 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
G1172Ffs*61 |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
G1172Ffs*61 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
G1172Ffs*61 |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
G1172Ffs*61 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
G1172Ffs*61 |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
S1514* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
S1514* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
S1514* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
S1514* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
S1514* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
S1514* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
S1514* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
BRD4 |
A1189V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
I254N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I254N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I254N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I254N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I254N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I254N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I254N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I254N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I254N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I254N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I254N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I254N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I255N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I255N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I255N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I255N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I255N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I255N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I255N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
K1219N |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K1219N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K1219N |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K1219N |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K1219N |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K1219N |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
PTEN |
D92H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
D92H |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
D92H |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
D92H |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
D92H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
D92H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
D92H |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
D92H |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
D92H |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
D92H |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
D92H |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
D92H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
D92H |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
D92H |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
D92H |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
D92H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
D92H |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
D92H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
D92H |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
D92H |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
D92H |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
D92H |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
D92H |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
D92H |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
D92H |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
RET |
Y483* |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
Y483* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Y483* |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
Y483* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Y483* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Y483* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Y483* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Y483* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Y483* |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
AKT3 |
D299Y), AKT3 MUT* (L344I |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
ESR1 |
M427I |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
RB1 |
E166* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E166* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E166* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E166* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E166* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E166* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E166* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
ATR |
E275* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
E275* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
E275* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
APC |
P1584Hfs*2 |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
JAK2 |
R1063C |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ROS1 |
D513Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
D513Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
D513Y |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
D513Y |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D513Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB4 |
R525H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
SMARCA4 |
E579* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
E579* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
E579* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
E579* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
E579* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
NF1 |
K2169* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
K2169* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
K2169* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K2169* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
K2169* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
K2169* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K2169* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
K2169* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K2169* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K2169* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K2169* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K2169* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K2169* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K2169* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K2169* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
K2169* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K2169* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K2169* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K2169* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K2169* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K2169* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
MEK inhibitor |
Resistant |
CANCER |
Pre-clinical |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
novel MEK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Case report |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
MAP2K1 |
Q56_E62delinsRK |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
Q56_E62delinsRK |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
SMARCA4 |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
splice_donor_variant |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
splice_donor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
splice_donor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
ERBB4 |
R927* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
R927* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
R927* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P835L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P835L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P835L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P835L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P835L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P835L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P835L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P835L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P835L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P835L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P835L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P835L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P835L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P835L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P835L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P835L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
SETD2 |
G675* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
G675* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SMARCA4 |
Y187* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Y187* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
Y187* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
Y187* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Y187* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
KRAS |
G12H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12H |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12H |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12H |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12H |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12H |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12H |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12H |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12H |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12H |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12H |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12H |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12H |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12H |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12H |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12H |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12H |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12H |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12H |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12H |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12H |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12H |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12H |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12H |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12H |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12H |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12H |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
KDR |
R961W |
Different Mutation |
VEGFR2 inhibitor |
Resistant |
COREAD |
Case report |
KDR |
R961W |
Different Mutation |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
COREAD |
Pre-clinical |
KDR |
R961W |
Complete Match |
Pazopanib (VEGFR inhibitor) |
Responsive |
BCC |
Case report |
KDR |
R961W |
Different Mutation |
VEGFR inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRD4 |
S1204R |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
RNF43 |
Q22* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ALK |
K721N |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K721N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
K721N |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
K721N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
K721N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
K721N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
K721N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
K721N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
K721N |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
K721N |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
K721N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
K721N |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
K721N |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K721N |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
K721N |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
K721N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
K721N |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
K721N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
K721N |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
Y1021C |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Y1021C |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Y1021C |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Y1021C |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Y1021C |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Y1021C |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Y1021C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Y1021C |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
MET |
R191W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
STK11 |
Q399* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Q399* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q399* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Q399* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Q399* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Q399* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q399* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q399* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Q399* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Q399* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q399* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q399* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
G106R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
G106R |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
G106R |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
G106R |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
G106R |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
G106R |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
G106R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
G106R |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
BRCA2 |
E254* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
E254* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E254* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
E254* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
E254* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
E254* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
E254* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
E254* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E254* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E254* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E254* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E254* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
E254* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E254* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
APC |
R405* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ERBB4 |
A1219T |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
L62F |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
L62F |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
L62F |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
L62F |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L62F |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L62F |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
L62F |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
L62F |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
L62F |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
L62F |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
L62F |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
L62F |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L62F |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
L62F |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
L62F |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
L62F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
L62F |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L62F |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
L62F |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
L62F |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
L62F |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
L62F |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
L62F |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
L62F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
L62F |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
L62F |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
L62F |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
L62F |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
L62F |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
L62F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
L62F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
L62F |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
L62F |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
L62F |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
L62F |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
L62F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
L62F |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
L62F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L62F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
FBXW7 |
G654S |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
G654S |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
G654S |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
G654S |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
RET |
P560L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
P560L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P560L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
P560L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P560L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P560L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P560L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P560L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P560L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
MET |
H1339Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
Gamma secretase inhibitor |
Responsive |
CANCER |
Early trials |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
Gamma secretase inhibitor;CDK4 inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
Gamma secretase inhibitor;MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
Gamma secretase inhibitor |
Responsive;Responsive |
ALL |
Early trials;Pre-clinical |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
NOTCH1 inhibitor |
Responsive |
ADCC |
Case report |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
OMP-52M51 (NOTCH1 inhibitor) |
Responsive |
CANCER |
Early trials |
NOTCH1 |
splice_acceptor_variant |
Different Mutation |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
splice_acceptor_variant |
Complete Match |
Gamma secretase inhibitor |
Responsive |
MCL |
Pre-clinical |
NOTCH1 |
splice_acceptor_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_acceptor_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRAF |
G265R |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G265R |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G265R |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G265R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
C141R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
Q503* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q503* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q503* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q503* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L137Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L137Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L137Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L137Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L137Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L137Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L137Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L137Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L137Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L137Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L137Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L137Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L137Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L137Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L137Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TMPRSS2 |
G242E |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
G242E |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
NTRK3 |
R130H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R130H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R130H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
RB1 |
S618* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
S618* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S618* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S618* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S618* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S618* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S618* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
EGFR |
S227F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
S227F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
AKT3 |
R95M |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
S696L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
S696L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
S696L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
S696L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
S696L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
S696L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
S696L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
S696L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
S696L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ARID1A |
E1802* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1802* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1802* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1802* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
R1617M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1617M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1617M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1617M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1617M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
C275F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C275F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C275F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C275F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C275F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C275F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C275F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C275F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C275F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
K265* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
K265* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
K265* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
K265* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
K265* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
K265* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
K265* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
TP53 |
T155P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T155P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T155P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T155P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T155P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T155P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T155P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T155P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T155P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
G122Pfs*108 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G122Pfs*108 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G122Pfs*108 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
G122Pfs*108 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E397* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E397* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
W1289* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
W1289* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
W1289* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
W1289* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
W1289* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
PIK3CA |
N1044S |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
N1044S |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
N1044S |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N1044S |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
N1044S |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N1044S |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
N1044S |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
N1044S |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
RET |
R817C |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R817C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R817C |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R817C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R817C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R817C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R817C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R817C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R817C |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NTRK3 |
R791Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R791Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R791Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ATM |
S1056* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
S1056* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
S1056* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
S1056* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
S1056* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
S1056* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
S1056* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
S1056* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
S1056* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
S1056* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
S1056* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
S1056* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
S1056* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R337C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (R337C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R337C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CRLF2 |
T223M |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
T223M |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2D |
R5027* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KMT2A |
E1690K |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
E1690K |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
E1690K |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
E1690K |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
E1690K |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
E1690K |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
E2039* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
E2039* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
E2039* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
E2039* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2039* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2039* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2039* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
E2039* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2039* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
E2039* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
E2039* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
E2039* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
E2039* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
TP53 |
L194V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L194V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L194V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L194V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L194V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L194V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L194V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L194V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L194V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L194V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L194V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L194V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FANCA |
splice_acceptor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
splice_acceptor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
NOTCH1 |
R1946H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1946H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
C238S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
S645* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S645* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S645* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S645* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SMARCA4 |
Q1472* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Q1472* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
Q1472* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
Q1472* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Q1472* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
RNF43 |
E334*), RNF43 MUT (S468* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
E2058* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2058* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E2058* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E2058* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RB1 |
R455* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R455* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R455* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R455* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R455* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R455* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R455* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
NTRK3 |
D75N |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
D75N |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
D75N |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
R678W |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
R678W |
Different Mutation |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
R678W |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
R678W |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
R678W |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
R678W |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
R678W |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
R678W |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
R678W |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
R678W |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
R678W |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
R678W |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
R678W |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
R678W |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
R678W |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
R678W |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
R678W |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
KMT2A |
P3818S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3818S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3818S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3818S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3818S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3818S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
GATA3 |
R306* |
Complete Match |
Aromatase ihibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
E494Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
L790F |
Different Mutation |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA, TH |
FDA guidelines |
RET |
L790F |
Different Mutation |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
TH |
Pre-clinical |
RET |
L790F |
Different Mutation |
RET inhibitor |
Responsive |
TH |
Early trials |
RET |
L790F |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
TH |
Pre-clinical |
RET |
L790F |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Resistant |
LUAD |
Pre-clinical |
RET |
L790F |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L790F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L790F |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L790F |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L790F |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L790F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L790F |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L790F |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L790F |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
H178P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H178P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H178P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H178P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H178P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H178P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H178P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H178P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H178P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H178P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H178P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H178P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H178P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H178P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H178P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
D609H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12S |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12S |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12S |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12S |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12S |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12S |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12S |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12S |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12S |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12S |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12S |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12S |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12S |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12S |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12S |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12S |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12S |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12S |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12S |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12S |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12S |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12S |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12S |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12S |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12S |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12S |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12S |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12S |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12S |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12S |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NOTCH1 |
A495T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A495T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
A730S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A730S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A730S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A730S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A730S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A730S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A730S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A730S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A730S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A730S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A730S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A730S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A730S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A730S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A730S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A730S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A730S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A730S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A730S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
P190R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P190R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P190R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P190R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P190R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P190R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P190R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P190R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P190R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P190R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P190R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P190R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
L1740*fs*1 |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
L1740*fs*1 |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
L1740*fs*1 |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
L1740*fs*1 |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
L1740*fs*1 |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
L1740*fs*1 |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
L1740*fs*1 |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
L145R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L145R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L145R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L145R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L145R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L145R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L145R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L145R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L145R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L145R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L145R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L145R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L145R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
S577G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S577G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S577G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S577G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S577G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S577G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
RB1 |
Y805* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
Y805* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y805* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Y805* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y805* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
Y805* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
Y805* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
CDKN1B |
E75* |
Complete Match |
CDK2/4 inhibitor |
Responsive |
CANCER |
Pre-clinical |
CDKN1B |
E75* |
Different Alteration |
CDK2/4 inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
G223R |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
N236T |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
N236T |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
N236T |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
N236T |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ROS1 |
T722M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T722M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T722M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T722M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T722M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TP53 |
S240R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
S240R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
S240R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
S240R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
S240R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
S240R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
S240R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S240R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S240R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
S240R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
S240R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
S240R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S240R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
S240R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
S240R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
V412A |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V412A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V412A |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V412A |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V412A |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V412A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V412A |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V412A |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V412A |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ABL1 |
V1031M), ABL1 MUT* (R1009* |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
V1031M), ABL1 MUT* (R1009* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V1031M), ABL1 MUT* (R1009* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
V1031M), ABL1 MUT* (R1009* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
V1031M), ABL1 MUT* (R1009* |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
V1031M), ABL1 MUT* (R1009* |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
FGFR2 |
P444L |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
P444L |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
MET |
R739C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NOTCH1 |
L2419I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
L2419I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P297T), BRD4 MUT* (R1121H |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRD4 |
I403V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
FBXW7 |
R658* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R658* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R658* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R658* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
C238W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C238W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C238W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C238W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C238W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C238W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C238W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C238W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C238W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C238W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C238W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C238W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
R46K |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R46K |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R46K |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R46K |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R46K |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R46K |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R46K |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R46K |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
ALK |
D1141N |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D1141N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D1141N |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D1141N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D1141N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D1141N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D1141N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D1141N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D1141N |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D1141N |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D1141N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D1141N |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D1141N |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D1141N |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D1141N |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D1141N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D1141N |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D1141N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D1141N |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ESR1 |
D218N |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
STAG2 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
G |
Pre-clinical |
ALK |
G756S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G756S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G756S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G756S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G756S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G756S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G756S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G756S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G756S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G756S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G756S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G756S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G756S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G756S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G756S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G756S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G756S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G756S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G756S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
E453K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E453K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E453K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E453K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E453K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E453K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E453K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E453K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
CDK12 |
E1177* |
Complete Match |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDK12 |
E1177* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ERBB4 |
Q900* |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
Q900* |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
Q900* |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
N268K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N268K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
N310Pfs*35 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N310Pfs*35 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N310Pfs*35 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N310Pfs*35 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N310Pfs*35 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N310Pfs*35 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N310Pfs*35 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N310Pfs*35 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N310Pfs*35 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N310Pfs*35 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N310Pfs*35 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N310Pfs*35 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N310Pfs*35 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N310Pfs*35 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N310Pfs*35 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FGFR2 |
Y376C), FGFR2 MUT (Y376C), FGFR2 MUT* (I379V |
Different Alteration |
FGFR inhibitor |
Resistant |
CH |
Early trials |
FGFR2 |
Y376C |
Different Mutation |
FGFR inhibitor |
Responsive |
LUSC |
Pre-clinical |
FGFR2 |
Y376C |
Different Mutation |
Dovitinib (FGFR inhibitor) |
Resistant |
ED |
Pre-clinical |
FGFR2 |
Y376C |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
ED |
Pre-clinical |
FGFR2 |
Y376C |
Different Mutation |
FGFR inhibitor |
Responsive |
ED |
Pre-clinical |
FGFR2 |
Y376C |
Different Mutation |
FGFR inhibitor |
Responsive |
L |
Pre-clinical |
FGFR2 |
Y376C |
Different Mutation |
FGFR inhibitor |
Responsive |
BT |
Case report |
FGFR2 |
Y376C |
Different Alteration |
FGFR inhibitor |
Responsive |
ST |
Early trials |
FGFR2 |
Y376C |
Different Alteration |
FGFR inhibitor |
Responsive |
BRCA |
Case report |
FGFR2 |
Y376C), FGFR2 MUT* (I379V |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
Y376C), FGFR2 MUT* (I379V |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ALK |
P97S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P97S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P97S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P97S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P97S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P97S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P97S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P97S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P97S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P97S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P97S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P97S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P97S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P97S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P97S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P97S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P97S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P97S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P97S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH2 |
R2051Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y27S |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y27S |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y27S |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y27S |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y27S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y27S |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y27S |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y27S |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y27S |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y27S |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y27S |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y27S |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y27S |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y27S |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y27S |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y27S |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y27S |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y27S |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y27S |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y27S |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y27S |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y27S |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y27S |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y27S |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y27S |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
NOTCH1 |
R1234Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1234Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
C1045Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
C1045Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NF1 |
L252* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
L252* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
L252* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
L252* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
L252* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
L252* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
L252* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
L252* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
L252* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
L252* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
L252* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
L252* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
L252* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
L252* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
L252* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
L252* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
L252* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
L252* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
L252* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
L252* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
L252* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
L252* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
L252* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
ROS1 |
Y2342C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
Y2342C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
Y2342C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
Y2342C |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
Y2342C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRD4 |
F698V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
MET |
R469Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
FGFR2 |
E466K |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
E466K |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
APC |
splice_acceptor_variant |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
SMARCA4 |
E1612* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
E1612* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
E1612* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
E1612* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
E1612* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
PDGFRA |
T276M |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
ARID1A |
E1490Kfs*11 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1490Kfs*11 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1490Kfs*11 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1490Kfs*11 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ESR1 |
R37W |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ERBB4 |
K722E |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ESR1 |
G204S |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ERBB4 |
P790S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1289V |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1289V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A1289V |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A1289V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A1289V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1289V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1289V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A1289V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A1289V |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1289V |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A1289V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A1289V |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A1289V |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1289V |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A1289V |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A1289V |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A1289V |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A1289V |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A1289V |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
E1017K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
T2180I), MLL MUT* (G47D |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
T2180I), MLL MUT* (G47D |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
T2180I), MLL MUT* (G47D |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
T2180I), MLL MUT* (G47D |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
T2180I), MLL MUT* (G47D |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
T2180I), MLL MUT* (G47D |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK3 |
G393D |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
G393D |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
G393D |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
A631V), NTRK1 MUT* (P392S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
A631V), NTRK1 MUT* (P392S |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
A631V), NTRK1 MUT* (P392S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
A631V), NTRK1 MUT* (P392S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NOTCH1 |
P743L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P743L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
A277V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
D40N |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D40N |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D40N |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D40N |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
NTRK3 |
R326H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R326H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R326H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
R1304Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TSC1 |
K168* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
K168* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
K168* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
K168* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
K168* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
K168* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
K168* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
RNF43 |
S216* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
BRD4 |
P1137L |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ARID1A |
Q412* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q412* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q412* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q412* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
V777L |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
V777L |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
V777L |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
V777L |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
V777L |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
V777L |
Different Mutation |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
V777L |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
V777L |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
V777L |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
V777L |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
V777L |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
V777L |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
V777L |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
V777L |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
V777L |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
V777L |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
V777L |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
V777L |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
V777L |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
V777L |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
V777L |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
V777L |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
KMT2D |
splice_acceptor_variant |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NTRK1 |
R748Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R748Q |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R748Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R748Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
RET |
E459K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E459K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E459K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E459K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E459K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E459K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E459K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E459K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E459K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ERBB4 |
R976S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
E2442Q |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
E2442Q |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
E2442Q |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
E2442Q |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
E2442Q |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
E2442Q |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
APC |
R332* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
FGFR2 |
V12L |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
V12L |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
SF3B1 |
K741N |
Different Mutation |
Spliceosome inhibitor |
Responsive |
CANCER |
Pre-clinical |
RET |
R144H |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R144H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R144H |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R144H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R144H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R144H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R144H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R144H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R144H |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
GNAS |
Q227L |
Different Mutation |
JAK inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
L112P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
L112P |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
L112P |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
L112P |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
L112P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
L112P |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
L112P |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
L112P |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
L112P |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
L112P |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
L112P |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
L112P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
L112P |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
L112P |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
L112P |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
L112P |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
L112P |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
L112P |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
L112P |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
L112P |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
L112P |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
L112P |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
L112P |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
L112P |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
L112P |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PDGFRA |
M642T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
RNF43 |
E278* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
Q515* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q515* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q515* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q515* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2D |
Q3364* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
PBRM1 |
E991* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
E991* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
E991* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
E991* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
E991* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R267Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R267Q |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R267Q |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R267Q |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R267Q |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R267Q |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R267Q |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267Q |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267Q |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R267Q |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R267Q |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267Q |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267Q |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R267Q |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267Q |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
N106Tfs*4 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N106Tfs*4 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N106Tfs*4 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
N106Tfs*4 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
MET |
S1356L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NTRK3 |
R735C |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R735C |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R735C |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
RET |
K603I |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
K603I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
K603I |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
K603I |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
K603I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
K603I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
K603I |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
K603I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
K603I |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ERBB4 |
N822K |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
S1554L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S1554L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S1554L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S1554L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S1554L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S1554L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
G2130R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G2130R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
A636V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
A636V |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
A636V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
A636V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
SETD2 |
R1459* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
R1459* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
FLT3 |
W603* |
Different Mutation |
Quizartinib (Pan-TK inhibitor) |
Resistant |
AML |
Pre-clinical |
FLT3 |
W603* |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Resistant |
AML |
Pre-clinical |
FLT3 |
W603* |
Different Mutation |
Venetoclax (BCL2 inhibitor) |
Resistant |
AML |
Early trials |
FLT3 |
W603* |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
AML |
Early trials |
FLT3 |
W603* |
Different Mutation |
Quizartinib (Pan-TK inhibitor) |
Responsive |
AML |
Early trials |
FLT3 |
W603* |
Different Mutation |
Sorafenib;Azacytidine (Pan-TK inhibitor;Chemotherapy) |
Responsive |
AML |
Early trials |
FLT3 |
W603* |
Different Mutation |
FLT3 inhibitor |
Responsive |
AML |
Early trials |
FLT3 |
W603* |
Different Mutation |
Crenolanib (FLT3 inhibitor) |
Responsive |
AML |
Pre-clinical |
FLT3 |
W603* |
Different Mutation |
Midostaurin (Pan-TK inhibitor) |
Responsive |
AML |
Pre-clinical |
FLT3 |
W603* |
Different Mutation |
novel FLT3 inhibitor |
Responsive |
AML |
Pre-clinical |
FLT3 |
W603* |
Different Mutation |
Midostaurin (Pan-TK inhibitor) |
Responsive |
AML |
Case report |
FLT3 |
W603* |
Different Mutation |
Lestaurtinib (Pan-TK inhibitor) |
Responsive |
AML |
Case report |
TP53 |
L114Cfs*34 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
L114Cfs*34 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
L114Cfs*34 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
L114Cfs*34 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
L114Cfs*34 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
L114Cfs*34 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
L114Cfs*34 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L114Cfs*34 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L114Cfs*34 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
L114Cfs*34 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
L114Cfs*34 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
L114Cfs*34 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L114Cfs*34 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
L114Cfs*34 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
L114Cfs*34 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I1900M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1900M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1900M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1900M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1900M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
splice_acceptor_variant), KRAS MUT (G12D |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), KRAS MUT (G12D |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
splice_acceptor_variant), KRAS MUT (G12D |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
RB1 |
E748Afs*36 |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E748Afs*36 |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E748Afs*36 |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E748Afs*36 |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E748Afs*36 |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E748Afs*36 |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E748Afs*36 |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
ERBB4 |
Q446K |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q1411* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1411* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1411* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1411* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PIK3CA |
M1043I |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
M1043I |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
M1043I |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
M1043I |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
M1043I |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
M1043I |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
M1043I |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
M1043I |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PBRM1 |
H899Lfs*12 |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
H899Lfs*12 |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
H899Lfs*12 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
H899Lfs*12 |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
H899Lfs*12 |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
L14Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
L14Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EGFR |
R255Q |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
R255Q |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
R255Q |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
R255Q |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R255Q |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R255Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
R255Q |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
R255Q |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
R255Q |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
R255Q |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
R255Q |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
R255Q |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R255Q |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
R255Q |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
R255Q |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
R255Q |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
R255Q |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R255Q |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
R255Q |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
R255Q |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R255Q |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
R255Q |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
R255Q |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
R255Q |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
R255Q |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
R255Q |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
R255Q |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
R255Q |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
R255Q |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
R255Q |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
R255Q |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
R255Q |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
R255Q |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
R255Q |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
R255Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
R255Q |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
R255Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R255Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
KRAS |
G13P |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13P |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G13P |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G13P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G13P |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G13P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G13P |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13P |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G13P |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G13P |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13P |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G13P |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13P |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G13P |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13P |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G13P |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G13P |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G13P |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G13P |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G13P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13P |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G13P |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13P |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G13P |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13P |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13P |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G13P |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13P |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G13P |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13P |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G13P |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13P |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G13P |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G13P |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G13P |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
H179P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
H179P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
H179P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
H179P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
H179P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
H179P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
H179P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
H179P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
H179P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
H179P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
H179P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
H179P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
P48Q |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P48Q |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P48Q |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
P48Q |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P48Q |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
P48Q |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
P48Q |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
P48Q |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
BRAF |
N580D |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
N580D |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
N580D |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
N580D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
SETD2 |
Q1932* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1932* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RNF43 |
W15* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
N1951Kfs*9 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N1951Kfs*9 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N1951Kfs*9 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
N1951Kfs*9 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1931* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1931* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
D24H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
D24H |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
D24H |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
D24H |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
D24H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
D24H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
D24H |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
D24H |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
D24H |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
D24H |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
D24H |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
D24H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
D24H |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
D24H |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
D24H |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
D24H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
D24H |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
D24H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
D24H |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
D24H |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
D24H |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
D24H |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
D24H |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
D24H |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
D24H |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
FLT3 |
V592I |
Different Mutation |
Quizartinib (Pan-TK inhibitor) |
Resistant |
AML |
Pre-clinical |
FLT3 |
V592I |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Resistant |
AML |
Pre-clinical |
FLT3 |
V592I |
Different Mutation |
Venetoclax (BCL2 inhibitor) |
Resistant |
AML |
Early trials |
FLT3 |
V592I |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
AML |
Early trials |
FLT3 |
V592I |
Different Mutation |
Quizartinib (Pan-TK inhibitor) |
Responsive |
AML |
Early trials |
FLT3 |
V592I |
Different Mutation |
Sorafenib;Azacytidine (Pan-TK inhibitor;Chemotherapy) |
Responsive |
AML |
Early trials |
FLT3 |
V592I |
Different Mutation |
FLT3 inhibitor |
Responsive |
AML |
Early trials |
FLT3 |
V592I |
Different Mutation |
Crenolanib (FLT3 inhibitor) |
Responsive |
AML |
Pre-clinical |
FLT3 |
V592I |
Different Mutation |
Midostaurin (Pan-TK inhibitor) |
Responsive |
AML |
Pre-clinical |
FLT3 |
V592I |
Different Mutation |
novel FLT3 inhibitor |
Responsive |
AML |
Pre-clinical |
FLT3 |
V592I |
Different Mutation |
Midostaurin (Pan-TK inhibitor) |
Responsive |
AML |
Case report |
FLT3 |
V592I |
Different Mutation |
Lestaurtinib (Pan-TK inhibitor) |
Responsive |
AML |
Case report |
TP53 |
K120R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K120R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K120R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K120R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K120R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K120R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K120R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K120R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K120R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K120R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K120R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K120R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K120R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K120R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K120R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
SETD2 |
Q1750*), SETD2 MUT (Q2139* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1750*), SETD2 MUT (Q2139* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2A |
R1811Q |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R1811Q |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R1811Q |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R1811Q |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R1811Q |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R1811Q |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ERBB4 |
P170T |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V2089M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
V2089M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
V2089M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
V2089M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
V2089M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CDKN2A |
L94Rfs*16 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L94Rfs*16 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L94Rfs*16 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
L94Rfs*16 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L94Rfs*16 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L94Rfs*16 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L94Rfs*16 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L94Rfs*16 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
FGFR2 |
C492Y |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
C492Y |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
SETD2 |
E1636* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E1636* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RB1 |
E465* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
E465* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E465* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E465* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E465* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
E465* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
E465* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
AKT3 |
K68T |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
Q857* |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
Q857* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q857* |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
Q857* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q857* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
Q857* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q857* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q857* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
Q857* |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2D |
Q4045* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
SETD2 |
Q1619* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1619* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
RB1 |
S634* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
S634* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S634* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S634* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S634* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S634* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S634* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
ARID1A |
P1621Cfs*26 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P1621Cfs*26 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
P1621Cfs*26 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
P1621Cfs*26 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
EZH2 |
E636* |
Different Mutation |
EZH2 inhibitor |
Responsive |
LY |
Pre-clinical |
EZH2 |
E636* |
Different Mutation |
EZH2 inhibitor |
Responsive |
LY |
Early trials |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
D52N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
D52N |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
D52N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
D52N |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
D52N |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D52N |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
D52N |
Different Mutation |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D52N |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D52N |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
D52N |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
D52N |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
D52N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
D52N |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D52N |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
D52N |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
D52N |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
D52N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
D52N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
D52N |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E56*), TP53 MUT (V157I |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E56*), TP53 MUT (V157I |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
Q488* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
TP53 |
D259F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D259F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D259F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D259F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D259F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D259F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D259F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D259F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D259F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D259F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D259F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D259F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D259F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
C633* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
C633* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
C633* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
C633* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
C633* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
C633* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
C633* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
C633* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
C633* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
C633* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
C633* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
C633* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
C633* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RET |
R189H |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R189H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189H |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R189H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189H |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189H |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189H |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
CRLF2 |
R153W |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
R153W |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
ATM |
R2598* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2598* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2598* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2598* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2598* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2598* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2598* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2598* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2598* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2598* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2598* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2598* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2598* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12R), KRAS MUT (G12C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12R), KRAS MUT (G12C |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12R), KRAS MUT (G12C |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NTRK3 |
V451I |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
V451I |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
V451I |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
F992L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
F992L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
F992L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
F992L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
F992L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CDKN2A |
N42K |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
N42K |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
N42K |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
N42K |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
N42K |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
N42K |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
N42K |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
N42K |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
TP53 |
R273H), TP53 MUT (L264V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R273H), TP53 MUT (L264V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R273H), TP53 MUT (L264V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C176L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C176L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C176L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C176L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C176L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C176L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C176L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C176L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C176L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C176L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C176L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M246K |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M246K |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M246K |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M246K |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M246K |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M246K |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M246K |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246K |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246K |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M246K |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M246K |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M246K |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246K |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M246K |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M246K |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
A505T |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M133T), TP53 MUT (R175H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133T), TP53 MUT (R175H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R174W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R174W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R174W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R174W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R174W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R174W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R174W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R174W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R174W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R174W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R174W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R174W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R174W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R174W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R174W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FANCC |
Q366* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
FANCC |
Q366* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12V), KRAS MUT (L19F |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12V), KRAS MUT (L19F |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
PIK3CA |
E542Q |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E542Q |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E542Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E542Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E542Q |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E542Q |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E542Q |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E542Q |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ARID1A |
Q497* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q497* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q497* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q497* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
R1275W |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ATM |
R2034* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2034* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2034* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2034* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2034* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2034* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2034* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2034* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2034* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2034* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2034* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2034* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2034* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ARID1A |
Q172* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q172* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q172* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q172* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
AKT3 |
H351Q |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D), KRAS MUT (A146V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (A146V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12D), KRAS MUT (A146V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
AKT1 |
L52R |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
AKT1 |
L52R |
Different Mutation |
allosteric AKT inhibitor |
Responsive |
CANCER |
Early trials |
AKT1 |
L52R |
Different Mutation |
non-allosteric AKT inhibitor |
Responsive |
CANCER |
Early trials |
AKT1 |
L52R |
Different Mutation |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
AKT1 |
L52R |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Early trials |
AKT1 |
L52R |
Different Mutation |
AKT inhibitor |
Responsive |
CANCER |
Pre-clinical |
AKT1 |
L52R |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
FH |
Case report |
ROS1 |
R1910Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1910Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1910Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1910Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1910Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
VHL |
R64P |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
ARID1A |
C1105* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
C1105* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
C1105* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
C1105* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RNF43 |
Q518* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDKN2A |
L65Hfs*50 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L65Hfs*50 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L65Hfs*50 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
L65Hfs*50 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L65Hfs*50 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L65Hfs*50 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L65Hfs*50 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L65Hfs*50 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
NF2 |
W74* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
W74* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
W74* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
W74* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
W74* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
W74* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
W74* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
W74* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
W74* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
W74* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
W74* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
W74* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
W74* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
W74* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
W74* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
W74* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
W74* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
W74* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
W74* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
W74* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
W74* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
W74* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
W74* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
W74* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
W74* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
VHL |
S65A |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
RNF43 |
Q84* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
PBRM1 |
Q478* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
Q478* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
Q478* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
Q478* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
Q478* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
JAK2 |
V617F |
Complete Match |
JAK inhibitor |
Responsive |
AML |
Pre-clinical |
JAK2 |
V617F |
Complete Match |
Ruxolitinib (JAK inhibitor) |
Responsive |
AML |
Early trials |
JAK2 |
V617F |
Complete Match |
Ruxolitinib (JAK inhibitor) |
Responsive |
MY |
FDA guidelines |
JAK2 |
V617F |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Case report |
JAK2 |
V617F |
Different Alteration |
JAK inhibitor |
Responsive |
BRCA |
Pre-clinical |
JAK2 |
V617F |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ARID1A |
Q492* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q492* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q492* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q492* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
G655* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G655* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G655* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
G655* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
A602T |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
A602T |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A602T |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
A602T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A602T |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
A602T |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
PALB2 |
C828* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
C828* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
C828* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
C828* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
C828* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
C828* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
C828* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
C828* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R181H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (R181H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R181H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK3 |
H532Y |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
H532Y |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
H532Y |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ABL1 |
G924V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G924V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G924V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G924V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G924V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G924V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
RET |
C585* |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
C585* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
C585* |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
C585* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
C585* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
C585* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
C585* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
C585* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
C585* |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
B2M |
splice_donor_variant |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Case report |
ALK |
R753Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R753Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R753Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R753Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R753Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R753Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R753Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R753Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R753Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R753Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R753Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R753Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R753Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R753Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R753Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R753Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R753Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R753Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R753Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q581* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q581* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q581* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q581* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C124R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C124R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C124R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C124R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C124R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C124R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C124R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C124R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C124R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C124R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C124R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C124R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C124R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R181P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R181P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R181P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R181P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R181P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R181P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R181P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R181P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R181P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R181P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R181P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R181P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R181P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R181P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R181P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
AKT3 |
R249C |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRAS |
G13D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
G13D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
G13D |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
G13D |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
G13D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
G13D |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
G13D |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
G13D |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
G13D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
G13D |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
G13D |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
G13D |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
G13D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
G13D |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
D594N |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594N |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594N |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594N |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
D594N |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
D594N |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
D594N |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
D594N |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
D594N |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
D594N |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
D594N |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
D594N |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
D594N |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
D594N |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
D594N |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
D594N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
D594N |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
D594N |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
D594N |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
D594N |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
D594N |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
D594N |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
D594N |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
D594N |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
D594N |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
D594N |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
D594N |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
D594N |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
NF1 |
splice_acceptor_variant |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
splice_acceptor_variant |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
splice_acceptor_variant |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
splice_acceptor_variant |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
splice_acceptor_variant |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
TP53 |
K164* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K164* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K164* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K164* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K164* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K164* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K164* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K164* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K164* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K164* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K164* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K164* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K164* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K164* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K164* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FBXW7 |
Y545H |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
Y545H |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
Y545H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
Y545H |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TP53 |
Y220D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y220D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y220D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y220D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y220D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y220D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y220D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y220D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y220D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y220D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y220D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y220D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R805* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R805* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R805* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R805* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R805* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R805* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R805* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R805* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R805* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R805* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R805* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R805* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R805* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
PIK3R1 |
E52* |
Complete Match |
AKT inhibitor |
Responsive |
G |
Pre-clinical |
PIK3R1 |
E52* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED |
Case report |
MET |
H748Y |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
PDGFRA |
P553L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PBRM1 |
R921* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Pre-clinical |
PBRM1 |
R921* |
Complete Match |
anti-PD1 inhibitor |
Responsive |
RCCC |
Early trials |
PBRM1 |
R921* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RCC |
Early trials |
PBRM1 |
R921* |
Complete Match |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PBRM1 |
R921* |
Different Alteration |
EZH2 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NF1 |
R304* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
R304* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
R304* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R304* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
R304* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
R304* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R304* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
R304* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R304* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R304* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R304* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R304* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R304* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R304* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R304* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R304* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
R304* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R304* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R304* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R304* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R304* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R304* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R304* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
splice_acceptor_variant), CDKN2A MUT (H83Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
RNF43 |
Y357* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
RB1 |
S565* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
S565* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S565* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S565* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S565* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S565* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S565* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
BRD4 |
T573M |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
NOTCH2 |
D1189H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
V25Gfs*17 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
V25Gfs*17 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
V25Gfs*17 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
V25Gfs*17 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
V25Gfs*17 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
V25Gfs*17 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
V25Gfs*17 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
V25Gfs*17 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
RNF43 |
W259* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDKN2A |
L104R |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L104R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L104R |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
L104R |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L104R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
L104R |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
L104R |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
L104R |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
RET |
P684T |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
P684T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P684T |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
P684T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P684T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
P684T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P684T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P684T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
P684T |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2D |
Q2380* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NTRK1 |
R104C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R104C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R104C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R104C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NTRK3 |
E322Q |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E322Q |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
E322Q |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
M239I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
M239I |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
M239I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
M239I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NOTCH2 |
P2322H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
V1575L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V1575L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
G1250S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G1250S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ESR1 |
P325L |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
E343* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E343* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E343* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E343* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E343* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E343* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E343* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E343* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E343* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E343* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E343* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E343* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E343* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E343* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E343* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G899S), ALK MUT* (G903E |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FBXW7 |
G391D |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
G391D |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
G391D |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
G391D |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
TSC2 |
S487* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
S487* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
S487* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
S487* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
S487* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
S487* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
S487* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
NOTCH1 |
P2340S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P2340S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
E286A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E286A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E286A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E286A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E286A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E286A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E286A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E286A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E286A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E286A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E286A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E286A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NF1 |
K200* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
K200* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
K200* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K200* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
K200* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
K200* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K200* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
K200* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K200* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K200* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K200* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K200* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K200* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
K200* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
K200* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K200* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
K200* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
K200* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
K200* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
K200* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
K200* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
K200* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
K200* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NOTCH1 |
V2024I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V2024I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
R1250W |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RB1 |
R358* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
R358* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R358* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R358* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R358* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
R358* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
R358* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
ERBB4 |
D300H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
AKT3 |
E232K |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
ABL1 |
S1119C |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
S1119C |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
S1119C |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
S1119C |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
S1119C |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
S1119C |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
FGFR3 |
R223H |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R223H |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R223H |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NOTCH1 |
A1931T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A1931T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
SETD2 |
E1959* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
E1959* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
NTRK3 |
R306H |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R306H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R306H |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
SETD2 |
splice_donor_variant |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
splice_donor_variant |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
KMT2D |
Q3651* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ESR1 |
R269H |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
NTRK3 |
R518C |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R518C |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R518C |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
RET |
R1050* |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R1050* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R1050* |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R1050* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R1050* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R1050* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R1050* |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R1050* |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R1050* |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
K117N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
K117N |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
K117N |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
K117N |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
K117N |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
K117N |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
K117N |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
K117N |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
K117N |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
K117N |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
K117N |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
K117N |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
K117N |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
K117N |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
K117N |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
K117N |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
K117N |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
K117N |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
K117N |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
K117N |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
K117N |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
K117N |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
K117N |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
K117N |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
K117N |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
K117N |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
K117N |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
K117N |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
K117N |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
K117N |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
K117N |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
K117N |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NOTCH2 |
D1042H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ATM |
Y2371* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Y2371* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Y2371* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Y2371* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Y2371* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Y2371* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Y2371* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Y2371* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Y2371* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Y2371* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Y2371* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Y2371* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Y2371* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ROS1 |
D2108N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
D2108N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
D2108N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
D2108N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D2108N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NTRK3 |
T578N |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T578N |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T578N |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
V203M |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V203M |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V203M |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V203M |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V203M |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V203M |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V203M |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V203M |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V203M |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V203M |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V203M |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V203M |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V203M |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V203M |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V203M |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P316Afs*29 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P316Afs*29 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P316Afs*29 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P316Afs*29 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P316Afs*29 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P316Afs*29 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P316Afs*29 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P316Afs*29 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P316Afs*29 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P316Afs*29 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P316Afs*29 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P316Afs*29 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P316Afs*29 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P316Afs*29 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P316Afs*29 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB3 |
M60R |
Different Mutation |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
M60R |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
M60R |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
M60R |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB3 |
M60R |
Different Mutation |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
M60R |
Different Mutation |
ERBB3 mAb inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
M60R |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
MAP2K1 |
P124L |
Complete Match |
MEK inhibitor |
Resistant |
CANCER |
Pre-clinical |
MAP2K1 |
P124L |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
P124L |
Complete Match |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
P124L |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
MAP2K1 |
P124L |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
P124L |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
P124L |
Complete Match |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
P124L |
Different Mutation |
Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Case report |
MAP2K1 |
P124L |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
MAP2K1 |
P124L |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Early trials |
MAP2K1 |
P124L |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
P124L |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
ERBB4 |
R837T |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
V600_W604delinsE |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
V600_W604delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_W604delinsE |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
V600_W604delinsE |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
V600_W604delinsE |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
V600_W604delinsE |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TP53 |
D281G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D281G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D281G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D281G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D281G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D281G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D281G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D281G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D281G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D281G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D281G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D281G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
E424K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
E424K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
F134C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
F134C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
F134C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
F134C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
F134C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
F134C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
F134C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
F134C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
F134C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
F134C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
F134C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
F134C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RNF43 |
R330* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
STK11 |
K84* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
K84* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K84* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
K84* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
K84* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
K84* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K84* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K84* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
K84* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
K84* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K84* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K84* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K84*), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
K84*), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
K84*), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
K84*), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
A76Qfs*20 |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20 |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
A76Qfs*20 |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
A76Qfs*20 |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
A76Qfs*20 |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20 |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20 |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
A76Qfs*20 |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
A76Qfs*20 |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20 |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20 |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20), KRAS MUT (G12D |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
A76Qfs*20), KRAS MUT (G12D |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
A76Qfs*20), KRAS MUT (G12D |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
A76Qfs*20), KRAS MUT (G12D |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
FGFR3 |
L542M |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
L542M |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
L542M |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R174_R175delinsSG |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R174_R175delinsSG |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R174_R175delinsSG |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R174_R175delinsSG |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R174_R175delinsSG |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R174_R175delinsSG |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R174_R175delinsSG |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R174_R175delinsSG |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195A |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I195A |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I195A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I195A |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I195A |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I195A |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I195A |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195A |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195A |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I195A |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I195A |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I195A |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195A |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I195A |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I195A |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RB1 |
T116*fs*1 |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
T116*fs*1 |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
T116*fs*1 |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
T116*fs*1 |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
T116*fs*1 |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
T116*fs*1 |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
T116*fs*1 |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
ERBB4 |
M832I |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
AKT3 |
D271E |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
P72Afs*51 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
P72Afs*51 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
P72Afs*51 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
P72Afs*51 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
P72Afs*51 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
P72Afs*51 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
P72Afs*51 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P72Afs*51 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P72Afs*51 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
P72Afs*51 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
P72Afs*51 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
P72Afs*51 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P72Afs*51 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
P72Afs*51 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
P72Afs*51 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
R1461* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1461* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1461* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1461* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ATR |
E1360* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
E1360* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
E1360* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
ERBB3 |
D297Y |
Different Mutation |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
D297Y |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
D297Y |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
D297Y |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB3 |
D297Y |
Different Mutation |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
D297Y |
Different Mutation |
ERBB3 mAb inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB3 |
D297Y |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
FANCA |
R591* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
R591* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
RAF1 |
P271L |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
P271L |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
P271L |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NTRK3 |
T149K |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T149K |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T149K |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Q185* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q185* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q185* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q185* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
V600_K601delinsE |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
V600_K601delinsE |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
V600_K601delinsE |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
V600_K601delinsE |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
V600_K601delinsE |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
V600_K601delinsE |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
TSC2 |
E1692* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
E1692* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
E1692* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
E1692* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
E1692* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
E1692* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
E1692* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TP53 |
Y163H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y163H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y163H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y163H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y163H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y163H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y163H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y163H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y163H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y163H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y163H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y163H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CDKN2A |
R22Lfs*4 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R22Lfs*4 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R22Lfs*4 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R22Lfs*4 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R22Lfs*4 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R22Lfs*4 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R22Lfs*4 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R22Lfs*4 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
PDGFRA |
D846Y |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
PDGFRA |
D846Y |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
NCCN guidelines |
PDGFRA |
D846Y |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
NCCN guidelines |
PDGFRA |
D846Y |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
NCCN guidelines |
PDGFRA |
D846Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Pre-clinical |
PDGFRA |
D846Y |
Different Mutation |
Crenolanib (FLT3 inhibitor) |
Responsive |
CM |
Pre-clinical |
PDGFRA |
D846Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES |
Case report |
PDGFRA |
D846Y |
Different Mutation |
Crenolanib (FLT3 inhibitor) |
Responsive |
GIST |
Early trials |
PDGFRA |
D846Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
PDGFRA |
D846Y |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
GIST |
Pre-clinical |
PDGFRA |
D846Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
PDGFRA |
D846Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
PDGFRA |
D846Y |
Different Mutation |
PDGFR inhibitor |
Responsive |
GIST |
Early trials |
PDGFRA |
D846Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Resistant |
GIST |
Late trials |
PDGFRA |
D846Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
PDGFRA |
D846Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
PDGFRA |
D846Y |
Different Alteration |
PDGFR inhibitor |
No Responsive |
G |
Pre-clinical |
PDGFRA |
D846Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
CRLF2 |
P119H |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
P119H |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
JAK2 |
R803* |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
CBL |
Y371H |
Complete Match |
JAK inhibitor |
Responsive |
MDPS |
Pre-clinical |
CBL |
Y371H |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
MDPS |
Pre-clinical |
U2AF1 |
N38I |
Complete Match |
FLT3 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R290Lfs*15 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R290Lfs*15 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R290Lfs*15 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R290Lfs*15 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R290Lfs*15 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R290Lfs*15 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R290Lfs*15 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R290Lfs*15 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R290Lfs*15 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R290Lfs*15 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R290Lfs*15 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R290Lfs*15 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R290Lfs*15 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R290Lfs*15 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R290Lfs*15 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
S1085* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1085* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1085* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S1085* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1786* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1786* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1786* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1786* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ESR1 |
R256* |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
TP53 |
R65* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R65* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R65* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R65* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R65* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R65* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R65* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R65* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R65* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R65* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R65* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R65* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R65* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R65* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R65* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
R1287Hfs*11 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1287Hfs*11 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R1287Hfs*11 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R1287Hfs*11 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D148Ifs*32 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D148Ifs*32 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D148Ifs*32 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D148Ifs*32 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D148Ifs*32 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D148Ifs*32 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D148Ifs*32 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D148Ifs*32 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D148Ifs*32 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D148Ifs*32 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D148Ifs*32 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D148Ifs*32 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D148Ifs*32 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D148Ifs*32 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D148Ifs*32 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PDGFRA |
P28A |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
CDKN2A |
G6Afs*20 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G6Afs*20 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G6Afs*20 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
G6Afs*20 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G6Afs*20 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
G6Afs*20 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
G6Afs*20 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
G6Afs*20 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KRAS |
A146P |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
A146P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
A146P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
A146P |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
A146P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
A146P |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
A146P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
A146P |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
A146P |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
A146P |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
A146P |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146P |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
A146P |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146P |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
A146P |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146P |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
A146P |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
A146P |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
A146P |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
A146P |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
A146P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146P |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
A146P |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146P |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
A146P |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
A146P |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146P |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
A146P |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
A146P |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
A146P |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
A146P |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
A146P |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
A146P |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
A146P |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
A146P |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
A146P |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
MAP2K1 |
C121S |
Different Mutation |
MEK inhibitor |
Resistant |
CANCER |
Pre-clinical |
MAP2K1 |
C121S |
Complete Match |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
C121S |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
C121S |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
MAP2K1 |
C121S |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
C121S |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
C121S |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
C121S |
Different Mutation |
Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Case report |
MAP2K1 |
C121S |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
MAP2K1 |
C121S |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
MAP2K1 |
C121S |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
C121S |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
KMT2A |
R1064* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R1064* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R1064* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R1064* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R1064* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R1064* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ERBB4 |
S1173Y |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRCA2 |
E335* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
E335* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E335* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
E335* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
E335* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
E335* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
E335* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
E335* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
E335* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E335* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E335* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
E335* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
E335* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
E335* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDKN2A |
V59Afs*56 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
V59Afs*56 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
V59Afs*56 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
V59Afs*56 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
V59Afs*56 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
V59Afs*56 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
V59Afs*56 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
V59Afs*56 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KMT2A |
Q805* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
Q805* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
Q805* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
Q805* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
Q805* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
Q805* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
PIK3R2 |
E5* |
Different Mutation |
MTOR inhibitor |
Responsive |
ED |
Pre-clinical |
ARID1A |
G85Afs*14 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G85Afs*14 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G85Afs*14 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
G85Afs*14 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275W |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C275W |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C275W |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C275W |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C275W |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C275W |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C275W |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275W |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275W |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C275W |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C275W |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C275W |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275W |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C275W |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C275W |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
Q456* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q456* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q456* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q456* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
M51Ifs*110 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
M51Ifs*110 |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110 |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
M51Ifs*110 |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
M51Ifs*110 |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
M51Ifs*110 |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110 |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110 |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
M51Ifs*110 |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
M51Ifs*110 |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110 |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110 |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110), KRAS MUT (Q61H |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
M51Ifs*110), KRAS MUT (Q61H |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
M51Ifs*110), KRAS MUT (Q61H |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
M51Ifs*110), KRAS MUT (Q61H |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
TP53 |
K120N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K120N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K120N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K120N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K120N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K120N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K120N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K120N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K120N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K120N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K120N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K120N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K120N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K120N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K120N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RAF1 |
V379G |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
V379G |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
V379G |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
KMT2A |
P3115R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3115R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3115R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3115R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3115R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3115R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
PIK3CA |
P104A |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
P104A |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
P104A |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P104A |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
P104A |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P104A |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
P104A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
P104A |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
CDKN2A |
A5Rfs*24 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A5Rfs*24 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A5Rfs*24 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
A5Rfs*24 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A5Rfs*24 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A5Rfs*24 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A5Rfs*24 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A5Rfs*24 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
BCOR |
Q156* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
FGFR2 |
F7V |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
F7V |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ALK |
G156R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G156R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G156R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G156R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G156R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G156R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G156R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G156R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G156R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G156R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G156R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G156R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G156R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G156R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G156R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G156R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G156R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G156R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G156R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K146* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
K146* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K146* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
K146* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
K146* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
K146* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K146* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K146* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
K146* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
K146* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K146* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
K146* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
Q546H |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Q546H |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546H |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546H |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Q546H |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546H |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Q546H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Q546H |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
EGFR |
splice_acceptor_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
splice_acceptor_variant |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
FGFR2 |
R255G |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
R255G |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
RNF43 |
C451* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
BRD4 |
R1331W |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
RET |
R813Q |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R813Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R813Q |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R813Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R813Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R813Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R813Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R813Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R813Q |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ERBB4 |
R106H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
M160Ifs*6 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M160Ifs*6 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M160Ifs*6 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M160Ifs*6 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M160Ifs*6 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M160Ifs*6 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M160Ifs*6 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M160Ifs*6 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M160Ifs*6 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M160Ifs*6 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M160Ifs*6 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M160Ifs*6 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M160Ifs*6 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M160Ifs*6 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M160Ifs*6 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155_R156delinsNC |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T155_R156delinsNC |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T155_R156delinsNC |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T155_R156delinsNC |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T155_R156delinsNC |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T155_R156delinsNC |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T155_R156delinsNC |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T155_R156delinsNC |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T155_R156delinsNC |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
R189C |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
R189C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189C |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
R189C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
R189C |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189C |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
R189C |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRCA2 |
Y1672* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Y1672* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Y1672* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Y1672* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Y1672* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Y1672* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Y1672* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Y1672* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Y1672* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Y1672* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y1672* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y1672* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y1672* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Y1672* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
RAF1 |
F240V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
F240V |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
F240V |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
ALK |
D70E |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D70E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D70E |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D70E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D70E |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D70E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D70E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D70E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D70E |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D70E |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D70E |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D70E |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D70E |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D70E |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D70E |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D70E |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D70E |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D70E |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D70E |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRD4 |
A1268V |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ALK |
Q778K |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q778K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Q778K |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Q778K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Q778K |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q778K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q778K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Q778K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q778K |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q778K |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Q778K |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Q778K |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q778K |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q778K |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q778K |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q778K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Q778K |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Q778K |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q778K |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
SMARCA4 |
Q555* |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Q555* |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
Q555* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
Q555* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Q555* |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
MET |
N635S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
I255S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I255S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I255S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I255S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I255S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I255S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I255S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I255S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I255S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I255S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I255S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I255S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PIK3CA |
Q546P |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Q546P |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Q546P |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546P |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Q546P |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Q546P |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Q546P |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Q546P |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ROS1 |
W215G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
W215G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
W215G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
W215G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
W215G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB4 |
V226I |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
APC |
S104* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
KMT2D |
Q1717* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
FBXW7 |
R479* |
Complete Match |
Steroid |
Responsive |
ALL |
Late trials |
FBXW7 |
R479* |
Complete Match |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
FBXW7 |
R479* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
COREAD |
Pre-clinical |
FBXW7 |
R479* |
Different Alteration |
Tubulin inhibitor |
Resistant |
CANCER |
Pre-clinical |
NF1 |
R440* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
R440* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
R440* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R440* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
R440* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
R440* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R440* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
R440* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R440* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R440* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R440* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R440* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R440* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R440* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R440* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R440* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
R440* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R440* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R440* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R440* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R440* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R440* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R440* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NOTCH1 |
S2471L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
S2471L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
D305N |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D305N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D305N |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D305N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D305N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D305N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D305N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D305N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D305N |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D305N |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D305N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D305N |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D305N |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D305N |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D305N |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D305N |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D305N |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D305N |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D305N |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
A837V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
K1000I |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K1000I |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K1000I |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K1000I |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K1000I |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K1000I |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
BAP1 |
Q483* |
Complete Match |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
Q483* |
Complete Match |
PARP inhibitor |
Responsive |
R, CANCER |
Pre-clinical |
BAP1 |
Q483* |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
BAP1 |
Q483* |
Different Alteration |
PARP inhibitor |
Responsive |
CANCER, R |
Pre-clinical |
BAP1 |
Q483* |
Different Alteration |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
Q483* |
Different Alteration |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
ATR |
E1861* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
E1861* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
E1861* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
RNF43 |
E66* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ARID1A |
Q507* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q507* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q507* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q507* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RAF1 |
E286K |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
E286K |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
E286K |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NTRK1 |
R686C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R686C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R686C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R686C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ABL1 |
L69V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
L69V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L69V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
L69V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L69V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
L69V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
TP53 |
I232T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I232T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I232T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I232T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I232T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I232T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I232T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I232T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I232T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I232T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I232T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I232T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
E1853* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1853* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1853* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1853* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
V986F |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TP53 |
R267G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R267G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R267G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R267G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R267G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R267G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R267G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R267G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R267G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R267G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R267G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R267G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
D170E |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
NOTCH2 |
N1629K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ARID1A |
Q481* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q481* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q481* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q481* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
E256* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
E256* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E256* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
E256* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
E256* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
E256* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E256* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E256* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
E256* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
E256* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E256* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E256* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
E256*), KRAS MUT (Q61R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
E256*), KRAS MUT (Q61R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
E256*), KRAS MUT (Q61R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
E256*), KRAS MUT (Q61R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
ARID1A |
R693*), ARID1A MUT (G414* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R693*), ARID1A MUT (G414* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
R693*), ARID1A MUT (G414* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
R693*), ARID1A MUT (G414* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
Y1021C), PIK3CA MUT (E545K), PIK3CA MUT (E103G |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
FAT1 |
C3738* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
ALK |
A120P |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A120P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A120P |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A120P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A120P |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A120P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A120P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A120P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A120P |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A120P |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A120P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A120P |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A120P |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A120P |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A120P |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A120P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A120P |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A120P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A120P |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G643V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
G643V |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
G643V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
G643V |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E545K), PIK3CA MUT (R108H |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
EGFR |
R836C |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
R836C |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
R836C |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
R836C |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R836C |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R836C |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
R836C |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
R836C |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
R836C |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
R836C |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
R836C |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
R836C |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R836C |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
R836C |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
R836C |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
R836C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
R836C |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R836C |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
R836C |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
R836C |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R836C |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
R836C |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R836C |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
R836C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
R836C |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
R836C |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
R836C |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
R836C |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
R836C |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
R836C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
R836C |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
R836C |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
R836C |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
R836C |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
R836C |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
R836C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
R836C |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
R836C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R836C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
JAK2 |
I973S |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
SMARCB1 |
R201* |
Complete Match |
HDAC inhibitor |
Responsive |
MRT |
Pre-clinical |
SMARCB1 |
R201* |
Complete Match |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
SMARCB1 |
R201* |
Different Alteration |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
PIK3CA |
V344A |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
V344A |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
V344A |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V344A |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
V344A |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V344A |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
V344A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
V344A |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
splice_donor_variant), RET MUT* (T244A |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
MSH2 |
R621* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
MSH2 |
R621* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
APC |
R283* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
TP53 |
K351* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K351* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K351* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K351* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K351* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K351* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K351* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K351* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K351* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K351* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K351* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K351* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K351* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K351* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K351* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
N1800D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
N1800D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
N1800D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
N1800D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
N1800D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
G3318D |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G3318D |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G3318D |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G3318D |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G3318D |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G3318D |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
AKT3 |
D188D |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61_E62delinsRK |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61_E62delinsRK |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61_E62delinsRK |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61_E62delinsRK |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61_E62delinsRK |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61_E62delinsRK |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61_E62delinsRK |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61_E62delinsRK |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61_E62delinsRK |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61_E62delinsRK |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61_E62delinsRK |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61_E62delinsRK |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
ALK |
A29T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A29T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
A29T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
A29T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
A29T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A29T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A29T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
A29T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
A29T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A29T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
A29T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
A29T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
A29T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A29T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
A29T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
A29T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
A29T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
A29T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
A29T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FGFR2 |
R251* |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
R251* |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R337C), TP53 MUT (R181C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337C), TP53 MUT (R181C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2D |
R4904* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12D), KRAS MUT (K117R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (K117R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12D), KRAS MUT (K117R |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
JAK2 |
V63A |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PTEN |
Q298E |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Q298E |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Q298E |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Q298E |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Q298E |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Q298E |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Q298E |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Q298E |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Q298E |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Q298E |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Q298E |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Q298E |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Q298E |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Q298E |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Q298E |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Q298E |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Q298E |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Q298E |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Q298E |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Q298E |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Q298E |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Q298E |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Q298E |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Q298E |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Q298E |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PIK3CA |
R93Q |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
R93Q |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
R93Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R93Q |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
R93Q |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
R93Q |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
R93Q |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
R93Q |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ROS1 |
D2055G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
D2055G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
D2055G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
D2055G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D2055G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
R1211Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1211Q |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
I788M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
I788M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I788M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
I788M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I788M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I788M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I788M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I788M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I788M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NOTCH2 |
S2162F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
K895R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K895R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K895R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K895R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K895R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K895R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH2 |
V1759A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
JAK2 |
E965G |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PDGFRA |
R822C |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
R |
Pre-clinical |
PDGFRA |
R822C |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
NCCN guidelines |
PDGFRA |
R822C |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
GIST |
NCCN guidelines |
PDGFRA |
R822C |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
NCCN guidelines |
PDGFRA |
R822C |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Pre-clinical |
PDGFRA |
R822C |
Different Mutation |
Crenolanib (FLT3 inhibitor) |
Responsive |
CM |
Pre-clinical |
PDGFRA |
R822C |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES |
Case report |
PDGFRA |
R822C |
Different Mutation |
Crenolanib (FLT3 inhibitor) |
Responsive |
GIST |
Early trials |
PDGFRA |
R822C |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
PDGFRA |
R822C |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
GIST |
Pre-clinical |
PDGFRA |
R822C |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
PDGFRA |
R822C |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
PDGFRA |
R822C |
Different Mutation |
PDGFR inhibitor |
Responsive |
GIST |
Early trials |
PDGFRA |
R822C |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Resistant |
GIST |
Late trials |
PDGFRA |
R822C |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
PDGFRA |
R822C |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
PDGFRA |
R822C |
Different Alteration |
PDGFR inhibitor |
No Responsive |
G |
Pre-clinical |
PDGFRA |
R822C |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
FGFR3 |
Y770N), FGFR3 MUT* (Y337N), FGFR3 MUT* (G295D |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
Y770N), FGFR3 MUT* (Y337N), FGFR3 MUT* (G295D |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
Y770N), FGFR3 MUT* (Y337N), FGFR3 MUT* (G295D |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NOTCH1 |
Q1037E), NOTCH1 MUT* (P1367L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q1037E), NOTCH1 MUT* (P1367L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BCR |
A226V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
A226V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
A226V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
A226V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
A226V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
A226V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BRCA2 |
R2659K |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
R2659K |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R2659K |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
R2659K |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
R2659K |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
R2659K |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
R2659K |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
R2659K |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
R2659K |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R2659K |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2659K |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2659K |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
R2659K |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
R2659K |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
NOTCH1 |
D528Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
D528Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
TP53 |
C141Pfs*4 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141Pfs*4 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141Pfs*4 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141Pfs*4 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141Pfs*4 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141Pfs*4 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141Pfs*4 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Pfs*4 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Pfs*4 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141Pfs*4 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141Pfs*4 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141Pfs*4 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141Pfs*4 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141Pfs*4 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141Pfs*4 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
H582Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R560H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R560H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R560H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R560H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R560H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R188C |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R188C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R188C |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R188C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R188C |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R188C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R188C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R188C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R188C |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R188C |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R188C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R188C |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R188C |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R188C |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R188C |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R188C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R188C |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R188C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R188C |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ESR1 |
T76S |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ARID1A |
S1828* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1828* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1828* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S1828* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
EGFR |
L25P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
L25P |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
BRCA1 |
R71G |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
R71G |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
R71G |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
R71G |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
R71G |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
R71G |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
R71G |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
R71G |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
R71G |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
R71G |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
R71G |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
R71G |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ROS1 |
T1735M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T1735M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T1735M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T1735M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T1735M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ARID1A |
Q1145* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1145* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q1145* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q1145* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y234D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Y234D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Y234D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Y234D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Y234D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Y234D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Y234D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Y234D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Y234D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Y234D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Y234D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Y234D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
AKT3 |
A300T |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
I1870T |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
I1870T |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
I1870T |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
I1870T |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
I1870T |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
I1870T |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ERBB4 |
R393W |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
CM |
Pre-clinical |
ERBB4 |
R393W |
Different Mutation |
ERBB2 inhibitor |
Resistant |
BRCA |
Case report |
ERBB4 |
R393W |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
P2377L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P2377L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
G28W |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G28W |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G28W |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G28W |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G28W |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G28W |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G279R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G279R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G279R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G279R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G279R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G279R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G279R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G279R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G279R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G279R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G279R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G279R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G279R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G279R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G279R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ESR1 |
H216R |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
NOTCH1 |
N1489S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N1489S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
D333Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
C2308W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
C2308W |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
splice_acceptor_variant |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
splice_acceptor_variant |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
FGFR3 |
P460L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P460L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P460L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
PALB2 |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
splice_donor_variant |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
splice_donor_variant |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
splice_donor_variant |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
splice_donor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
splice_donor_variant |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
splice_donor_variant |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
NOTCH1 |
S2491Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
S2491Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRCA2 |
K3019* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
K3019* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K3019* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
K3019* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
K3019* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
K3019* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
K3019* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
K3019* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
K3019* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K3019* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K3019* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
K3019* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
K3019* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
K3019* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
EGFR |
S1130G |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
S1130G |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ABL1 |
D748V |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
D748V |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
D748V |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
D748V |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
D748V |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
D748V |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
STK11 |
Q159* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Q159* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q159* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Q159* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Q159* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Q159* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q159* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q159* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Q159* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Q159* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q159* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q159* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Q159*), KRAS MUT (G12V |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Q159*), KRAS MUT (G12V |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Q159*), KRAS MUT (G12V |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Q159*), KRAS MUT (G12V |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
NOTCH1 |
V1829M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V1829M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
L1018F |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L1018F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L1018F |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L1018F |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L1018F |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L1018F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L1018F |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L1018F |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L1018F |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BCR |
D936E |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
D936E |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
D936E |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
D936E |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
D936E |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
D936E |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
TP53 |
R282W), TP53 MUT (K164E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R282W), TP53 MUT (K164E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R282W), TP53 MUT (K164E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
RET |
G938D |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
G938D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G938D |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
G938D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G938D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G938D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G938D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G938D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G938D |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
TP53 |
K101* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K101* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K101* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K101* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K101* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K101* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K101* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K101* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K101* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K101* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K101* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K101* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K101* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K101* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K101* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
S2315N |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S2315N |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S2315N |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S2315N |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S2315N |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S2315N |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
SETD2 |
K1587* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
K1587* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
DNMT3A |
S663* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
MPL |
W515R |
Different Mutation |
JAK inhibitor |
Responsive |
MDPS |
Pre-clinical |
TMPRSS2 |
3-UTRSNV |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
3-UTRSNV |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
BRAF |
T212A |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
T212A |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
T212A |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
T212A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ROS1 |
P1558T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
P1558T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
P1558T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
P1558T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P1558T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
EGFR |
Y891C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
Y891C |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
BRCA1 |
E1380* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
E1380* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
E1380* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
E1380* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E1380* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E1380* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
E1380* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
E1380* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
E1380* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E1380* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
E1380* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E1380* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
NOTCH1 |
V413M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V413M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
Y419H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
Y419H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
Y419H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
Y419H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
Y419H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1214C |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1214C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1214C |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1214C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1214C |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1214C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1214C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1214C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1214C |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1214C |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1214C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1214C |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1214C |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1214C |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1214C |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1214C |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1214C |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1214C |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1214C |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRD4 |
V1155M |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
NOTCH1 |
V874I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V874I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
SMARCB1 |
splice_donor_variant |
Complete Match |
HDAC inhibitor |
Responsive |
MRT |
Pre-clinical |
SMARCB1 |
splice_donor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
SMARCB1 |
splice_donor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
MRT |
Case report |
STK11 |
Y246*), STK11 MUT (S240* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
PA |
Case report |
STK11 |
Y246*), STK11 MUT (S240* |
Complete Match |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Complete Match |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Complete Match |
BET inhibitor |
Resistant |
L |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Complete Match |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y246*), STK11 MUT (S240* |
Complete Match |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Complete Match |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Different Alteration |
MTOR inhibitor |
Responsive |
CANCER |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Different Alteration |
PD1 inhibitor |
Resistant |
CANCER |
Early trials |
STK11 |
Y246*), STK11 MUT (S240* |
Different Alteration |
Phenformin (Anti-diabetic) |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240* |
Different Alteration |
SRC inhibitor;PI3K/MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240*), KRAS MUT (G12R |
Complete Match |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
STK11 |
Y246*), STK11 MUT (S240*), KRAS MUT (G12R |
Complete Match |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y246*), STK11 MUT (S240*), KRAS MUT (G12R |
Different Alteration |
PD1 Ab inhibitor |
Resistant |
LUAD |
Early trials |
STK11 |
Y246*), STK11 MUT (S240*), KRAS MUT (G12R |
Different Alteration |
MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) |
Resistant |
LUAD |
Pre-clinical |
NTRK1 |
R347H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R347H |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R347H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R347H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
FGFR3 |
V423L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
V423L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
V423L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
ALK |
P671T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P671T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
P671T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
P671T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
P671T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P671T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P671T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
P671T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
P671T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P671T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
P671T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
P671T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
P671T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P671T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
P671T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
P671T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
P671T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
P671T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
P671T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
G748D |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
G748D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G748D |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
G748D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G748D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
G748D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G748D |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G748D |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
G748D |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RAF1 |
R318Q |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R318Q |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R318Q |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NOTCH2 |
P2274S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
MAP2K1 |
D67N |
Complete Match |
MEK inhibitor |
Resistant |
CANCER |
Pre-clinical |
MAP2K1 |
D67N |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
D67N |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
D67N |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
MAP2K1 |
D67N |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
D67N |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
D67N |
Different Mutation |
Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Case report |
MAP2K1 |
D67N |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
MAP2K1 |
D67N |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
MAP2K1 |
D67N |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
D67N |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
KMT2A |
R160* |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
R160* |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
R160* |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
R160* |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
R160* |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
R160* |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
C182Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
C182Y |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
K601E |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
K601E |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
K601E |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
K601E |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
K601E |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
K601E |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
K601E |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
K601E |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
K601E |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
K601E |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
K601E |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
K601E |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
K601E |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
K601E |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
K601E |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
K601E |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
K601E |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
K601E |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
K601E |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
K601E |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
K601E |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
K601E |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
K601E |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
K601E |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
K601E |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
K601E |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
K601E |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
K601E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
MAP2K1 |
D67N), BRAF MUT (K601E |
Different Mutation |
BRAF inhibitor |
Responsive |
CM |
Case report |
ABL1 |
G829S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
G829S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G829S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
G829S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
G829S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
G829S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
APC |
S89* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
PDGFRA |
H966R |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
KMT2A |
S2256G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S2256G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S2256G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S2256G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S2256G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S2256G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
RET |
A325T |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
A325T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A325T |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
A325T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A325T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
A325T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A325T |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A325T |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
A325T |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ROS1 |
H62N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
H62N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
H62N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
H62N |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
H62N |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
S1277L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S1277L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S1277L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S1277L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S1277L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S1277L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
LRP1B |
R1632* |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
R1632* |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
TP53 |
R213P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R213P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R213P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R213P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R213P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R213P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R213P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R213P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R213P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R213P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R213P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R213P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ARID1A |
Q479* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q479* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q479* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q479* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
R1084Q |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R1084Q |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R1084Q |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R1084Q |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R1084Q |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R1084Q |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ROS1 |
F1807L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
F1807L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
F1807L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
F1807L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
F1807L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH2 |
R2047G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
Y1622S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
Y1622S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
Y1622S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
Y1622S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
Y1622S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
Y1622S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G279E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G279E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G279E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G279E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G279E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G279E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G279E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G279E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G279E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G279E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G279E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G279E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G279E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G279E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G279E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
K658E |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
K658E |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BCR |
M1083T |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
M1083T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
M1083T |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
M1083T |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
M1083T |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
M1083T |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
JAK2 |
P97S |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
RAF1 |
I32V |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
I32V |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
I32V |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
PDGFRA |
R585G |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PALB2 |
E159* |
Complete Match |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
E159* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
E159* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
E159* |
Complete Match |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
E159* |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Early trials |
PALB2 |
E159* |
Different Alteration |
PARP inhibitor |
Responsive |
PA |
Pre-clinical |
PALB2 |
E159* |
Different Alteration |
Mytomycin C (Chemotherapy) |
Responsive |
PA |
Case report |
PALB2 |
E159* |
Different Alteration |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRAF |
L597R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
NCCN guidelines |
BRAF |
L597R |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
L597R |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
L597R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
L597R |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
L597R |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
L597R |
Complete Match |
MEK inhibitor |
Responsive |
CM |
Case report |
BRAF |
L597R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
L597R |
Complete Match |
BRAF inhibitor |
Responsive |
CM |
Case report |
BRAF |
L597R |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
L597R |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor;HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
L597R |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
L597R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
L597R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
L597R |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor;PI3K pathway inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
L597R |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
L597R |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
L597R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor;CDK2/4 inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
L597R |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
L597R |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
L597R |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
L597R |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
L597R |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
L597R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
L597R |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
L597R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
L597R |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
L597R |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
L597R |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
L597R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ALK |
Q1429R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1429R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Q1429R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Q1429R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Q1429R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q1429R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q1429R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Q1429R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q1429R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q1429R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Q1429R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Q1429R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q1429R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1429R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1429R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q1429R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Q1429R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Q1429R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q1429R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
E545D |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E545D |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E545D |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545D |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E545D |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E545D |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E545D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E545D |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
KMT2D |
W1973* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
EGFR |
A822T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A822T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
NOTCH2 |
R1675H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
H2777R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
H2777R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
H2777R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
H2777R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
H2777R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
H2777R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
RET |
L398V |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
L398V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L398V |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
L398V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L398V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
L398V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L398V |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L398V |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
L398V |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
NRG1 |
S514R |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
S514R |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
PDGFRA |
Q323E |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
RNF43 |
Q305* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
ROS1 |
A320D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A320D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A320D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A320D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A320D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Y1655* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Y1655* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Y1655* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Y1655* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Y1655* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y1655* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Y1655* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Y1655* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ERBB4 |
G660E |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK3 |
L378V |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
L378V |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
L378V |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G13R |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G13R |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G13R |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G13R |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G13R |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13R |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G13R |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G13R |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G13R |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G13R |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13R |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G13R |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G13R |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G13R |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G13R |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G13R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13R |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G13R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13R |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G13R |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G13R |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13R |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G13R |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G13R |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G13R |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G13R |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G13R |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G13R |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G13R |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G13R |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G13R |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
IDH1 |
R132G |
Complete Match |
Venetoclax (BCL2 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132G |
Complete Match |
IDH1 inhibitor |
Responsive |
AML |
Early trials |
IDH1 |
R132G |
Complete Match |
AG-120 (IDH1 inhibitor) |
Responsive |
G |
Early trials |
IDH1 |
R132G |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CH |
Early trials |
IDH1 |
R132G |
Complete Match |
Ivosidenib (IDH1 inhibitor) |
Responsive |
AML |
Early trials |
IDH1 |
R132G |
Complete Match |
BCL2 inhibitor |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132G |
Complete Match |
BCL2 inhibitor (BCL2 inhibitor) |
Responsive |
AML |
Pre-clinical |
IDH1 |
R132G |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
BT |
Pre-clinical |
IDH1 |
R132G |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ERBB4 |
Q216K |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
R1598H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1598H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
N34S |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ALK |
R860I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R860I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R860I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R860I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R860I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R860I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R860I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R860I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R860I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R860I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R860I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R860I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R860I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R860I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R860I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R860I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R860I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R860I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R860I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q761* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q761* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q761* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q761* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12V), KRAS MUT (G13D |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12V), KRAS MUT (G13D |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NTRK3 |
T404K |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T404K |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T404K |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A159V), TP53 MUT (N235S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A159V), TP53 MUT (N235S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH2 |
E1147K |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RET |
E511K |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E511K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E511K |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E511K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E511K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E511K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E511K |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E511K |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E511K |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2A |
S3662G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S3662G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S3662G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S3662G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S3662G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S3662G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH2 |
T942A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
PDGFRA |
D423N |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
BAP1 |
E647* |
Complete Match |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
E647* |
Complete Match |
PARP inhibitor |
Responsive |
R, CANCER |
Pre-clinical |
BAP1 |
E647* |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
BAP1 |
E647* |
Different Alteration |
PARP inhibitor |
Responsive |
CANCER, R |
Pre-clinical |
BAP1 |
E647* |
Different Alteration |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
E647* |
Different Alteration |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
SMO |
A235T |
Different Mutation |
Vismodegib (SHH inhibitor) |
Resistant |
BCC |
Case report |
SMO |
A235T |
Different Mutation |
Vismodegib (SHH inhibitor) |
Responsive |
L |
Case report |
SMO |
A235T |
Different Mutation |
Vismodegib (SHH inhibitor) |
Resistant |
MB |
Case report |
KMT2A |
S809F |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S809F |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S809F |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S809F |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S809F |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S809F |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KMT2D |
Q3944* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ROS1 |
D1853A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
D1853A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
D1853A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
D1853A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D1853A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
A1742S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A1742S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB4 |
G1061E |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
N528I |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
N528I |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TP53 |
E285* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
E285* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
E285* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
E285* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
E285* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
E285* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
E285* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E285* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E285* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
E285* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
E285* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
E285* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E285* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
E285* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
E285* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
R806H |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R806H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R806H |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R806H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R806H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R806H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R806H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R806H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R806H |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R806H |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R806H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R806H |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R806H |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R806H |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R806H |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R806H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R806H |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R806H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R806H |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
L79Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
L79Q |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
L79Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
L79Q |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
BRAF |
V487G |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
V487G |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
V487G |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
V487G |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ATM |
R2138* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2138* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2138* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2138* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2138* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2138* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2138* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2138* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2138* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2138* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2138* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2138* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2138* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
BRD4 |
R1290C |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
G266E), TP53 MUT (R306* |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G266E), TP53 MUT (R306* |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G266E), TP53 MUT (R306* |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
E2265* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E2265* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E2265* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E2265* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E2265* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ESR1 |
G90D |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
R2763*), ATM MUT (CdsStartSNV |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
MET |
A1372T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
FGFR3 |
R110Q |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R110Q |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R110Q |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
BRCA2 |
S2835* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
S2835* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
S2835* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
S2835* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
S2835* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
S2835* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
S2835* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
S2835* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
S2835* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
S2835* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
S2835* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
S2835* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
S2835* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
S2835* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
CDKN2A |
I49S |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
I49S |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
I49S |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
I49S |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
I49S |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
I49S |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
I49S |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
I49S |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
ROS1 |
K689R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
K689R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
K689R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
K689R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
K689R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
K609R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K609R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K609R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K609R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K609R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K609R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK3 |
T500I |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T500I |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T500I |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH2 |
S688F |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
P695L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
P695L |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
P695L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
P695L |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NOTCH1 |
L2081P |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
L2081P |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
T292K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
T292K |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
T292K |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
T292K |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
CTNNB1 |
D32A |
Different Mutation |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
D32A |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
RET |
D850Y |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
D850Y |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D850Y |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
D850Y |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D850Y |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D850Y |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D850Y |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D850Y |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D850Y |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRAF |
Q94K |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
Q94K |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
Q94K |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
Q94K |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
PIK3CA |
N345Y |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
N345Y |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
N345Y |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N345Y |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
N345Y |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N345Y |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
N345Y |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
N345Y |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
RNF43 |
Q414* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
KMT2A |
I2562V |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
I2562V |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
I2562V |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
I2562V |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
I2562V |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
I2562V |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
Q2881* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
Q2881* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
Q2881* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
Q2881* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q2881* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q2881* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q2881* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
Q2881* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q2881* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
Q2881* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
Q2881* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
Q2881* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
Q2881* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
PDGFRA |
P975R |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
ROS1 |
E1541K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E1541K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E1541K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E1541K |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E1541K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2D |
Q4473* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ALK |
G1121D |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1121D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G1121D |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G1121D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G1121D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1121D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1121D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G1121D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1121D |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1121D |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G1121D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G1121D |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G1121D |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1121D |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1121D |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1121D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G1121D |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G1121D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1121D |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
R1413H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1413H |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ESR1 |
L544V |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
KMT2D |
Q4262* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KMT2A |
S1910L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
S1910L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
S1910L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
S1910L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
S1910L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
S1910L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATM |
W156* |
Different Mutation |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ATM |
W156* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ATM |
W156* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
ST, PRAD |
Early trials |
ATM |
W156* |
Complete Match |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
W156* |
Complete Match |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
W156* |
Complete Match |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
W156* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATM |
W156* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
W156* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
ATM |
W156* |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
LY |
Pre-clinical |
ATM |
W156* |
Different Alteration |
PARP inhibitor |
Responsive |
ST |
Early trials |
ATM |
W156* |
Different Alteration |
ATR inhibitor |
Responsive |
COREAD |
Case report |
ATM |
W156* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
ALK |
R1120R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1120R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1120R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1120R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1120R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1120R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1120R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1120R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1120R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1120R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1120R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1120R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1120R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1120R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1120R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1120R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1120R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1120R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1120R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
N796T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
ERBB4 |
R168Q |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
HES, ALL, MDS, SM, ECL, MDPS, CML |
FDA guidelines |
KIT |
H697Y |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Case report |
KIT |
H697Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
SM |
Early trials |
KIT |
H697Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Case report |
KIT |
H697Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
H697Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Early trials |
KIT |
H697Y |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Early trials |
KIT |
H697Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Late trials |
KIT |
H697Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive;Responsive |
CM |
Late trials;NCCN guidelines |
KIT |
H697Y |
Complete Match |
Regorafenib (Pan-kinase inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
H697Y |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
H697Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
CM |
Late trials |
KIT |
H697Y |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
FDA guidelines |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
CM |
Early trials |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
THYM |
Case report |
KIT |
H697Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
H697Y |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KIT |
H697Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
THYM |
Case report |
KIT |
H697Y |
Different Mutation |
HSP90 inhibitor |
Responsive |
GIST |
Pre-clinical |
KIT |
H697Y |
Complete Match |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THYM |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
AML |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
GIST |
Late trials |
KIT |
H697Y |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Late trials |
KIT |
H697Y |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive;Resistant |
GIST |
FDA guidelines;Pre-clinical |
KIT |
H697Y |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
GIST |
Early trials |
KIT |
H697Y |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
GIST |
Pre-clinical |
KIT |
H697Y |
Different Mutation |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CM |
Case report |
KIT |
H697Y |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
CM |
Case report |
KIT |
H697Y |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
No Responsive |
CM |
Early trials |
KIT |
H697Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
No Responsive |
CM |
Early trials |
ARID1A |
E72* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E72* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E72* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E72* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH2 |
V2221L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12D), KRAS MUT (V14G |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12D), KRAS MUT (V14G |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
K164E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
K164E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
K164E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
K164E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
K164E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
K164E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
K164E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K164E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K164E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
K164E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
K164E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
K164E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K164E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
K164E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
K164E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
APC |
R1687* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ESR1 |
A571V |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
FAT1 |
splice_acceptor_variant |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
TP53 |
R158C |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R158C |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R158C |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R158C |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R158C |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R158C |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158C |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158C |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158C |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R158C |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R158C |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158C |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158C |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R158C |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158C |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
K783E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
HRAS |
Q61R |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CER |
Pre-clinical |
HRAS |
Q61R |
Complete Match |
MEK inhibitor +/- MTOR inhibitor |
Responsive |
AML |
Pre-clinical |
HRAS |
Q61R |
Complete Match |
MTOR inhibitor |
Responsive |
CESC |
Pre-clinical |
HRAS |
Q61R |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
Responsive |
CANCER |
Early trials |
TSC1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
splice_donor_variant |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
splice_donor_variant |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
splice_donor_variant |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
BCR |
R1262G |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
R1262G |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
R1262G |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
R1262G |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
R1262G |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
R1262G |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ROS1 |
A1750P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A1750P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A1750P |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A1750P |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A1750P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BCR |
E1079K |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
E1079K |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
E1079K |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
E1079K |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
E1079K |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
E1079K |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
NOTCH1 |
S1941C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
S1941C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
P3248L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3248L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3248L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3248L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3248L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3248L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
FGFR3 |
S610Y |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
S610Y |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
S610Y |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
RAF1 |
S77I |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
S77I |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
S77I |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
NOTCH1 |
H709R), NOTCH1 MUT* (G995S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
H709R), NOTCH1 MUT* (G995S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
V1023M |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V1023M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
V1023M |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
V1023M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
V1023M |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V1023M |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V1023M |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
V1023M |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
V1023M |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V1023M |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
V1023M |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
V1023M |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
V1023M |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V1023M |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
V1023M |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
V1023M |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
V1023M |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
V1023M |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
V1023M |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
Q920* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q920* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q920* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q920* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ALK |
E1000G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E1000G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
E1000G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
E1000G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
E1000G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E1000G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E1000G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
E1000G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E1000G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E1000G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
E1000G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
E1000G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
E1000G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E1000G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E1000G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E1000G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
E1000G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
E1000G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E1000G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
P1386L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P1386L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
RAF1 |
R218* |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R218* |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
R218* |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
ROS1 |
R863Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R863Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R863Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R863Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R863Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
FGFR2 |
D273D |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
D273D |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
TP53 |
C141F |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C141F |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C141F |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C141F |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C141F |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C141F |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C141F |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141F |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141F |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C141F |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C141F |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C141F |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141F |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C141F |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C141F |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
DNMT3A |
R771* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R283S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175H), TP53 MUT (R283S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175H), TP53 MUT (R283S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NOTCH1 |
S225L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
S225L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
S490S |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
FGFR3 |
R238L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R238L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R238L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
PIK3CA |
N345K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
N345K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
N345K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N345K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
N345K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
N345K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
N345K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
N345K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ARID1A |
Q297* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q297* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q297* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q297* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH1 |
N325N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
N325N |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
AKT3 |
R465P |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
P3306T |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3306T |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3306T |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3306T |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3306T |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3306T |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
VHL |
R113P |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
AKT3 |
5-UTRSNV |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, BRCA, GEJA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) |
Responsive |
SOLID |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Complete Match |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER, BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
S310Y |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
CANCER |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Case report |
ERBB2 |
S310Y |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BRCA, LUAD |
Case report |
ERBB2 |
S310Y |
Different Mutation |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
L |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Case report |
ERBB2 |
S310Y |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Case report |
ERBB2 |
S310Y |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Resistant |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
CANCER |
Pre-clinical |
ERBB2 |
S310Y |
Complete Match |
Temsirolimus (MTOR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Complete Match |
Dacomitinib (Pan ERBB inhibitor) |
Responsive |
NSCLC |
Early trials |
ERBB2 |
S310Y |
Complete Match |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
ERBB2 inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
ERBB2 mAb inhibitor |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Neratinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Mutation |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
LUAD |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
S310Y |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
COREAD |
Late trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
OV |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
BLCA |
Case report |
ERBB2 |
S310Y |
Different Alteration |
Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) |
Responsive |
COREAD |
Case report |
ERBB2 |
S310Y |
Different Alteration |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
S310Y |
Different Alteration |
Osimertinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
BT |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) |
Responsive |
BRCA |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
HER2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
Pertuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
ST, GEJA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
ERBB2 inhibitor;CDK4/6 inhibitor |
Responsive |
BRCA |
Pre-clinical |
ERBB2 |
S310Y |
Different Alteration |
Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) |
Responsive |
BRCA |
FDA guidelines |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
Responsive |
HNC |
Case report |
ERBB2 |
S310Y |
Different Alteration |
Neratinib (ERBB2 inhibitor) |
Responsive |
BRCA |
Late trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab (ERBB2 mAb inhibitor) |
No Responsive |
ED |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Responsive |
ED |
Pre-clinical |
ERBB2 |
S310Y |
Different Alteration |
Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) |
Responsive |
ST |
Early trials |
ERBB2 |
S310Y |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
ST |
Case report |
ERBB2 |
S310Y |
Different Alteration |
EGFR inhibitor |
Resistant |
LUAD |
Pre-clinical |
RNF43 |
E401* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
FGFR3 |
D758N |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
D758N |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
D758N |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
ALK |
S737S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S737S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S737S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S737S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S737S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S737S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S737S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S737S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S737S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S737S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S737S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S737S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S737S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S737S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S737S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S737S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S737S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S737S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S737S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
T75A |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
T75A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T75A |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
T75A |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T75A |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T75A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T75A |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T75A |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T75A |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
CDKN2A |
R24P |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R24P |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R24P |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R24P |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R24P |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R24P |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R24P |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R24P |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
VHL |
R108H |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
EPHA2 |
splice_donor_variant |
Different Mutation |
MTOR inhibitor |
Responsive |
LUSC |
Pre-clinical |
EPHA2 |
splice_donor_variant |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUSC |
Pre-clinical |
EPHA2 |
splice_donor_variant |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
CANCER |
Pre-clinical |
NTRK1 |
R750H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R750H |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R750H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R750H |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
ROS1 |
T280T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T280T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T280T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T280T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T280T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ARID1A |
E1767* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1767* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
E1767* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
E1767* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
RET |
N763N |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
N763N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N763N |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
N763N |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N763N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
N763N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N763N |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N763N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
N763N |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
RAF1 |
C637Y |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
C637Y |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
C637Y |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
MET |
V1173L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
APC |
E201* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ALK |
E296Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E296Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
E296Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
E296Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
E296Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E296Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E296Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
E296Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E296Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E296Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
E296Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
E296Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
E296Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E296Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E296Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E296Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
E296Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
E296Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E296Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PTEN |
L25* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
L25* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
L25* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
L25* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
L25* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
L25* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
L25* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
L25* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
L25* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
L25* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
L25* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
L25* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
L25* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
L25* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
L25* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
L25* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
L25* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
L25* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
L25* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
L25* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
L25* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
L25* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
L25* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
L25* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
L25* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
KMT2D |
Q4228* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NOTCH2 |
S2090T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
G2248G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
G2248G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
G2248G |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
G2248G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
G2248G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
FGFR3 |
R116H |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
R116H |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
R116H |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
MSH3 |
M518Ifs*18 |
Complete Match |
DNA-PKc inhibitor |
Responsive |
CANCER |
Pre-clinical |
NTRK3 |
L657I |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
L657I |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
L657I |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
ALK |
G1125G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1125G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G1125G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G1125G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G1125G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1125G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1125G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G1125G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1125G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1125G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G1125G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G1125G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G1125G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1125G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1125G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1125G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G1125G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G1125G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1125G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
I1050T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
I1050T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ATR |
splice_donor_variant |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
splice_donor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
FGFR2 |
A516T |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
A516T |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
KMT2D |
R5448* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KMT2A |
3-UTRSNV |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
3-UTRSNV |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
3-UTRSNV |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
3-UTRSNV |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
3-UTRSNV |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
3-UTRSNV |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TMPRSS2 |
V133M |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
V133M |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
NOTCH1 |
T692A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
T692A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
S30R |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
S30R |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
RB1 |
S567* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
S567* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S567* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S567* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S567* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S567* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S567* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
EGFR |
A419S), EGFR MUT* (V85V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
A419S), EGFR MUT* (V85V |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
APC |
G2597* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G578G), ALK MUT* (Q1134K |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
G660* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G660* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
G660* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
G660* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ABL1 |
P684P |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
P684P |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
P684P |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
P684P |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
P684P |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
P684P |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
FAT1 |
G2130* |
Complete Match |
BET inhibitor |
Responsive |
HNSC |
Pre-clinical |
DNMT3A |
E94* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
RB1 |
S780* |
Different Alteration |
Palbociclib (CDK4/6 inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RB1 |
S780* |
Complete Match |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S780* |
Complete Match |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S780* |
Complete Match |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S780* |
Different Alteration |
MDM2/MDMX inhibitor |
Responsive |
RB |
Pre-clinical |
RB1 |
S780* |
Different Alteration |
Cisplatin (Chemotherapy) |
Responsive |
BLCA |
Early trials |
RB1 |
S780* |
Different Alteration |
HDAC inhibitor |
Responsive |
RB |
Pre-clinical |
KMT2A |
G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G2161C), MLL MUT* (A1670S), MLL MUT* (V1414V |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NOTCH1 |
Q462K), NOTCH1 MUT* (Q619K), NOTCH1 MUT* (C826F), NOTCH1 MUT* (L2276L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
Q462K), NOTCH1 MUT* (Q619K), NOTCH1 MUT* (C826F), NOTCH1 MUT* (L2276L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
A1203A |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
EGFR |
Q581Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
Q581Q |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ALK |
D954H |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D954H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D954H |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D954H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D954H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D954H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D954H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D954H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D954H |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D954H |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D954H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D954H |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D954H |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D954H |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D954H |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D954H |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D954H |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D954H |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D954H |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
TMPRSS2 |
CdsStartSNV |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
CdsStartSNV |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
MAP2K1 |
E203K |
Different Mutation |
MEK inhibitor |
Resistant |
CANCER |
Pre-clinical |
MAP2K1 |
E203K |
Different Mutation |
novel MEK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
E203K |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
E203K |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
E203K |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
MAP2K1 |
E203K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
E203K |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
E203K |
Different Mutation |
Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Case report |
MAP2K1 |
E203K |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
MAP2K1 |
E203K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
MAP2K1 |
E203K |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
E203K |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NRG1 |
S157L |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
S157L |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
BRD4 |
P1022L |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
A311T |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
A311T |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
A311T |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
A311T |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
PIK3CA |
P104S |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
P104S |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
P104S |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P104S |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
P104S |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
P104S |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
P104S |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
P104S |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
ABL1 |
R134H |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
R134H |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R134H |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
R134H |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
R134H |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
R134H |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
KMT2A |
A1669A |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
A1669A |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
A1669A |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
A1669A |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
A1669A |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
A1669A |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ROS1 |
S1581S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
S1581S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
S1581S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
S1581S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
S1581S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
MET |
T440P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
ARID1A |
Y1279* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y1279* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Y1279* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Y1279* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
ROS1 |
R1609* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1609* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1609* |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1609* |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1609* |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
TSC2 |
R905Q |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
R905Q |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
R905Q |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
R905Q |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
R905Q |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
R905Q |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
R905Q |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
ROS1 |
E698K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E698K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E698K |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E698K |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E698K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
L2242V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
L2242V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
P284L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
P284L |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
LRP1B |
Q2396* |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
Q2396* |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
AKT3 |
L272L |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
H801Y |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
H801Y |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
H801Y |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
H801Y |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
H801Y |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
H801Y |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
FGFR3 |
A334T |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
A334T |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
A334T |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NOTCH1 |
R1663R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1663R |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BAP1 |
splice_acceptor_variant |
Complete Match |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
splice_acceptor_variant |
Complete Match |
PARP inhibitor |
Responsive |
R, CANCER |
Pre-clinical |
BAP1 |
splice_acceptor_variant |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
BAP1 |
splice_acceptor_variant |
Different Alteration |
PARP inhibitor |
Responsive |
CANCER, R |
Pre-clinical |
BAP1 |
splice_acceptor_variant |
Different Alteration |
EZH2 inhibitor |
Responsive |
MESO |
Pre-clinical |
BAP1 |
splice_acceptor_variant |
Different Alteration |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
F53L |
Different Mutation |
MEK inhibitor |
Resistant |
CANCER |
Pre-clinical |
MAP2K1 |
F53L |
Different Mutation |
novel MEK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
F53L |
Different Mutation |
MEK inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
F53L |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
F53L |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
MAP2K1 |
F53L |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
MAP2K1 |
F53L |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MAP2K1 |
F53L |
Different Mutation |
Panitumumab;Trametinib (EGFR mAb inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Case report |
MAP2K1 |
F53L |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
MAP2K1 |
F53L |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
MAP2K1 |
F53L |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
MAP2K1 |
F53L |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
BRD4 |
L1327L), BRD4 MUT* (A1328Pfs*20 |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
PDGFRA |
Q412E |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
NOTCH1 |
I2547I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
I2547I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
EGFR |
E534K), EGFR MUT* (L267F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
E534K), EGFR MUT* (L267F |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
Q1177Q), ALK MUT* (G1468G), ALK MUT* (P1469L), ALK MUT* (V1492I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ABL1 |
F621F), ABL1 MUT* (S157N |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
F621F), ABL1 MUT* (S157N |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
F621F), ABL1 MUT* (S157N |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
F621F), ABL1 MUT* (S157N |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
F621F), ABL1 MUT* (S157N |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
F621F), ABL1 MUT* (S157N |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
JAK2 |
S593F), JAK2 MUT* (G2R |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
PDGFRA |
D902N), PDGFRA MUT* (splice_donor_variant), PDGFRA MUT* (V594M), PDGFRA MUT* (P344S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
POLE |
splice_donor_variant |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
POLE |
splice_donor_variant |
Complete Match |
PD1 Ab inhibitor |
Responsive |
COREAD |
Case report |
POLE |
splice_donor_variant |
Different Mutation |
PD1 Ab inhibitor |
Responsive |
G, ED |
Case report |
POLE |
splice_donor_variant |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
FGFR3 |
T338I), FGFR3 MUT* (E336K |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
T338I), FGFR3 MUT* (E336K |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
T338I), FGFR3 MUT* (E336K |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
E991K), RET MUT* (Q857Q |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ROS1 |
E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
E563E), ROS1 MUT* (V614I), ROS1 MUT* (L1995L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2A |
P3362S), MLL MUT* (intron_variant |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3362S), MLL MUT* (intron_variant |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3362S), MLL MUT* (intron_variant |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3362S), MLL MUT* (intron_variant |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3362S), MLL MUT* (intron_variant |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3362S), MLL MUT* (intron_variant |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NTRK3 |
A124V |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
A124V |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
A124V |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
splice_donor_variant), NOTCH1 MUT* (C788C), NOTCH1 MUT* (E843E), NOTCH1 MUT* (G925S), NOTCH1 MUT* (P1417L), NOTCH1 MUT* (R1438H), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1917G), NOTCH1 MUT* (T2063T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
splice_donor_variant), NOTCH1 MUT* (C788C), NOTCH1 MUT* (E843E), NOTCH1 MUT* (G925S), NOTCH1 MUT* (P1417L), NOTCH1 MUT* (R1438H), NOTCH1 MUT* (intron_variant), NOTCH1 MUT* (G1917G), NOTCH1 MUT* (T2063T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P1033L |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
NOTCH1 |
V1232M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V1232M |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
AKT3 |
A135A |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
R1758C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
R1758C |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
L1508L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
L1508L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
L1508L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
L1508L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
L1508L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NOTCH1 |
A1869S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A1869S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
P996T |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
CRLF2 |
A177A |
Different Alteration |
MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
CRLF2 |
A177A |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
ALK |
G1123G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1123G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G1123G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G1123G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G1123G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1123G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1123G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G1123G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1123G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1123G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G1123G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G1123G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G1123G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1123G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1123G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1123G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G1123G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G1123G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1123G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
MET |
N704D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
NTRK3 |
T93M |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T93M |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
T93M |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
V485M), NOTCH1 MUT* (T1379T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
V485M), NOTCH1 MUT* (T1379T |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
T1506T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
T1506T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
T1506T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
T1506T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
T1506T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
T1506T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
T1506T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
T1506T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
T1506T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
T1506T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
T1506T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
T1506T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
T1506T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
T1506T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
T1506T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
T1506T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
T1506T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
T1506T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
T1506T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRD4 |
P723A |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
JAK2 |
S797C), JAK2 MUT* (L453L |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ERBB4 |
R50R |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ARID1A |
S1138* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1138* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
S1138* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
S1138* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NRAS |
Q61L |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
Q61L |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
Q61L |
Complete Match |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
Q61L |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
Q61L |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
Q61L |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
Q61L |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
Q61L |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
Q61L |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
Q61L |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
Q61L |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
Q61L |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
Q61L |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
Q61L |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
RAF1 |
T303A |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
T303A |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
T303A |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
BRD4 |
P759P |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
ESR1 |
T594M |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ROS1 |
F542L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
F542L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
F542L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
F542L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
F542L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
CDKN2A |
D153Y |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D153Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D153Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
D153Y |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D153Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
D153Y |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
D153Y |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
D153Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
ROS1 |
A99S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A99S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A99S |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A99S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A99S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
BRCA1 |
E848* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
E848* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
E848* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
E848* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E848* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E848* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
E848* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
E848* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
E848* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
E848* |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
E848* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
E848* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
A74Vfs*45 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
A74Vfs*45 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
A74Vfs*45 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
A74Vfs*45 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
A74Vfs*45 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
A74Vfs*45 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
A74Vfs*45 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A74Vfs*45 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A74Vfs*45 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
A74Vfs*45 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
A74Vfs*45 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
A74Vfs*45 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A74Vfs*45 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
A74Vfs*45 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
A74Vfs*45 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
LRP1B |
R3064* |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
R3064* |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
RAF1 |
K375N |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
K375N |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
K375N |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y346* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y346* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y346* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y346* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y346* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y346* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y346* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y346* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y346* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y346* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y346* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y346* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y346* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y346* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y346* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y346* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y346* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y346* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y346* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y346* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y346* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y346* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y346* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y346* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y346* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
LRP1B |
K3039* |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
K3039* |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
NF1 |
R1968* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
R1968* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
R1968* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R1968* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
R1968* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
R1968* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R1968* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
R1968* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R1968* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R1968* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R1968* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R1968* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R1968* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
R1968* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
R1968* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
R1968* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
R1968* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
R1968* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
R1968* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
R1968* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
R1968* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
FGFR3 |
P300S |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P300S |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P300S |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
EGFR |
R108K |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
R108K |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
R108K |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
R108K |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R108K |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R108K |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
R108K |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
R108K |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
R108K |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
R108K |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
R108K |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
R108K |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
R108K |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R108K |
Complete Match |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
R108K |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R108K |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
R108K |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
R108K |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
R108K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
R108K |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
R108K |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R108K |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
R108K |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
R108K |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
R108K |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
R108K |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
R108K |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
R108K |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
R108K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
R108K |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
R108K |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
R108K |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
R108K |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
R108K |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
R108K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
R108K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
R108K |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
R108K |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
R108K |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
R108K |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
R108K |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
R108K |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
R108K), EGFR MUT* (R324L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R108K), EGFR MUT* (R324L |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
TSC2 |
T993Nfs*12 |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
T993Nfs*12 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
T993Nfs*12 |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
T993Nfs*12 |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
T993Nfs*12 |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
T993Nfs*12 |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
T993Nfs*12 |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R158C), TP53 MUT (P177S |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158C), TP53 MUT (P177S |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
PDGFRA |
L521L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
GNAQ |
Q209P |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
CM |
Early trials |
GNAQ |
Q209P |
Complete Match |
HDAC inhibitor |
Responsive |
CM |
Pre-clinical |
GNAQ |
Q209P |
Complete Match |
PKC inhibitor |
Responsive |
CM |
Pre-clinical |
GNAQ |
Q209P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
APC |
S2054* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
BCOR |
E1518* |
Complete Match |
Enzastaurin (PKCb inhibitor) |
Responsive |
ST |
Pre-clinical |
CTNNB1 |
D32V |
Complete Match |
Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) |
Responsive |
ED |
Early trials |
CTNNB1 |
D32V |
Complete Match |
Tankyrase inhibitor |
Resistant |
COREAD |
Pre-clinical |
ESR1 |
G262E), ESR1 MUT* (intron_variant |
Different Alteration |
ESR1 inhibitor |
Resistant |
BRCA |
Pre-clinical |
ERBB4 |
L110F |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
K294K |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
K294K |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
intron_variant), ALK MUT* (E974K |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ABL1 |
E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
E925K), ABL1 MUT* (D444D), ABL1 MUT* (K356K |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
SETD2 |
W1460* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
W1460* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PDGFRA |
V598I), PDGFRA MUT* (R554R), PDGFRA MUT* (T364I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
LRP1B |
W4421* |
Complete Match |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
LRP1B |
W4421* |
Different Alteration |
Liposomal Doxorubicin (Chemotherapy) |
Resistant |
OV |
Early trials |
FANCA |
W386* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
W386* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FGFR3 |
P550S), FGFR3 MUT* (E231K), FGFR3 MUT* (P220P |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P550S), FGFR3 MUT* (E231K), FGFR3 MUT* (P220P |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P550S), FGFR3 MUT* (E231K), FGFR3 MUT* (P220P |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
TMPRSS2 |
S419S |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
S419S |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
DNMT3A |
R736C |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
ROS1 |
L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
L426L), ROS1 MUT* (V1260M), ROS1 MUT* (R2096R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
MET |
splice_donor_variant), MET MUT* (C561Y), MET MUT* (E240E |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
KMT2A |
G967E |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G967E |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G967E |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G967E |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G967E |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G967E |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
NF1 |
E2749* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
E2749* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
E2749* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
E2749* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
E2749* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
E2749* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2749* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
E2749* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2749* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
E2749* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
E2749* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2749* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
E2749* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
E2749* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
E2749* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
E2749* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
E2749* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
E2749* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
E2749* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
E2749* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
E2749* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NTRK1 |
R583H), NTRK1 MUT* (T580I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R583H), NTRK1 MUT* (T580I |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R583H), NTRK1 MUT* (T580I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R583H), NTRK1 MUT* (T580I |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
NOTCH1 |
W133* |
Different Mutation |
Gamma secretase inhibitor |
Responsive |
CANCER |
Early trials |
NOTCH1 |
W133* |
Different Mutation |
Gamma secretase inhibitor;CDK4 inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
W133* |
Different Mutation |
Gamma secretase inhibitor;MTOR inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
W133* |
Different Mutation |
Gamma secretase inhibitor |
Responsive;Responsive |
ALL |
Early trials;Pre-clinical |
NOTCH1 |
W133* |
Different Mutation |
NOTCH1 inhibitor |
Responsive |
ADCC |
Case report |
NOTCH1 |
W133* |
Different Mutation |
OMP-52M51 (NOTCH1 inhibitor) |
Responsive |
CANCER |
Early trials |
NOTCH1 |
W133* |
Different Mutation |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
W133* |
Complete Match |
Gamma secretase inhibitor |
Responsive |
MCL |
Pre-clinical |
NOTCH1 |
W133*), NOTCH1 MUT* (V322M), NOTCH1 MUT* (D1348D), NOTCH1 MUT* (G1366D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
W133*), NOTCH1 MUT* (V322M), NOTCH1 MUT* (D1348D), NOTCH1 MUT* (G1366D |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
G187G), BRD4 MUT* (P310H), BRD4 MUT* (A481V), BRD4 MUT* (intron_variant |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
BRAF |
S602F |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HISEC, HISLC, NSCLC |
NCCN guidelines |
BRAF |
S602F |
Different Mutation |
Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
S602F |
Different Mutation |
Trametinib (MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
S602F |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
S602F |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CANCER |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CANCER |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
ERK inhibitor |
Responsive |
HNSC, BT |
Case report |
BRAF |
S602F |
Different Mutation |
EGFR TK inhibitor |
Resistant |
LUAD |
Case report |
BRAF |
S602F |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
Early trials |
BRAF |
S602F |
Different Mutation |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
No Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) |
Responsive |
COREAD |
NCCN guidelines |
BRAF |
S602F |
Different Mutation |
Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor |
Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
MA |
Early trials |
BRAF |
S602F |
Different Mutation |
BRAF inhibitor;MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
S602F |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
S602F |
Different Mutation |
Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) |
Responsive |
COREAD |
Early trials |
BRAF |
S602F |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
BRAF |
S602F |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
BRAF |
S602F |
Different Mutation |
MEK inhibitor |
Responsive |
TH |
Early trials |
BRAF |
S602F |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
LUAD, TH |
Early trials |
BRAF |
S602F |
Different Mutation |
MEK inhibitor |
Responsive |
OV |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
HCL, LUAD, MYMA |
Case report |
BRAF |
S602F |
Different Mutation |
Pan-RAF inhibitor |
Responsive |
CM |
Early trials |
BRAF |
S602F |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
BRAF |
S602F |
Different Mutation |
BRAF inhibitor |
Responsive |
G |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
PLX4720 (BRAF inhibitor) |
Responsive |
MA |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Responsive |
THCA |
Early trials |
BRAF |
S602F |
Different Mutation |
Selumetinib (MEK inhibitor) |
Responsive |
PG |
Early trials |
BRAF |
S602F |
Different Mutation |
ERK inhibitor |
Responsive |
LUAD |
Early trials |
BRAF |
S602F |
Different Mutation |
ERK inhibitor |
Responsive |
CM |
Pre-clinical |
BRAF |
S602F |
Different Mutation |
Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) |
Responsive |
NEU |
Case report |
BRAF |
S602F |
Different Mutation |
BRAF inhibitor |
Responsive |
OV |
Case report |
BRAF |
S602F |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
GIST |
Case report |
BRAF |
S602F |
Different Mutation |
Dabrafenib (BRAF inhibitor) |
Responsive |
CM |
FDA guidelines |
BRAF |
S602F |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
LUAD |
Case report |
BRAF |
S602F), BRAF MUT* (G758G |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G758G |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
S602F), BRAF MUT* (G758G |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
S602F), BRAF MUT* (G758G |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
PTEN |
S170N), PTEN MUT (L108F), BRAF MUT (S602F |
Complete Match |
MEK inhibitor |
Resistant |
CM |
Pre-clinical |
PTEN |
S170N), PTEN MUT (L108F), BRAF MUT (S602F |
Complete Match |
BRAF inhibitor |
Resistant |
CM |
Early trials |
PTEN |
S170N), PTEN MUT (L108F), BRAF MUT (S602F |
Different Alteration |
BRAF inhibitor |
Resistant |
CM |
Early trials |
PTEN |
S170N), PTEN MUT (L108F), BRAF MUT (S602F |
Different Alteration |
MEK inhibitor |
Resistant |
CM |
Pre-clinical |
NF1 |
E2749*), BRAF MUT (S602F |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
NF1 |
E2749*), BRAF MUT (S602F |
Complete Match |
Selumetinib (MEK inhibitor) |
Resistant |
CM |
Case report |
NF1 |
E2749*), BRAF MUT (S602F |
Different Alteration |
Selumetinib (MEK inhibitor) |
Resistant |
CM |
Case report |
NF1 |
E2749*), BRAF MUT (S602F |
Different Alteration |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Case report |
VHL |
S65L |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
TP53 |
I254T |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
I254T |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
I254T |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
I254T |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
I254T |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
I254T |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
I254T |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254T |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254T |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
I254T |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
I254T |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
I254T |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I254T |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
I254T |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
I254T |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61R), KRAS MUT (E62A |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61R), KRAS MUT (E62A |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62A |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61R), KRAS MUT (E62A |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
FGFR3 |
H721H |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
H721H |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
H721H |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
FGFR2 |
E275Q |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
E275Q |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ABL1 |
A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
A287V), ABL1 MUT* (V280M), ABL1 MUT* (T277T |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
PTEN |
C250Y |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
C250Y |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
C250Y |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
C250Y |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
C250Y |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
C250Y |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
C250Y |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
C250Y |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
C250Y |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
C250Y |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
C250Y |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
C250Y |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
C250Y |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
C250Y |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
C250Y |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
C250Y |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
C250Y |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
C250Y |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
C250Y |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
C250Y |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
C250Y |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
C250Y |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
C250Y |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
C250Y |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
C250Y |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
FGFR3 |
K705E), FGFR3 MUT* (P401T |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
K705E), FGFR3 MUT* (P401T |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
K705E), FGFR3 MUT* (P401T |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NOTCH1 |
intron_variant), NOTCH1 MUT* (intron_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
intron_variant), NOTCH1 MUT* (intron_variant |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ABL1 |
L298L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
L298L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L298L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
L298L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
L298L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
L298L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
NRAS |
E63K |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
NRAS |
E63K |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
NRAS |
E63K |
Different Mutation |
MEK inhibitor |
Responsive |
CM |
Late trials |
NRAS |
E63K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Early trials |
NRAS |
E63K |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CM |
Early trials |
NRAS |
E63K |
Complete Match |
HSP90 inhibitor |
Responsive |
CM |
Pre-clinical |
NRAS |
E63K |
Complete Match |
MEK inhibitor |
Responsive |
AML, LUAD, ALL |
Pre-clinical |
NRAS |
E63K |
Complete Match |
Pan-RAF inhibitor |
Responsive |
CM |
Case report |
NRAS |
E63K |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
NRAS |
E63K |
Complete Match |
ERK inhibitor |
Responsive |
CM |
Case report |
NRAS |
E63K |
Complete Match |
MEK inhibitor +/- PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
NRAS |
E63K |
Complete Match |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NRAS |
E63K |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
MYMA |
Pre-clinical |
NRAS |
E63K |
Different Mutation |
ERK inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G334V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G334V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G334V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G334V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G334V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G334V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G334V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G334V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G334V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G334V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G334V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G334V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G334V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G334V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G334V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
VHL |
A149S |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
FGFR3 |
P694L |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
P694L |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
P694L |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
BRAF |
K630E |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
K630E |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
K630E |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
K630E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
ABL1 |
S749L |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
ABL1 |
S749L |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
S749L |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
ABL1 |
S749L |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ABL1 |
S749L |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
ABL1 |
S749L |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
T754T), RET MUT* (L362I |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2A |
V46G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
V46G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
V46G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
V46G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
V46G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
V46G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ATR |
Y628* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
Y628* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
Y628* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
BCR |
R1090R |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
R1090R |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
R1090R |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
R1090R |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
R1090R |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
R1090R |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
TP53 |
C242R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
C242R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
C242R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
C242R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
C242R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
C242R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
C242R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
C242R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
C242R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
C242R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
C242R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
C242R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
R95H |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D2135V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
D2135V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
D2135V |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
D2135V |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
D2135V |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
E119D |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E119D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
E119D |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
E119D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
E119D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E119D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E119D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
E119D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
E119D |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E119D |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
E119D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
E119D |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
E119D |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E119D |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
E119D |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
E119D |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
E119D |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
E119D |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
E119D |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NOTCH1 |
A40G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A40G |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
KMT2A |
G48G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G48G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G48G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G48G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G48G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G48G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
PIK3CA |
G106V |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
G106V |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
G106V |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
G106V |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
G106V |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
G106V |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
G106V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
G106V |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
KMT2A |
K2502R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
K2502R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
K2502R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
K2502R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
K2502R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
K2502R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ALK |
L1425L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L1425L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
L1425L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
L1425L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
L1425L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
L1425L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
L1425L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
L1425L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
L1425L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
L1425L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
L1425L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
L1425L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
L1425L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L1425L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L1425L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
L1425L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
L1425L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
L1425L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
L1425L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NTRK3 |
C362F |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
C362F |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
C362F |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
BRCA2 |
N3124I |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
N3124I |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
N3124I |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
N3124I |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
N3124I |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
N3124I |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
N3124I |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
N3124I |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
N3124I |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
N3124I |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
N3124I |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
N3124I |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
N3124I |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
N3124I |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
R158G |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R158G |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R158G |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R158G |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R158G |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R158G |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R158G |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158G |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158G |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R158G |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R158G |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R158G |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158G |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R158G |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R158G |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
FANCA |
splice_donor_variant |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
FANCA |
splice_donor_variant |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Case report |
BRCA2 |
Q1037* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
Q1037* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1037* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
Q1037* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
Q1037* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
Q1037* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
Q1037* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
Q1037* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
Q1037* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1037* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1037* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1037* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
Q1037* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
Q1037* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
BRCA1 |
R1495M |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA1 |
R1495M |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA1 |
R1495M |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA1 |
R1495M |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
R1495M |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
R1495M |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Case report |
BRCA1 |
R1495M |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA1 |
R1495M |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA1 |
R1495M |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA1 |
R1495M |
Complete Match |
PARP inhibitor |
Responsive |
PA |
Case report |
BRCA1 |
R1495M |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA1 |
R1495M |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
S15Y), ALK MUT* (A17T |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PTEN |
Y68H |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y68H |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Y68H |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Y68H |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Y68H |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Y68H |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y68H |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y68H |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y68H |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Y68H |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y68H |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y68H |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Y68H |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y68H |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y68H |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y68H |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Y68H |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Y68H |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Y68H |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Y68H |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Y68H |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Y68H |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Y68H |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Y68H |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Y68H |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
W1498* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
W1498* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
W1498* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
W1498* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
NOTCH2 |
T197I |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ATR |
R1653* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
R1653* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
R1653* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |
RET |
D842N |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
D842N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D842N |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
D842N |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D842N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
D842N |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D842N |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D842N |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
D842N |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
KMT2A |
G48G), MLL MUT* (V46G), MLL MUT* (G43R |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
G48G), MLL MUT* (V46G), MLL MUT* (G43R |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
G48G), MLL MUT* (V46G), MLL MUT* (G43R |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
G48G), MLL MUT* (V46G), MLL MUT* (G43R |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
G48G), MLL MUT* (V46G), MLL MUT* (G43R |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
G48G), MLL MUT* (V46G), MLL MUT* (G43R |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D208V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
D208V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
D208V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
D208V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
D208V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
D208V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
D208V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D208V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D208V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
D208V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
D208V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
D208V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D208V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
D208V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
D208V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
MET |
V378I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
TP53 |
M133I), TP53 MUT (F134V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M133I), TP53 MUT (F134V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M133I), TP53 MUT (F134V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRCA2 |
C2473* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Case report |
BRCA2 |
C2473* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
C2473* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
OV |
Late trials |
BRCA2 |
C2473* |
Complete Match |
Chemotherapy (PARP inhibitor;Chemotherapy) |
Responsive |
OV |
Early trials |
BRCA2 |
C2473* |
Complete Match |
PARP inhibitor;Chemotherapy |
Responsive |
OV |
Early trials |
BRCA2 |
C2473* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
PA |
Case report |
BRCA2 |
C2473* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
PRAD |
Early trials |
BRCA2 |
C2473* |
Complete Match |
Rucaparib (PARP inhibitor) |
Responsive |
OV |
FDA guidelines |
BRCA2 |
C2473* |
Complete Match |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
C2473* |
Complete Match |
Veliparib;Cisplatin (PARP inhibitor;Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
C2473* |
Complete Match |
Platinum Agent (Chemotherapy) |
Responsive |
BRCA |
Early trials |
BRCA2 |
C2473* |
Complete Match |
PARP inhibitor |
Responsive |
BRCA |
Early trials |
BRCA2 |
C2473* |
Different Alteration |
PD1/PDL1 inhibitor |
Responsive |
UTH |
Early trials |
BRCA2 |
C2473* |
Different Alteration |
PARP inhibitor |
Responsive |
OV |
Pre-clinical |
TP53 |
M237V |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
M237V |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
M237V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
M237V |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
M237V |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
M237V |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
M237V |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237V |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237V |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
M237V |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
M237V |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
M237V |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237V |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
M237V |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
M237V |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
VHL |
P81S |
Complete Match |
VEGFR inhibitor |
Responsive |
R |
Pre-clinical |
FGFR3 |
3-UTRBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
3-UTRBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
3-UTRBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NOTCH2 |
V1925V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NRG1 |
E76G |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
LUAD |
Pre-clinical |
NRG1 |
E76G |
Different Alteration |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Case report |
MTOR |
L1460P |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Pre-clinical |
MTOR |
L1460P |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
MTOR |
L1460P |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
AS, R, ST, AG |
Case report |
MTOR |
L1460P |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Case report |
MTOR |
L1460P |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
ST |
Case report |
MTOR |
L1460P |
Different Mutation |
Everolimus (MTOR inhibitor) |
Resistant |
THCA |
Case report |
MTOR |
L1460P |
Different Mutation |
MTOR kinase inhibitor |
Responsive |
CANCER |
Pre-clinical |
PDGFRA |
D452Y |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
PIK3CA |
V344M |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
V344M |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
V344M |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V344M |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
V344M |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
V344M |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
V344M |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
V344M |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
PTEN |
Q245* |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Q245* |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
PTEN |
Q245* |
Different Mutation |
BYL719 (PIK3CA inhibitor) |
Resistant |
BRCA |
Case report |
PTEN |
Q245* |
Complete Match |
ATM inhibitor |
Responsive |
BRCA |
Pre-clinical |
PTEN |
Q245* |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA, ED, TH, CANCER, L, G, OV |
Pre-clinical |
PTEN |
Q245* |
Complete Match |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Q245* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Q245* |
Complete Match |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Q245* |
Complete Match |
PD1 Ab inhibitor |
Resistant |
CM |
Early trials |
PTEN |
Q245* |
Complete Match |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Q245* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Q245* |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
PTEN |
Q245* |
Complete Match |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Q245* |
Complete Match |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Q245* |
Complete Match |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Q245* |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
L, BRCA, CANCER, G, ED, TH, OV |
Pre-clinical |
PTEN |
Q245* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
PRAD |
Early trials |
PTEN |
Q245* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
CANCER |
Early trials |
PTEN |
Q245* |
Different Alteration |
PARP inhibitor |
Responsive |
ED |
Case report |
PTEN |
Q245* |
Different Alteration |
PIK3CB inhibitor |
Responsive |
PRAD |
Case report |
PTEN |
Q245* |
Different Alteration |
EGFR mAb inhibitor |
Resistant |
COREAD |
Late trials |
PTEN |
Q245* |
Different Alteration |
MTOR inhibitor |
No Responsive |
ED |
Early trials |
PTEN |
Q245* |
Different Alteration |
AKT inhibitor |
Responsive |
PA |
Case report |
PTEN |
Q245* |
Different Alteration |
PI3K pathway inhibitor;AR antagonist |
Responsive |
PRAD |
Pre-clinical |
PTEN |
Q245* |
Different Alteration |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
OV |
Pre-clinical |
DNMT3A |
E491* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NTRK3 |
K627N |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
K627N |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
K627N |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
BRD4 |
H990Q |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
Q100Rfs*23 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q100Rfs*23 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q100Rfs*23 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q100Rfs*23 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q100Rfs*23 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q100Rfs*23 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q100Rfs*23 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q100Rfs*23 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q100Rfs*23 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
CBL |
G415R |
Different Mutation |
JAK inhibitor |
Responsive |
MDPS |
Pre-clinical |
CBL |
G415R |
Different Mutation |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
MDPS |
Pre-clinical |
NOTCH2 |
P6S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ALK |
G1585S |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1585S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
G1585S |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
G1585S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
G1585S |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1585S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1585S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
G1585S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
G1585S |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1585S |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
G1585S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
G1585S |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
G1585S |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1585S |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
G1585S |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
G1585S |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
G1585S |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
G1585S |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
G1585S |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A860D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
A860D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
A860D |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
A860D |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
A860D |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
EGFR |
V536M |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
V536M |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
PDGFRA |
R500Q |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
RAF1 |
L541P |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
L541P |
Different Alteration |
Pan-RAF inhibitor |
Responsive |
PRAD |
Pre-clinical |
RAF1 |
L541P |
Different Alteration |
U0126 (MEK inhibitor) |
Responsive |
PRAD |
Pre-clinical |
ALK |
I4I |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
I4I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
I4I |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
I4I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
I4I |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
I4I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
I4I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
I4I |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
I4I |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
I4I |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
I4I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
I4I |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
I4I |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
I4I |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
I4I |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
I4I |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
I4I |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
I4I |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
I4I |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
FGFR3 |
G654S |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
G654S |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
G654S |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
NTRK3 |
intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant), NTRK3 MUT* (intron_variant |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
BCR |
intron_variant), BCR MUT* (intron_variant |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
intron_variant), BCR MUT* (intron_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
intron_variant), BCR MUT* (intron_variant |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
intron_variant), BCR MUT* (intron_variant |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
intron_variant), BCR MUT* (intron_variant |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
intron_variant), BCR MUT* (intron_variant |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
KMT2A |
D525G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
D525G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
D525G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
D525G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
D525G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
D525G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
KMT2A |
P3403L |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3403L |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3403L |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3403L |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3403L |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3403L |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
EGFR |
R427C), EGFR MUT* (R224H |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
R427C), EGFR MUT* (R224H |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
KRAS |
G12_G13delinsVD |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12_G13delinsVD |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
G12_G13delinsVD |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
G12_G13delinsVD |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
G12_G13delinsVD |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12_G13delinsVD |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
G12_G13delinsVD |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
G12_G13delinsVD |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
G12_G13delinsVD |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
G12_G13delinsVD |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
G12_G13delinsVD |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
G12_G13delinsVD |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
G12_G13delinsVD |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
G12_G13delinsVD |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
NTRK3 |
R116L |
Different Alteration |
IGF1R inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R116L |
Different Alteration |
PI3K pathway inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK3 |
R116L |
Different Alteration |
Midostaurin (Pan-TK inhibitor) |
Responsive |
BRCA |
Pre-clinical |
TP53 |
Q331H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q331H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q331H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q331H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q331H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q331H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q331H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q331H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q331H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q331H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q331H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q331H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q331H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q331H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q331H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ROS1 |
I1507T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
I1507T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
I1507T |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
I1507T |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
I1507T |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2D |
Q3601* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
ALK |
L1609P |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L1609P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
L1609P |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
L1609P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
L1609P |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
L1609P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
L1609P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
L1609P |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
L1609P |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
L1609P |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
L1609P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
L1609P |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
L1609P |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L1609P |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L1609P |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
L1609P |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
L1609P |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
L1609P |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
L1609P |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
PIK3CA |
E39K |
Different Mutation |
BRAF inhibitor |
Resistant |
CM |
Case report |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BLCA, HNC |
Case report |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
HNSC |
Case report |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
G, THCA |
Pre-clinical |
PIK3CA |
E39K |
Complete Match |
Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) |
Responsive |
BRCA |
Late trials |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
ED, OV, CESC |
Early trials |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive |
BRCA |
Late trials |
PIK3CA |
E39K |
Complete Match |
PIK3CA inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E39K |
Complete Match |
PIK3CA inhibitor |
Responsive |
ST |
Case report |
PIK3CA |
E39K |
Complete Match |
AKT inhibitor |
Responsive |
BRCA |
Early trials |
PIK3CA |
E39K |
Complete Match |
PI3K pathway inhibitor |
Responsive;Responsive |
L |
Pre-clinical;Case report |
PIK3CA |
E39K |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Late trials |
PIK3CA |
E39K |
Different Alteration |
PI3K pathway inhibitor |
Resistant |
BRCA |
Pre-clinical |
RET |
V804M |
Different Mutation |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA, TH |
FDA guidelines |
RET |
V804M |
Different Mutation |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
TH |
Pre-clinical |
RET |
V804M |
Different Mutation |
RET inhibitor |
Responsive |
TH |
Early trials |
RET |
V804M |
Different Mutation |
Sunitinib (Pan-TK inhibitor) |
Responsive |
TH |
Pre-clinical |
RET |
V804M |
Different Mutation |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Resistant |
LUAD |
Pre-clinical |
RET |
V804M |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
V804M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V804M |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
V804M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V804M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
V804M |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V804M |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V804M |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
V804M |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
FGFR3 |
3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution), FGFR3 MUT* (intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution), FGFR3 MUT* (intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution), FGFR3 MUT* (intron_variant |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
MET |
intron_variant), MET MUT* (IntronicBlockSubstitution |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
G |
Case report |
EGFR |
S229T |
Different Alteration |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
COREAD |
FDA guidelines |
EGFR |
S229T |
Different Alteration |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
EGFR |
S229T |
Different Mutation |
Rindopepimut (Vaccine) |
Responsive |
GB |
Late trials |
EGFR |
S229T |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
S229T |
Different Mutation |
Gefitinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
S229T |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Afatinib;Cetuximab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
MEK inhibitor |
Responsive |
L |
Pre-clinical |
EGFR |
S229T |
Different Mutation |
EGFR TK inhibitor |
Responsive |
L |
Late trials |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
NCCN guidelines |
EGFR |
S229T |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Resistant |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
EGFR-TKI's (EGFR inhibitor) |
Resistant |
L |
Late trials |
EGFR |
S229T |
Different Mutation |
HSP90 inhibitor |
Responsive |
L |
Case report |
EGFR |
S229T |
Different Mutation |
EGFR inhibitor |
Resistant |
L |
Late trials |
EGFR |
S229T |
Different Mutation |
Poziotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Pre-clinical |
EGFR |
S229T |
Different Mutation |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
G |
Pre-clinical |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
S229T |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Rociletinib (EGFR inhibitor) |
Resistant |
LUAD |
Case report |
EGFR |
S229T |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Responsive |
COREAD |
Case report |
EGFR |
S229T |
Different Mutation |
novel EGFR mAb inhibitor |
Responsive |
COREAD |
Early trials |
EGFR |
S229T |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
S229T |
Different Mutation |
Cetuximab;Sirolimus (EGFR mAb inhibitor;MTOR inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
S229T |
Different Mutation |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Case report |
EGFR |
S229T |
Different Mutation |
EGFR inhibitor |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
S229T |
Different Mutation |
Osimertinib (EGFR inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
EGFR |
S229T |
Different Mutation |
EGFR inhibitor |
Responsive |
NSCLC |
Late trials |
EGFR |
S229T |
Different Mutation |
Afatinib;Nimotuzumab (ERBB2 & EGFR inhibitor;EGFR mAb inhibitor) |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Resistant |
L |
NCCN/CAP guidelines |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Early trials |
EGFR |
S229T |
Different Mutation |
Afatinib (ERBB2 & EGFR inhibitor) |
Responsive |
L |
Late trials |
EGFR |
S229T |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Pre-clinical |
EGFR |
S229T |
Different Mutation |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Case report |
EGFR |
S229T |
Different Mutation |
Lapatinib (ERBB2 inhibitor) |
Responsive |
ED |
Case report |
EGFR |
S229T |
Different Mutation |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
S229T |
Different Mutation |
EGFR inhibitor |
Resistant |
NSCLC |
Case report |
EGFR |
S229T |
Different Mutation |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
Case report |
EGFR |
S229T |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant;Resistant |
COREAD |
Pre-clinical;Case report |
EGFR |
S229T |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Responsive |
HNC |
Case report |
EGFR |
S229T |
Different Alteration |
Gefitinib (EGFR inhibitor) |
Responsive |
ED |
Late trials |
EGFR |
S229T |
Different Alteration |
Gefitinib (EGFR inhibitor) |
No Responsive |
HNC |
Early trials |
EGFR |
S229T |
Different Alteration |
EGFR inhibitor |
Responsive |
HNSC |
Case report |
EGFR |
S229T |
Different Alteration |
EGFR inhibitor |
No Responsive |
G |
Early trials |
EGFR |
S229T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
L |
Early trials |
EGFR |
S229T |
Different Alteration |
EGFR mAb inhibitor |
Responsive |
COREAD |
Late trials |
EGFR |
S229T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
S229T |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
DNMT3A |
Y528* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2D |
Q3965* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
RNF43 |
W200* |
Complete Match |
Porcupine inhibitor |
Responsive |
COREAD |
Case report |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
R80*), CDKN2A MUT (H83Y |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
BCR |
intron_variant |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
intron_variant |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
intron_variant |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
intron_variant |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
intron_variant |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
intron_variant |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
TP53 |
Q16Wfs*28 |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
Q16Wfs*28 |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
Q16Wfs*28 |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
Q16Wfs*28 |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
Q16Wfs*28 |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
Q16Wfs*28 |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
Q16Wfs*28 |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
Q16Wfs*28 |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
Q16Wfs*28 |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
NTRK1 |
IntronicBlockSubstitution |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
IntronicBlockSubstitution |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
IntronicBlockSubstitution |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
IntronicBlockSubstitution |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
AKT3 |
Q442* |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
G1258S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
G1258S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
DNMT3A |
R598* |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NOTCH1 |
A1570A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A1570A |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
NTRK1 |
E581K |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
E581K |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
E581K |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
E581K |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
KMT2D |
S1223* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
KMT2A |
P1354S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P1354S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P1354S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P1354S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P1354S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P1354S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
ALK |
D460G |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D460G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
D460G |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
D460G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
D460G |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D460G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D460G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
D460G |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
D460G |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D460G |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
D460G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
D460G |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
D460G |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D460G |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
D460G |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
D460G |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
D460G |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
D460G |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
D460G |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KMT2A |
D2681G |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
D2681G |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
D2681G |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
D2681G |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
D2681G |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
D2681G |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
FGFR2 |
G647A |
Different Alteration |
FGFR inhibitor |
Responsive |
COREAD |
Early trials |
FGFR2 |
G647A |
Different Alteration |
FGFR inhibitor |
Responsive |
BT |
Early trials |
ALK |
R136Q |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R136Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R136Q |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R136Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R136Q |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R136Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R136Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R136Q |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R136Q |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R136Q |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R136Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R136Q |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R136Q |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R136Q |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R136Q |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R136Q |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R136Q |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R136Q |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R136Q |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
EGFR |
D1168Y |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
L |
Case report |
EGFR |
D1168Y |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Responsive |
NSCLC |
Case report |
SETD2 |
Q1344* |
Complete Match |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
SETD2 |
Q1344* |
Different Alteration |
WEE1 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Different Mutation |
Temsirolimus (MTOR inhibitor) |
Responsive |
ED |
Case report |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA, GCA |
FDA guidelines |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Complete Match |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
THCA |
Case report |
TSC2 |
W1610*), TSC2 MUT (Q572* |
Different Alteration |
SRC inhibitor |
Responsive |
LAM |
Pre-clinical |
NF1 |
Q2228* |
Different Mutation |
Vemurafenib (BRAF inhibitor) |
Resistant |
CM |
Pre-clinical |
NF1 |
Q2228* |
Different Mutation |
Everolimus (MTOR inhibitor) |
Responsive |
HNC |
Case report |
NF1 |
Q2228* |
Complete Match |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Complete Match |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
Q2228* |
Complete Match |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Complete Match |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
NF |
Late trials |
NF1 |
Q2228* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Complete Match |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
MPN, PLEN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
HNC, SG |
Case report |
NF1 |
Q2228* |
Complete Match |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
Q2228* |
Complete Match |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
MEK inhibitor |
Responsive |
LK, G |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Complete Match |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
MTOR inhibitor |
Responsive |
LK, G, MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Everolimus;Pazopanib (MTOR inhibitor;VEGFR inhibitor) |
Responsive |
HC |
Case report |
NF1 |
Q2228* |
Complete Match |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
Q2228* |
Complete Match |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Complete Match |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
Q2228* |
Complete Match |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Complete Match |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Complete Match |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
Q2228* |
Complete Match |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Complete Match |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
Q2228* |
Complete Match |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
Q2228* |
Different Alteration |
MTOR inhibitor |
Responsive |
MPN, G, LK |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
PLX3397 (Pan-TK inhibitor) |
Responsive |
PLEN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Different Alteration |
BRD4 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Trametinib (MEK inhibitor) |
No Responsive |
OS |
Case report |
NF1 |
Q2228* |
Different Alteration |
Cediranib (ALK inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Different Alteration |
MEK inhibitor |
Responsive |
G, LK |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Vinblastine (Chemotherapy) |
Responsive |
G |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Sorafenib;Sirolimus (Pan-TK inhibitor;MTOR inhibitor) |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Everolimus;Bevacizumab (MTOR inhibitor;VEGFR mAb inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Resistant |
L |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
MTOR inhibitor;HSP90 inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Sirolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Tamoxifen (Hormonal therapy) |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SG, HNC |
Case report |
NF1 |
Q2228* |
Different Alteration |
Pan-RAF inhibitor;MEK inhibitor |
Responsive |
CM |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Tipifarnib (Farnesyltransferase inhibitor) |
No Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Retinoic Acid |
Resistant |
NB |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Everolimus (MTOR inhibitor) |
No Responsive |
MPN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Sirolimus (MTOR inhibitor) |
Responsive |
PLEN |
Early trials |
NF1 |
Q2228* |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
PLEN, MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Vinblastine;Nilotinib (Chemotherapy;BCR-ABL inhibitor) |
Responsive |
G |
Case report |
NF1 |
Q2228* |
Different Alteration |
Trametinib (MEK inhibitor) |
Responsive |
CM |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
AURK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
Everolimus;Erlotinib (MTOR inhibitor;EGFR inhibitor) |
No Responsive |
G |
Case report |
NF1 |
Q2228* |
Different Alteration |
PD1 Ab inhibitor |
Responsive |
CM |
Early trials |
NF1 |
Q2228* |
Different Alteration |
MEK inhibitor |
Responsive |
MPN |
Pre-clinical |
NF1 |
Q2228* |
Different Alteration |
KIT inhibitor;MTOR inhibitor |
Responsive |
MPN |
Pre-clinical |
NTRK1 |
T403S |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
T403S |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
T403S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
T403S |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
JAK2 |
Y570* |
Different Alteration |
Ruxolitinib (JAK inhibitor) |
Responsive |
ALL |
Pre-clinical |
ALK |
L143R |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L143R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
L143R |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
L143R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
L143R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
L143R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
L143R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
L143R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
L143R |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
L143R |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
L143R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
L143R |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
L143R |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L143R |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
L143R |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
L143R |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
L143R |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
L143R |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
L143R |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
RET |
I1028F |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
I1028F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I1028F |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
I1028F |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I1028F |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
I1028F |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I1028F |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I1028F |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
I1028F |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
BRAF |
IntronicBlockSubstitution |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
IntronicBlockSubstitution |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
IntronicBlockSubstitution |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
IntronicBlockSubstitution |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
FGFR3 |
3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
BLCA |
Case report |
FGFR3 |
3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
G |
Early trials |
FGFR3 |
3-UTRBlockSubstitution), FGFR3 MUT* (3-UTRBlockSubstitution |
Different Alteration |
FGFR inhibitor |
Responsive |
NSCLC |
Pre-clinical |
BCR |
I200I |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
I200I |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
I200I |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
I200I |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
I200I |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
I200I |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
ERBB4 |
L521V |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T859R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
T859R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
T859R |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
T859R |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
T859R |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
PDGFRA |
R383H |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
MDPS, MDS, ECL, HES |
FDA guidelines |
ARID1A |
N106Afs*5 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N106Afs*5 |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
N106Afs*5 |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
N106Afs*5 |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
PIK3R2 |
E210* |
Different Mutation |
MTOR inhibitor |
Responsive |
ED |
Pre-clinical |
ALK |
R1113W |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1113W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
R1113W |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
R1113W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
R1113W |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1113W |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1113W |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
R1113W |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
R1113W |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1113W |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
R1113W |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
R1113W |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
R1113W |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1113W |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
R1113W |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
R1113W |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
R1113W |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
R1113W |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
R1113W |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
AKT3 |
R66Q |
Different Alteration |
ATP competitive AKT inhibitor |
Responsive |
BRCA |
Pre-clinical |
NOTCH1 |
A2256V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
ALL |
Pre-clinical |
NOTCH1 |
A2256V |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
ROS1 |
P696A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
P696A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
P696A |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
P696A |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
P696A |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
NTRK1 |
R452C |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Case report |
NTRK1 |
R452C |
Different Alteration |
Pan-TKR inhibitor |
Responsive |
CANCER |
Early trials |
NTRK1 |
R452C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
LUAD |
Pre-clinical |
NTRK1 |
R452C |
Different Alteration |
Pan-TK inhibitor |
Responsive |
COREAD |
Case report |
TMPRSS2 |
C157C |
Different Alteration |
DNA-PKc inhibitor |
Responsive |
PRAD |
Pre-clinical |
TMPRSS2 |
C157C |
Different Alteration |
PARP inhibitor |
Responsive |
PRAD |
Pre-clinical |
BCR |
F77S |
Different Alteration |
Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
CML, ALL |
FDA guidelines |
BCR |
F77S |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BCR |
F77S |
Different Alteration |
Nilotinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
F77S |
Different Alteration |
Bosutinib (BCR-ABL inhibitor) |
Responsive |
CML |
FDA guidelines |
BCR |
F77S |
Different Alteration |
Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) |
Responsive |
ALL |
Pre-clinical |
BCR |
F77S |
Different Alteration |
Dasatinib (BCR-ABL inhibitor) |
Responsive |
ALL, CML |
FDA guidelines |
BRD4 |
M926K |
Different Alteration |
BET inhibitor |
Responsive |
NMC |
Case report |
TP53 |
V143E |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
V143E |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
V143E |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
V143E |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
V143E |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
V143E |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
V143E |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143E |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143E |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
V143E |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
V143E |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
V143E |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V143E |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
V143E |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
V143E |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ALK |
M1223L |
Different Alteration |
ALK inhibitor;SRC inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1223L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
GB, LY |
Early trials |
ALK |
M1223L |
Different Alteration |
Lorlatinib (ALK&ROS1 inhibitor) |
Responsive |
NSCLC |
Early trials |
ALK |
M1223L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
THCA, IM |
Case report |
ALK |
M1223L |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M1223L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M1223L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
IM, COREAD |
Case report |
ALK |
M1223L |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD, NSCLC |
FDA guidelines |
ALK |
M1223L |
Different Alteration |
Brigatinib (Pan-TK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M1223L |
Different Alteration |
Entrictinib (Pan-TK inhibitor) |
Responsive |
COREAD |
Case report |
ALK |
M1223L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
LUAD |
FDA guidelines |
ALK |
M1223L |
Different Alteration |
HSP90 inhibitor (HSP90 inhibitor) |
Responsive |
LUAD |
Early trials |
ALK |
M1223L |
Different Alteration |
ALK inhibitor;IGF1R inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1223L |
Different Alteration |
ALK inhibitor;MEK inhibitor |
Responsive |
LUAD |
Pre-clinical |
ALK |
M1223L |
Different Alteration |
novel ALK inhibitor |
Responsive |
LUAD |
Early trials |
ALK |
M1223L |
Different Alteration |
Ceritinib (ALK inhibitor) |
Responsive |
HEMATO |
Early trials |
ALK |
M1223L |
Different Alteration |
ALK inhibitor |
Responsive |
COREAD |
Case report |
ALK |
M1223L |
Different Alteration |
Alectinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ALK |
M1223L |
Different Alteration |
MEK inhibitor (ALK inhibitor;MEK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1948H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
IM |
Case report |
ROS1 |
R1948H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
NSCLC |
FDA guidelines |
ROS1 |
R1948H |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Case report |
ROS1 |
R1948H |
Different Alteration |
HSP90 inhibitor |
Responsive |
LUAD |
Pre-clinical |
ROS1 |
R1948H |
Different Alteration |
Crizotinib (ALK inhibitor) |
Responsive |
LUAD |
Early trials |
KMT2D |
Q3845* |
Complete Match |
Bicalutamide (AR inhibitor) |
Responsive |
LUSC |
Pre-clinical |
NPM1 |
splice_donor_variant |
Complete Match |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
NPM1 |
splice_donor_variant |
Complete Match |
DOT1L inhibitor;MLL1 inhibitor |
Responsive |
AML |
Pre-clinical |
RET |
S365L |
Different Alteration |
Nintedanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Case report |
RET |
S365L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
S365L |
Different Alteration |
RET inhibitor |
Responsive |
LUAD |
Pre-clinical |
RET |
S365L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
S365L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
LUAD |
Early trials |
RET |
S365L |
Different Alteration |
Cabozantinib (Pan-kinase inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
S365L |
Different Alteration |
Vandetanib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
S365L |
Different Alteration |
Sunitinib (Pan-TK inhibitor) |
Responsive |
THCA |
Pre-clinical |
RET |
S365L |
Different Alteration |
RET inhibitor |
Responsive |
TH |
Pre-clinical |
ARID1A |
Q2026* |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q2026* |
Complete Match |
PD1 inhibitor |
Responsive |
OV |
Pre-clinical |
ARID1A |
Q2026* |
Complete Match |
PARP inhibitor |
Responsive |
CANCER |
Pre-clinical |
ARID1A |
Q2026* |
Complete Match |
ATR inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R337P |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R337P |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R337P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R337P |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R337P |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R337P |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R337P |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337P |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337P |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R337P |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R337P |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R337P |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337P |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R337P |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R337P |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KMT2A |
P3493S |
Different Alteration |
EPZ-5676 (DOT1L inhibitor) |
Responsive |
ALL, MDS, AML |
Early trials |
KMT2A |
P3493S |
Different Alteration |
BET inhibitor |
Responsive |
ALL |
Pre-clinical |
KMT2A |
P3493S |
Different Alteration |
BET inhibitor |
Responsive |
AML |
Pre-clinical |
KMT2A |
P3493S |
Different Alteration |
Daunorubicin (Chemotherapy) |
Responsive |
AML |
FDA guidelines |
KMT2A |
P3493S |
Different Alteration |
Belinostat (HDAC inhibitor) |
Responsive |
AML |
Early trials |
KMT2A |
P3493S |
Different Alteration |
DOT1L inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G154D |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G154D |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G154D |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G154D |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G154D |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G154D |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G154D |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G154D |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G154D |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G154D |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G154D |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G154D |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G154D |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G154D |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G154D |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
KRAS |
Q61P |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61P |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61P |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61P |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61P |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61P |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61P |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61P |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61P |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61P |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61P |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61P |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61P |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61P |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61P |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61P |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61P |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61P |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61P |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61P |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61P |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61P |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61P |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61P |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
TP53 |
R175L |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
R175L |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
R175L |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
R175L |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
R175L |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
R175L |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
R175L |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175L |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175L |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
R175L |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
R175L |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
R175L |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175L |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
R175L |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
R175L |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N239H |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
N239H |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
N239H |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
N239H |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
N239H |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
N239H |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
N239H |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239H |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239H |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
N239H |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
N239H |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
N239H |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239H |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
N239H |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
N239H |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T211N |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
T211N |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
T211N |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
T211N |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
T211N |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
T211N |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
T211N |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T211N |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T211N |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
T211N |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
T211N |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
T211N |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T211N |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
T211N |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
T211N |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
ERBB4 |
R1112L |
Different Alteration |
Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) |
Responsive |
LUAD |
Pre-clinical |
APC |
Q412*), APC MUT (E1408* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
APC |
Y1027* |
Complete Match |
Tankyrase inhibitor |
Responsive |
COREAD |
Pre-clinical |
TSC1 |
S1084* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
BLCA |
Early trials |
TSC1 |
S1084* |
Complete Match |
MTOR inhibitor |
Responsive |
RA |
Early trials |
TSC1 |
S1084* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
RA |
FDA guidelines |
TSC1 |
S1084* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
ST, S |
Case report |
TSC1 |
S1084* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TSC1 |
S1084* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
GCA |
FDA guidelines |
TSC1 |
S1084* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
R |
Case report |
TP53 |
G244R |
Different Mutation |
HSP90 inhibitor |
Responsive |
CANCER |
Pre-clinical |
TP53 |
G244R |
Complete Match |
Decitabine (Chemotherapy) |
Responsive |
AML, MDPS |
Early trials |
TP53 |
G244R |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Resistant |
BRCA |
Early trials |
TP53 |
G244R |
Different Mutation |
HDM2 inhibitor |
Responsive |
AML |
Early trials |
TP53 |
G244R |
Complete Match |
Cisplatin (Chemotherapy) |
Resistant |
FGCT, MGCT |
Early trials |
TP53 |
G244R |
Complete Match |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
TP53 |
G244R |
Complete Match |
Gemcitabine (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244R |
Complete Match |
Mitomycin C (Chemotherapy) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244R |
Complete Match |
WEE1 inhibitor |
Responsive |
HNC |
Pre-clinical |
TP53 |
G244R |
Complete Match |
MDM2 inhibitor |
Resistant |
LIP |
Early trials |
TP53 |
G244R |
Complete Match |
Doxorubicin (Anthracycline antitumor antibiotic) |
Responsive |
BLCA |
Pre-clinical |
TP53 |
G244R |
Complete Match |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244R |
Complete Match |
WEE1 inhibitor |
Responsive |
OV |
Early trials |
TP53 |
G244R |
Different Alteration |
Pramlintide (Amylin analogue) |
Responsive |
THYM |
Pre-clinical |
TP53 |
G244R |
Different Alteration |
AZD6738 (ATR inhibitor) |
Responsive |
BCL |
Early trials |
BRAF |
G503E |
Different Alteration |
Sorafenib (Pan-TK inhibitor) |
Responsive |
CM, LUAD, PRAD |
Pre-clinical |
BRAF |
G503E |
Different Alteration |
MEK inhibitor |
Responsive |
LUAD, CM, PRAD |
Pre-clinical |
BRAF |
G503E |
Different Alteration |
Selumetinib (MEK inhibitor) |
Responsive |
OV |
Case report |
BRAF |
G503E |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Responsive |
LUAD |
Case report |
NOTCH2 |
N1723S |
Different Alteration |
Gamma secretase inhibitor |
Responsive |
BRCA |
Pre-clinical |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Complete Match |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Complete Match |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Complete Match |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CANCER, G |
Pre-clinical |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Different Alteration |
Ilorasertib (AURKA-VEGF inhibitor) |
Responsive |
CANCER |
Early trials |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Different Alteration |
PD1 inhibitor |
Resistant |
CM |
Early trials |
CDKN2A |
A36Cfs*17), CDKN2A MUT (L37Afs*6 |
Different Alteration |
CDK4/6 inhibitor |
Responsive |
CM |
Case report |
KRAS |
Q61R), KRAS MUT (E62V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
FDA guidelines |
KRAS |
Q61R), KRAS MUT (E62V |
Different Mutation |
Cetuximab (EGFR mAb inhibitor) |
No Responsive |
COREAD |
Late trials |
KRAS |
Q61R), KRAS MUT (E62V |
Different Mutation |
MEK inhibitor |
Responsive |
ALL |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Different Mutation |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Resistant |
GIST |
Case report |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
MEK inhibitor |
Responsive |
OV, CER, AML |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Abemaciclib (CDK4/6 inhibitor) |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
MEK inhibitor;PI3K pathway inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Cetuximab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) |
Responsive |
HC |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
EGFR inhibitor |
Resistant |
L |
NCCN guidelines |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
CDK4 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Selumetinib (MEK inhibitor) |
Responsive |
NSCLC |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
BET inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) |
Responsive |
OV |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
FAK inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
EGFR inhibitor |
Resistant |
NSCLC |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
EZH2 inhibitor |
Resistant |
CANCER |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
MEK inhibitor |
Responsive |
BT, L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
MEK inhibitor;IGF1R inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
MTOR inhibitor;BH3 mimetics |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
EGFR mAb inhibitor;MEK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
pan-RAF inhibitor |
Responsive |
ED |
Case report |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
EGFR mAb inhibitor |
Resistant |
ST |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Selumetinib (MEK inhibitor) |
No Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) |
Responsive |
LUAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) |
Resistant |
COREAD |
Late trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
pan-RAF inhibitor |
Responsive |
L |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
JAK/TBK1/IKKε inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
FAS inhibitor |
Responsive |
L |
Case report |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
HSP90 inhibitor |
Responsive |
L |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
ERK inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
PI3K pathway inhibitor;MEK inhibitor |
No Responsive |
PA |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
MEK inhibitor;BCL-XL inhibitor |
Responsive |
COREAD |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) |
Responsive |
PA |
Early trials |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
Panitumumab (EGFR mAb inhibitor) |
Resistant |
COREAD |
NCCN guidelines |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
PI3K pathway inhibitor |
Resistant |
ED |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Complete Match |
CDK4/6 inhibitor;MEK inhibitor |
Responsive |
CESC |
Pre-clinical |
KRAS |
Q61R), KRAS MUT (E62V |
Different Alteration |
BRAF inhibitor;MEK inhibitor |
Resistant |
COREAD |
Case report |
KRAS |
Q61R), KRAS MUT (E62V |
Different Alteration |
BRAF inhibitor;EGFR mAb inhibitor |
Resistant |
COREAD |
Case report |
JAK3 |
R657Q |
Complete Match |
JAK inhibitor |
Responsive |
MKB |
Pre-clinical |
JAK3 |
R657Q |
Different Mutation |
JAK inhibitor |
Responsive |
LY |
Pre-clinical |
NF2 |
K99* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
K99* |
Complete Match |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
K99* |
Complete Match |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
K99* |
Complete Match |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
K99* |
Complete Match |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
K99* |
Complete Match |
Lapatinib (ERBB2 inhibitor) |
Responsive |
NF, SCHW |
Early trials |
NF2 |
K99* |
Complete Match |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
K99* |
Complete Match |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
K99* |
Complete Match |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
K99* |
Complete Match |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
K99* |
Complete Match |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
K99* |
Complete Match |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
K99* |
Complete Match |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
K99* |
Complete Match |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
K99* |
Complete Match |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
K99* |
Complete Match |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
K99* |
Different Alteration |
FAK inhibitor |
Responsive |
OV |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
MEK inhibitor |
Responsive |
TH |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
Erlotinib (EGFR inhibitor) |
No Responsive |
SCHW |
Early trials |
NF2 |
K99* |
Different Alteration |
Everolimus;Octreotide (MTOR inhibitor;Somatostatin analog) |
Responsive |
MEN |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
PDK1 inhibitor |
Responsive |
SCHW |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
PAK inhibitor |
Responsive |
SCHW, MEN |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
Imatinib (BCR-ABL inhibitor & KIT inhibitor) |
Responsive |
SCHW |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
Temsirolimus;Chemotherapy (MTOR inhibitor;Chemotherapy) |
Responsive |
BRCA |
Case report |
NF2 |
K99* |
Different Alteration |
AR42 (HDAC inhibitor) |
Responsive |
MEN |
Early trials |
NF2 |
K99* |
Different Alteration |
FAK inhibitor |
Responsive;Responsive |
MESO |
Early trials;Pre-clinical |
NF2 |
K99* |
Different Alteration |
Bevacizumab (VEGFR mAb inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
K99* |
Different Alteration |
Lapatinib (ERBB2 inhibitor) |
Responsive |
SCHW, NF |
Early trials |
NF2 |
K99* |
Different Alteration |
Everolimus (MTOR inhibitor) |
Responsive |
SCHW |
Early trials |
NF2 |
K99* |
Different Alteration |
HSP90 inhibitor |
Responsive |
MEN |
Pre-clinical |
NF2 |
K99* |
Different Alteration |
MTOR inhibitor |
Responsive |
MEN |
Pre-clinical |
SMARCA4 |
Y834Sfs*24 |
Complete Match |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Y834Sfs*24 |
Complete Match |
AURKA inhibitor |
Responsive |
NSCLC |
Pre-clinical |
SMARCA4 |
Y834Sfs*24 |
Complete Match |
EZH2 inhibitor |
Responsive |
OV |
Case report |
SMARCA4 |
Y834Sfs*24 |
Different Alteration |
EZH2 inhibitor |
Responsive |
OVRT |
Case report |
SMARCA4 |
Y834Sfs*24 |
Different Alteration |
EZH2 inhibitor |
Responsive |
OV |
Case report |
ATR |
L1907* |
Complete Match |
Temozolomide (Chemotherapy) |
Responsive |
G |
Pre-clinical |
ATR |
L1907* |
Complete Match |
Olaparib (PARP inhibitor) |
Responsive |
CANCER, OV |
Pre-clinical |
ATR |
L1907* |
Different Alteration |
Olaparib (PARP inhibitor) |
Responsive |
OV, CANCER |
Pre-clinical |